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Reactive oxygen species
Perhaps the most important step in evolution was the Great Oxidation Event: 
a sudden rise in atmospheric O2 from an estimated 0.0002% to the current 
21%, which allowed for aerobic respiration to evolve about 2.4 billion years 
ago1. Aerobic respiration is about 16 times more efficient at generating ATP 
from glucose than anaerobic metabolism2, paving the way for eukaryotic, 
multicellular organisms to arise3. However, there was a downside to this 
event, since O2 is a potent four-electron oxidizing agent and the intermedi-
ates of oxygen reduction are all strong reactive oxygen species (ROS) as well 
(Figure 1a-b)4. Especially in the presence of transition metals like iron, which 
catalyze the formation of hydroxyl radicals (Figure 1c). These are the most 
reactive oxygen radical species.. The Great Oxidation Event posed a momen-
tous evolutionary challenge to life on earth: in order to survive, organisms 
had to evolve ways to prevent widespread oxidation of crucial cellular com-
ponents while also adapting metabolic reactions to harness the energetic 
advantage of oxygen, or retreat to an anaerobic niche5. Currently, ROS are 
not only a threat, but they are also used in signaling and, more importantly, 
play a fundamental role in the defense against invading pathogens.
The immune system
The immune system is the most diverse organ of the human body, with 
highly specialized cells in every compartment that are awaiting an invading 
bacterium, fungus, parasite or virus. Compartmentalization is crucial in 
immunology to generate the right response to each pathogen and the first 
subdivision differentiates the immune system into innate and adaptive. The 
innate immune system is the first line of defense against a large variety of 
pathogens, whether we have encountered these pathogens before or not. 
This works because many pathogens carry similar characteristic surface 
molecules, which are recognized by pathogen recognition receptors (PRRs) 
on innate immune cells such as macrophages. PRRs are a diverse group of 
receptors residing both on the surface and inside of immune cells and they 
range from Toll-like receptors (TLRs) to C-type lectin receptors, receptors 
containing nucleotide binding domains (NBDs) or leucine-rich repeats 
(LRRs) and retinoic acid-inducible gene-I like (RIG-I) receptors. PRRs are 
aimed at recognizing highly conserved patterns that are present 
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Figure 1. Reactive oxygen species.
A. The most common subspecies of ROS in biology. B. The four-step reduction of molec-
ular oxygen, yielding ROS intermediates and ending in the generation of two H2O. C. The 
cyclical Haber-Weiss reaction in which hydrogen peroxide is converted to a hydroxyl radical 
(Fenton reaction) with the aid of a transition metal, in this case ferrous iron. Hydroxyl radi-
cals are highly damaging in biology.
on many microorganisms6, resulting in the innate immune system’s broad 
sensitivity. Commonly found patterns are for example lipopolysaccharide 
(LPS) from Gram-negative bacteria, lipoteichoic acid from Gram-positive 
bacteria, flagellin from bacterial flagella, unmethylated cytosine-guanine 
dinucleotides or sequences (CpG) or double-stranded RNA from viruses. 
Upon recognition of such a pattern, cytokines and chemokines are released 
to recruit the right effector cells to the site of infection7. This ultimately 
allows for a swift, generic response to most of the common invading patho-
gens.
In contrast, the adaptive immune system uses its memory to mount specific 
responses against repeated exposures. Building this memory is a process that 
takes several days, but it is crucial for mounting specifically targeted respons-
es to pathogens, or to allow tolerance against a specific antigen8. The adap-
tive immune system does this by employing antigen presenting cells (APCs) 
which ingest pathogens and proteolytically process their proteins to present 
peptide fragments, called antigens, to T cells for an immune response spe-
cifically targeted at the antigen presented9,10. Depending on their subtype, T 
cells either have regulatory functions (CD4+ T helper cells) or can directly 
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kill cells expressing the target antigen (CD8+ cytotoxic T cells)11,12. Antigens 
are presented to T cells via the major histocompatibility complex (MHC), 
of which there are two subclasses. MHC-I is present on all cells (includ-
ing platelets) except for red blood cells. This subclass presents antigens for 
recognition by CD8+ T cells and if a cell presents an antigen that is recog-
nized, the T cell drives that cell into apoptosis. This line of defense protects 
against intracellular pathogens or virus infected cells and cancer. MHC-II is 
exclusive to APCs such as monocytes and dendritic cells, which they use to 
activate CD4+ T cell responses that ultimately lead to activation of antibody 
production by B cells and immune memory. This response defends mostly 
against extracellular pathogens such as bacteria, but also potentiates CD8+ T 
cell responses11.
The main antigen presenting cell is the dendritic cell (DC), which resides in 
tissues throughout the body, constantly sampling for antigens13. Upon en-
counter of an antigen, the DC undergoes a process called maturation, where 
it lowers expression of its integrins and other adhesion molecules, to allow it 
to home to the nearest draining lymph node where the naive T cells reside14. 
Dendritic cells have the unique capacity of cross-presenting antigens. This 
means that an antigen derived from an extracellular source (like a bacteri-
um), which is normally exclusively presented on MHC-II, is processed in 
such a way that it is presented on MHC-I as well with the aim of triggering 
a CD8+ T cell response9,15–17. This process is called cross-presentation and is 
crucial in anti-cancer immunity. There are two main pathways for cross-pre-
sentation: lysosomal and cytosolic. In the lysosomal pathway, antigens 
undergo the entire MHC-II processing route and are loaded onto MHC-I in 
the lysosomes. In the cytosolic pathway, antigens escape MHC-II processing 
by crossing the phagosomal membrane. This allows them to be processed 
by the proteasome in the cytosol, imported into the endoplasmic reticulum 
(ER) via TAP1 and loaded on MHC-I by the peptide-loading complex which 
consists of the proteins TAP1, tapasin, MHC-I, ERp57 and calreticulin. The 
peptide-loaded MHC-I complex is then trafficking to the plasma membrane 
via the ER18,19. Alternatively, peptides are generated and loaded onto MHC-I 
directly within the endo-/phagosomal lumen, which is called the vacuolar 
pathway20,21.
TLR signaling
Following recognition of a pathogen, TLRs initiate a signaling cascade that 
leads to gene expression, cytokine secretion and, in the case of DCs, cell mat-
uration. The human genome encodes ten TLRs, although their expression 
varies between different immune cells. Each TLR is capable of recognizing 
a specific set of pathogen-associated molecular patterns (PAMPs), allowing 
the immune system to differentiate between fungal, viral or bacterial infec-
tions and respond accordingly22. In this thesis, we only describe effects in 
cells stimulated with PAMPs that have their origin in Gram-negative bacte-
ria (LPS) or yeast (zymosan), therefore the focus will be on their respective 
TLRs (TLR4 and TLR2, respectively). TLR4 is the main PRR associated with 
LPS, but since LPS is a glycolipid it tends to aggregate in aqueous environ-
ments, hindering recognition by TLR4. Therefore, the soluble LPS binding 
protein (LBP) and the surface receptor CD14 play a crucial role in LPS-me-
diated TLR4 signaling by extracting and monomerizing LPS from aggregates 
for presentation to TLR423–25. This process is crucial for LPS recognition by 
TLR4, as CD14-/- mice were found to be highly resistant to a challenge with 
either live Gram-negative bacteria or isolated LPS26. The TLR4 signaling 
cascade is started by dimerization of two TLR4 molecules by LPS, leading 
to recruitment of the adaptor protein MyD88 to the intracellular TIR-do-
mains of dimerized TLR427,28. MyD88 then activates a broad range of in-
flammatory signaling pathways, including the p38/MAPK, JNK and NFκB 
leading to expression of inflammatory cytokines and chemokines such as 
IL-6 and TNF-α29. Zymosan is mainly recognized by TLR2, in conjunction 
with Dectin-130. TLR2 has the unique property to form heterodimers with 
TLR1 or TLR6 to recognize triacyl or diacyl lipopeptides, respectively, but 
the subsequent signaling also follows the MyD88 pathway. Additionally, both 
TLR2 and TLR4 signal transduction can occur via a heterodimer of TIR-do-
main-containing adapter-inducing interferon-β (TRIF) and TRIF-related 
adaptor molecule (TRAM)31. These adaptor proteins initiate type I interferon 
production which are an important part of the antiviral immune response29.
ROS in the immune system
At the base of both innate and adaptive immune responses lies the process of 
a cell taking up (part of) a pathogen, which is called endocytosis (for parti-
cles <0.5 µm or soluble proteins) or phagocytosis (for larger particles). Both 
processes resolve in a similar fashion, although there are some key differenc-
es in the regulation of uptake and downstream signaling of these processes. 
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Endocytosis can be mediated through cage proteins such as clathrin, while 
phagocytosis relies on actin for vesicle formation. Macrophages, neutrophils, 
monocytes and dendritic cells all phagocytose pathogens, cellular debris and 
other antigen-containing materials. These materials end up in phagosomes: 
small intracellular vesicles that have budded off from the plasma membrane 
and are transported through the cell. Phagocytosis is a multi-step process; 
a pathogen is first recognized by a PRR, then actin polymerizes around the 
early phagocytic cup to form a cage-like structure to aid in engulfing the 
pathogen. This structure is pulled into the cell and, following membrane fis-
sion, the phagosome buds off and is carried inward32. This process is mostly 
orchestrated by small GTPases like CDC42, Rac1 and RhoA33–35 which are 
activated by scaffolding proteins such as SWAP70 which are recruited to spe-
cific phosphoinositides in the membrane36. In the end, phagosomes fuse with 
lysosomes to fully degrade their content.
In the case of innate immunity, the primary aim of phagocytosis is to kill the 
ingested pathogen. This killing is mostly done by generating large amounts 
of ROS, generated for example by assembly of enzyme complexes like nico-
tinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX). In fact, 
neutrophils generate so much ROS during phagocytosis (up to 5 mM/pha-
gosome/second37–39) that they usually die in the process. In macrophages, the 
oxidative burst is equally short-lived, albeit not as strong as in neutrophils40. 
In contrast, dendritic cells generate ROS in much lower concentrations, but 
on a far longer time scale. Chapter 2 of this thesis discusses this in greater 
detail.
The main ROS-producing enzymes during phagocytosis are members of the 
NOX protein family, of which NOX2 is the most abundant in phagocytes. 
NOX2 is a protein complex featuring 2 membrane-bound subunits (gp91phox 
and p22phox) that form a stable heterodimer. Recruitment of the cytosolic 
subunits p40phox, p47phox and finally p67phox is needed for activation. Addi-
tionally, a small GTPase, usually Rac, is required41–43 (Figure 2). Once active, 
NOX2 generates superoxide anion in the phagosomal lumen by stepwise 
transfer of an electron from NADPH to oxygen via gp91phox-bound FAD to 
the first and then second heme group in the gp91phox subunit44. During pha-
gosome maturation, oxidized NOX2 is replenished from a lysosomal pool to 
ensure continued phagosomal superoxide anion generation45.
gp91phox p22phox
p40
p67 p47
GDP
GTP
NADPH NADP++H+
2 e-
2 O₂ 2 O₂·-
Activation
Figure 2. Assembly of the NOX2 complex.
Following immune cell activation, the cytosolic subunits p67phox, p47phox and p40phox are 
recruited to the membrane-bound heterodimer of gp91phox and p22phox together with a small 
GTPase (usually Rac1/2). Following assembly, NADPH is oxidized to generate two electrons 
to reduce two oxygen molecules to superoxide anion.
For APCs such as dendritic cells, antigen uptake and presentation is a major 
aim of phagocytosis in addition to killing46 and ROS carry out functions that 
aid in these processes. Superoxide anion, generated by NOX2, is not very 
reactive with non-radical molecules, therefore it often reacts with itself in 
a process called dismutation. In this process, it reacts with protons to form 
H2O2 and O2 at a rate constant of about 105 M-1s-1 at neutral pH4. This reac-
tion can also be catalyzed by enzymes of the superoxide dismutase (SOD) 
family, thereby shunting superoxide anion away from reactions that are 
highly damaging to the cell, such as the formation of peroxynitrite4. These 
enzymes are quite ubiquitously expressed, with specific variants localizing to 
the cytosol (SOD1), mitochondria and peroxisomes (SOD2) and extracellu-
lar matrix (SOD3). SOD3 can be passively internalized during phagocytosis 
to increase the rate of dismutation in the phagosomal lumen47. NOX2 activi-
ty in the phagosome preserves antigen in two ways: firstly, dismutation con-
sumes protons, leading to alkalization of the phagosomal lumen, reducing 
activity of proteases with low pH optima48. Secondly, H2O2 and other radical 
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species can induce disulfide bond formation in the catalytic sites of proteases 
such as cathepsin B, S and L49,50 or the vacuolar V-ATPase51,52 to inactivate 
them. This preserves antigens for presentation on MHC molecules53–55. In 
addition, NOX2 activity can cause lipid peroxidation of the phagosomal 
membrane, allowing antigen to leak into the cytosol, allowing them to enter 
the cytosolic cross-presentation pathway56.
Lipid peroxidation
The cellular components most vulnerable to peroxidation, as well as being 
one of the most ubiquitous, are unsaturated fatty acids. These form the mem-
branes that define the cell and its separate organelles and generally comprise 
≈40% of the total lipid content of membranes57. In addition, oxygen has a 
≈5-fold increased partition coefficient for lipid membranes compared to 
aqueous environments58, while there is a general lack of protection by antiox-
idants (since only α/γ-tocopherol are lipophilic antioxidants). An additional 
problem is that lipid peroxidation is a self-propagating reaction: during the 
initial steps of peroxidation, hydrogen is removed to form a carbon-cen-
tered lipid radical (L∙) which immediately oxidizes to a lipid peroxyl radical 
(LOO∙), which removes hydrogen from a lipid to generate another L∙ (start-
ing the chain reaction) and a lipid hydroperoxide end product (LOOH)59. 
LOOH can also propagate the chain reaction by forming peroxyl (LOO∙) or 
alkoxyl (LO∙) radicals by redox cycling a transition metal in a Fenton reac-
tion60. Aside from lipid hydroperoxides, many secondary products are also 
formed, of which malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) 
are the most studied61–63. In addition, various hydrocarbon gases like ethane 
and pentane can be formed as a result of lipid peroxidation 64. In chapter 4, 
we describe the formation of ethylene during lipid peroxidation and its pos-
sible use as a real-time breath marker for systemic inflammation.
Effects of lipid peroxidation products
Many of the secondary products of lipid peroxidation have effects on metab-
olism and even cellular signaling pathways. In contrast to oxygen radicals, 
which usually react within nanometer range of their origin, the aldehydes 
(such as MDA) formed by lipid peroxidation are more stable and thus able 
to diffuse across membranes and attack biomolecules throughout the cell or 
even in neighboring cells65,66. Lipid aldehydes often form adducts with pro-
teins67 or DNA68,69, causing dysfunctional proteins and extensive DNA dam-
age. Effects of MDA itself, which originates from oxidation of arachidonic 
acid (20:4) and larger PUFAs63, are relatively poorly described. Thus far, it is 
mostly known to act on insulin secretion via Wnt signaling70, as well as on 
collagen generation in the liver71. However, MDA is a strong electrophile and 
therefore readily forms adducts with for example basic amino acid residues 
(arginine, histidine, lysine)63,72. Acetaldehydes are a product of MDA metab-
olism and the presence of MDA and radicals results in generation of MDA 
acetaldehyde adducts73, which are strongly auto-immunogenic74–76. Like 
MDA, 4-HNE is highly reactive and readily forms adducts with cysteine, 
histidine or lysine amino acid residues77 or DNA78,79. However, in contrast 
to MDA, 4-HNE itself can exert a variety of effects on protein transcription, 
signaling, autophagy, proliferation and apoptosis59. For example, 4-HNE 
induces transcription of several matrix metalloproteinases via activation of 
the Erk and p38/MAPK pathways80–82. 4-HNE can even inhibit cross-presen-
tation by causing ER-stress, which prevents translocation of MHC-I via an 
unknown mechanism involving accumulation of lipid bodies83,84. Possibly, 
peptide-loading on MHC-I is also affected since this occurs in the ER18,19. 
4-HNE was also shown to activate phosphoinositides-3-kinase (PI3K)/Akt 
and JNK85, PTEN86, NF-κB87 and phospholipase C (PLC)88, all important 
factors in phagocytic and pro-inflammatory pathways.
Autophagy
Oxidation products such as the aforementioned adducts often affect cellular 
function and viability and the de facto way for a cell to clear these com-
pounds is by autophagy. Autophagy is a highly conserved catabolic pathway 
where cells encapsulate damaged components in double-membrane vesicles 
called autophagosomes, which subsequently fuse with lysosomes to degrade 
these components into smaller precursor molecules89–93. Lipid peroxidation 
can also induce autophagy directly via c-Jun terminal kinase (JNK)-medi-
ated induction of ER stress94. One of the major proteins mediating autoph-
agy is Microtubule Associated Protein 1 Light Chain 3 Beta (MAP1LC3B; 
LC3B), a structural protein that is integrated in the autophagosomal mem-
brane upon lipidation with phosphatidylethanolamine (PE)90. LC3B is the 
main regulatory protein in autophagy, responsible for the recruitment of 
most other proteins involved in this process, such as p62, ATG4 and ATG5-
1295. ROS and various oxidation products can greatly influence autophagy; 
ATG4, a cysteine protease which controls the recruitment and dissociation 
of phagosomal maturation protein ATG8, is inactivated upon oxidation of 
a cysteine residue near the catalytic site96. Inactivation of ATG4 by radicals 
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therefore leads to increased formation but decreased maturation of auto-
phagosomes. In LC3-associated phagocytosis, a process strongly related to 
autophagy, NOX2 activity is crucial for LC3 recruitment97,98. 4-HNE protein 
adducts were shown to increase LC3 lipidation via a JNK-mediated pathway 
by activating the unfolded-protein response in the ER94.
ROS: protection and signaling
Since ROS react indiscriminately with cellular components, cells need pro-
tective mechanisms in order to survive. Especially DCs, whose migration 
to the lymph node following encounter of a pathogen can take upwards of 
24 hours99, need these protective mechanisms to fulfill their role as APC. 
As mentioned above, the SOD enzyme family plays a major role in this by 
shunting superoxide anion away from reactions that form more dangerous 
radical species such as peroxynitrite in favor of H2O2, which can subsequent-
ly be degraded by catalase. The peroxiredoxin (Prx) enzyme family has a 
similar function and is capable of reducing hydroperoxides and even per-
oxynitrite100. Negative Regulator of ROS (NRROS) works on a different axis 
by blocking interaction between NOX2 subunits gp91phox and p22phox in the 
ER, resulting in degradation of gp91phox via the ERAD pathway101. In addition 
to these enzymes, there are several non-enzymatic antioxidants, most impor-
tantly uric acid, glutathione, tocopherols (vitamin E, as mentioned above) 
and vitamin C, which halt the oxidation cascade by accepting a free electron 
without forming a new radical themselves102. Aside from direct antioxidants, 
enzymes such as ferritin also contribute to maintaining a healthy redox state 
by chelating transition metals that would otherwise catalyze the production 
of highly reactive radical species, as described earlier.
Although the high reactivity of ROS poses a threat to cell viability, they also 
play important roles in for example cellular signaling103,104. Especially H2O2 
has been implied in several signaling pathways, since it is a relatively stable 
radical and does not carry a free electron, making it membrane-perme-
able105. But, since radicals can react with so many targets, achieving spatio-
temporal specificity of ROS signaling is a challenge. However, the antioxi-
dant peroxiredoxin 1 (Prx1) was shown to be able to control this. Following 
growth factor stimulation (for example PDGF or EGF), a membrane-local-
ized fraction of Prx1 is transiently phosphorylated, which prevents its anti-
oxidant function. This leads to local accumulation of H2O2 and thus a locally 
increased modification of cysteine residues, activating Src106 or inactivating 
PTEN107. The redox-mediated dissociation of thioredoxin from apoptosis 
signal-regulating kinase (ASK1), allowing ASK1 to activate its downstream 
targets is also dependent on cysteine oxidation108. Another major ROS-me-
diated transcription factor is Nrf2, which activates antioxidant and phase 
II drug-metabolizing enzymes that have an antioxidant-response element 
(ARE) in their promoter. Nrf2 is activated by oxidation of cysteine residues 
in the Nrf2-inhibitory protein Keap1 and is therefore probably mostly sensi-
tive to increased H2O2 levels109.
Hypoxia
An added effect of the NOX2-mediated generation of superoxide anion is 
that it rapidly consumes oxygen, leading to a localized lack of oxygen (hy-
poxia). Hypoxia is not only known to influence cellular metabolism, but 
also a variety of signaling pathways, many via Hypoxia Induced Factors 
(HIFs)110–112. This is a protein family of transcription factors whose stability 
is controlled by oxygen tension. The main subunits are HIF-1α, HIF-2α and 
HIF-1β, all of which are constitutively expressed113. However, when there is 
sufficient oxygen, prolyl hydroxylases (PHDs) modify proline residues on the 
α-subunits. Von Hippel-Lindau E3 ligase (VHL) then marks these hydrox-
ylated protein for proteasomal degradation by ubiquitination110. During hy-
poxia, PHDs can no longer function efficiently, allowing HIF-1α or HIF-2α 
to bind to HIF-1β. This HIF α-β dimer will subsequently promote transcrip-
tion of its target genes by binding to hypoxic response elements (HREs) in 
their promoter region114–117. HIF target genes range from various transcrip-
tion factors to cytokines, growth factors to many genes involved in angiogen-
esis or glycolysis. Additionally, there are several inflammatory pathways with 
hypoxia-regulated components, such as differentiation, migration and ac-
tivity of macrophages, T cells and B cells118. Most target genes are controlled 
by both HIF-1α and HIF-2α, however some are specific to HIF-1α, whereas 
HIF-2α contributes only modestly to the overall hypoxic response119,120. 
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Scope of this thesis
The recognition and subsequent uptake of a pathogen is one of the most fun-
damental events in both innate and adaptive immune responses. The exact 
type of phagocytic cell, type(s) of PRR and types of cytokines and chemo-
kines in the surrounding matrix during this early event are all involved in 
steering the direction the immune response will take7,10,14. Additionally, the 
physical and chemical properties of the environment in which this takes 
place also influence the immune response. A mismatch between the sig-
nals these properties generate can often misdirect or nullify signaling in the 
phagocyte, leading to tolerance or anergy14,121. A major factor in shaping 
this environment is the generation of oxygen radicals that follows pathogen 
recognition.
The aim of this thesis is to describe the dynamics of oxygen radical gener-
ation during phagocytosis and the consequences this rapid conversion of 
molecular oxygen to radicals has on phagocyte immune responses.
In chapter 2, we describe the kinetics and dynamics of oxygen radical 
generation by dendritic cells in real time. Since the conventional fluores-
cence-based ROS probes are not quantitative and have limited temporal 
resolution, we employed a method that measures oxygen concentration to 
quantify the amount of radicals generated per phagosome. We observed 
that the cellular environment of dendritic cells quickly become hypoxic 
upon TLR engagement due to NOX2-mediated oxygen consumption. In 
chapter 3, we describe an inflammatory signaling pathway in dendritic cells 
that is activated by hypoxia in a model of bacterial infection. We found that 
this pathway specifically potentiates release of the pro-inflammatory cyto-
kine TNF-α, which is coordinated by the hypoxia-controlled expression of 
MAP3K8, which activates p38/MAPK. Dendritic cells are a key mediator of 
anti-cancer immunity due to their ability to cross-present antigens. However, 
the tumor micro-environment is often hypoxic and also has high ROS levels, 
which greatly affects the capacity of DCs and other immune cells to raise a 
strong anti-cancer immune response. In chapter 4, we provide an overview 
of these effects and conclude that the hypoxic microenvironment forms an 
immunosuppressive trap for DCs. While ROS production by DCs is critical 
for cross-presentation, the effects of ROS in the tumor microenvironment 
strongly inhibits this process. Especially the internalization of lipid peroxida-
tion products by DCs strongly inhibits an efficient anti-tumor response.
During bacterial infections, NOX2-produced radicals react rapidly and 
indiscriminately with nearby cellular components such as proteins or lipids, 
damaging cells and tissues in the process. Oxidation of lipids is especially 
damaging, since this is a self-propagating reaction. In chapter 5, we applied a 
novel method to measure the lipid peroxidation linked to bacterial infection 
by detecting ethylene, a gaseous byproduct of this reaction, in human breath. 
This method may have future application as a real-time marker for bacte-
rial infection. We also show that dendritic cells are affected by the radicals 
they generated themselves, but that this does not affect their viability. How 
oxygen radicals affect cells has been studied before, however this has always 
been done by adding radical-generating chemicals to cell cultures as a whole. 
In chapter 6, we describe a novel method to generate radicals with organellar 
precision using a genetically encoded light-sensitive radical-generating pro-
tein. We induced targeted lipid peroxidation in cells expressing this protein 
in mitochondria, Golgi or endosomal vesicles, as well as increased autopha-
gy, a protective mechanism that clears damaged components.
In summary, this thesis describes the importance of both molecular oxygen 
and oxygen radicals in DC function and several possibilities for incorporat-
ing their effects in novel diagnostic and therapeutic strategies.
Chapter 2
Human Monocyte-Derived
Dendritic Cells Produce Millimolar 
Concentrations of ROS in
Phagosomes Per Second
L.M. Paardekooper, I. Dingjan, P.T.A. Linders, A.H.J. Staal,
S.M. Cristescu, W.C.E.P. Verberk, G. van den Bogaart.
Frontiers in Immunology 10 p. 1216, 2019
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Introduction
Reactive oxygen species (ROS) are a key component of the innate immune 
response, mostly in the neutrophil oxidative burst122. When neutrophils, 
macrophages or dendritic cells phagocytose a pathogen, they rapidly acti-
vate the protein complex NOX2 (nicotinamide adenine dinucleotide phos-
phate oxidase 2) to generate superoxide anions in the phagosomal lumen41. 
Activation is mediated by binding of the three cytosolic components of 
NOX2 (p40phox, p47phox and p67phox) and the small-GTPase Rac1/2 with the 
two membrane components (p22phox and gp91phox)41. Superoxide anion can 
convert to other species of ROS, such as the highly reactive hypochlorous 
acid (HOCl) catalyzed by myeloperoxidase (MPO), which is responsible 
for the killing of ingested pathogens123,124. Because of the oxidative damage 
inflicted by bursts of ROS production, neutrophils usually die together with 
the ingested pathogen and are subsequently cleared by macrophages. It is 
estimated that superoxide generation in neutrophils can reach rates as high 
as 5 mM/second per phagosome for the duration of 10-15 minutes and then 
these rates rapidly decline within 30 minutes37–39,125. Similarly, in macro-
phages the oxidative burst lasts for ~30 min after pathogen uptake40.
In contrast, dendritic cells of the adaptive immune system exhibit prolonged 
ROS production, which plays a key role not only in the killing of ingested 
pathogens46, but also in antigen presentation and cross-presentation48,55. 
Cross-presentation is the presentation of peptides derived from ingested 
antigens on major histocompatibility complex class I (MHC-I), which is 
normally restricted to endogenous peptides15,126. This process is essential 
for building cytolytic T cell immune responses to intracellular pathogens, 
certain viruses and various forms of cancer17,127. In order for antigens to be 
presented on MHC-I, they need to be preserved and allowed to leave the 
phagosome. Three mechanisms are described by which NOX2 promotes 
antigen cross-presentation. First, the dismutation of superoxide anion to 
hydrogen peroxide consumes protons that leads to alkalization of the endo/
phagosomal lumen, which counteracts the V-ATPase, inhibits activation of 
lysosomal hydrolases with low pH-optima and thus preserves antigen for 
cross-presentation48,55,128–130. Second, we previously showed that the ROS 
produced by NOX2 can oxidize lipids of the endo/phagosomal membrane 
leading to leakage of antigen from the lumen into the cytosol where it can 
enter the MHC-I pathway56,131. Finally, cysteine residues located in the cata-
lytic core of certain cathepsin proteases can be oxidatively modified, which 
Abstract
Neutrophils kill ingested pathogens by the so-called oxidative burst, where 
reactive oxygen species (ROS) are produced in the lumen of phagosomes at 
very high rates (mM/sec), although these rates can only be maintained for 
a short period (minutes). In contrast, dendritic cells produce ROS at much 
lower rates, but they can sustain production for much longer after pathogen 
uptake (hours). It is becoming increasingly clear that this slow but prolonged 
ROS production is essential for antigen cross-presentation to activate cyto-
lytic T cells and shapes the repertoire of antigen fragments for presentation 
to helper T cells. However, despite this importance of ROS production by 
dendritic cells for activation of the adaptive immune system, their actual 
ROS production rates have never been quantified. Here, we quantified ROS 
production in human monocyte-derived dendritic cells by measuring the 
oxygen consumption rate during phagocytosis. Although a large variation in 
oxygen consumption and phagocytic capacity was present among individuals 
and cells, we estimate a ROS production rate of on average ~0.5 mM/second 
per phagosome. Quantitative microscopy approaches showed that ROS is 
produced within minutes after pathogen encounter at the nascent phagocytic 
cup. H2DCFDA measurements revealed that ROS production is sustained for 
at least ~10 hours after uptake. While ROS are produced by dendritic cells 
at an about 10-fold lower rate than by neutrophils, the net total ROS pro-
duction is approximately similar. These are the first quantitative estimates of 
ROS production by a cell capable of antigen cross-presentation. Our findings 
provide a quantitative insight in how ROS affect dendritic cell function.
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also prevents excessive degradation of antigen53,132. The last mechanism also 
alters the epitopes generated for presentation on MHC-II to helper T cells54. 
The intracellular pathogen Leishmania evades host immunity by inhibiting 
antigen cross-presentation through disruption of NOX2 delivery to pathogen 
containing phagosome130. Since the process of antigen cross-presentation in 
dendritic cells is a much subtler process than that of pathogen elimination in 
neutrophils, lower ROS production rates can be expected, yet quantifications 
of ROS production rates in the phagosomes of dendritic cells are lacking.
Most ROS measurements rely on probes that change fluorescence upon 
oxidation, such as Amplex Red, H2DCFDA or ADPA. Unfortunately, most, 
if not all, of these compounds are only responsive to certain ROS133. How-
ever, most ROS can rapidly convert to various species, such as dismutation 
of superoxide anion to hydrogen peroxide and hydroxyl anion by Fenton 
chemistry. Moreover, as ROS are unstable, they are short-lived and readily 
react with proteins, lipids and nucleic acids134, making quantitative detec-
tion by ROS-sensitive probes impossible. However, since the production of 
superoxide anion by NOX2 consumes oxygen in a 1:1 ratio, an increase in 
oxygen consumption rate (OCR) during the oxidative burst directly reflects 
the rate at which superoxide anion is produced125. In this paper, we measured 
OCRs in the culture medium of human monocyte-derived dendritic cells in 
real time. These cells are derived from blood-circulating monocytes, capable 
of both MHC-II presentation and MHC-I cross-presentation. Monocyte-de-
rived dendritic cells are positive for dendritic cell markers CD11b, CD11c, 
CD14, HLA-DR, CD83 and CD86, and negative for monocyte and macro-
phage markers CD16 and CD68135, and, although their physiological role is 
unclear, they likely represent an inflammatory type of dendritic cell. Mono-
cyte-derived dendritic cells were pulsed with opsonized zymosan particles, 
which are relatively monodisperse ~4 µm-sized yeast cell wall fractions that 
are readily ingested by phagocytosis, triggering NOX2 activity45,56,131. Com-
bined with quantitative microscopy, this allowed us to estimate the rate and 
duration of ROS production inside the zymosan-containing phagosomes of 
these dendritic cells. 
Results
We first determined the time needed for the assembly of NOX2 following 
phagocytosis. Both the membrane component gp91phox and the cytosolic 
component p67phox, which is one of the last components to be added to the 
NOX2 complex for its assembly42, were visualized by immunofluorescence 
labeling. A confocal microscopy time-series of zymosan incubation showed 
that these subunits already overlapped at the phagosomal membrane after 5 
minutes (i.e., the earliest timepoint sampled after zymosan addition), con-
firming the rapid assembly of the NOX2 complex at phagosomes (Figure 
1A). To assess whether NOX2 was assembled already at the nascent cup of 
emerging phagosomes, we also performed microscopy experiments with 
fluorescein isothiocyanate (FITC)-conjugated zymosan particles. Following 
incubation, we fixed the cells and stained with an anti-FITC antibody before 
permeabilization, as described earlier36. This allowed us to visualize nascent 
cups, as the FITC staining is only present on zymosan particles that are not 
yet completely internalized. We observed assembly of NOX2 (i.e., the pres-
ence of gp91phox and p67phox) already before closure of the phagocytic cup 
(Figure 1B-E), indicating that NOX2 is activated rapidly upon encountering 
a pathogen. In line with this, we also observed the presence of gp91phox on 
~75% of phagosomes positive for the early endosomal marker EEA1 (Sup-
plementary Figure 1). These findings corroborate our previous findings that 
gp91phox is recruited to nascent phagosomes from the plasma membrane45,131.
To obtain insight in the time scale of ROS production following zymosan 
uptake, we stimulated dendritic cells with fluorescently labeled zymosan 
together with nitrotetrazolium blue chloride (NBT). NBT forms insoluble 
formazan crystals upon oxidation and this can be visualized as dark deposits 
in the transmission channel during live cell imaging. We observed crystal 
formation within 2 minutes after attachment of a zymosan particle to a den-
dritic cell (Figure 1F). This process continued for at least 25 minutes, after 
which most NBT was converted to formazan (Figure 1G). Together, these 
results show that NOX2 is assembled already at the nascent cup of emerging 
phagosomes and ROS production occurs rapidly (i.e., within minutes) after 
zymosan attachment.
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Figure 1. NOX2 assembly at the phagocytic cup in monocyte-derived dendritic cells.
A. Representative confocal micrograph of a cell pulsed for 5 min with Alexa Fluor 633-la-
beled zymosan (magenta in merge) and immunostained for gp91phox (cyan), p67phox (yellow) 
and DAPI (blue). Scale bar: 2 µm. Graph: fluorescence intensity cross-sections over zymosan 
particles for multiple phagosomes. The bold cross-sections are from the left-hand images 
(indicated with the dotted line). 21 phagosomes from 3 donors were analyzed. B. Represen-
tative confocal micrograph of cell pulsed with FITC-labeled zymosan (magenta in merge) 
and immunostained for anti-FITC (in absence of permeabilization; yellow), p67phox (with 
permeabilization; cyan) and DAPI (blue). Yellow arrow head: phagocytic cup. White arrow 
head: closed phagosome. Note the localization of p67phox at the phagocytic cup. Scale bar: 2 
µm. 29 phagosomes from 15 cells and 3 donors were analyzed. C. Same as panel B, but for 
gp91phox (cyan). Scale bar: 2 µm. 30 phagosomes from 16 cells and 3 donors were analyzed. 
D. Mean fluorescent intensity (MFI) of p67phox in the phagosome compared to the cytosol 
after 5 minutes of zymosan stimulation (as shown in panel B). 3 donors were analyzed, 
each dot represents a single cell. p < 0.0001; paired Student’s t-test. E. Same as panel D, but 
now for gp91phox as in panel C. p < 0.0001; paired Student’s t-test. F. Representative live cell 
epi-fluorescence imaging of a cell pulsed with zymosan labeled with both Alexa Fluor 633 
(magenta) and nitrotetrazolium blue chloride (NBT) (transmission channel). Oxidation of 
NBT results in formation of dark formazan crystals (yellow arrow heads). Scale bar: 4 µm. 
Video file in supplementary movie 1. G. Quantification of NBT crystal formation before and 
25 minutes after attachment of a zymosan particle for 6 different donors (see also supple-
mentary data 1). p = 0.009; paired Student’s t-test.
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Zymosan is a potent inducer of NOX2 activation45,56,131 as it activates sig-
naling of a number of pattern recognition receptors, including Toll-like 
receptor 2 (TLR2) and the C-type lectin Dectin-1136. Indeed, Amplex Red 
measurements showed that zymosan evoked the highest ROS production 
by monocyte-derived dendritic cells when compared to the soluble TLR 
agonist lipopolysaccharide (LPS; TLR4), ovalbumin (binds to the C-type 
lectin CD206) and to the other phagocytic cargoes PAM3CSK4-coated beads 
(TLR2) and depleted zymosan (only Dectin-1) (Figure 2A). In these exper-
iments, the cells were all stimulated with the same amount of 5 particles per 
cell for the phagocytic cargoes: zymosan, PAM3CSK4-coated latex beads, 
depleted zymosan and naked latex beads (negative control). For the soluble 
ligands LPS and ovalbumin, we could not directly relate their concentrations 
to that of large phagocytic particles and used final concentrations of 1 µg/ml 
for LPS and 2.5 µg/ml for ovalbumin. We also compared ROS production of 
human monocyte-derived dendritic cells with the murine cell lines JAWS-II 
and RAW264.7 using the intracellular fluorescent ROS probe H2DCFDA137. 
JAWS-II is an immortalized cell line from mouse bone marrow and is a fre-
quently used model system for dendritic cell function capable of phagocyto-
sis and antigen presentation. RAW264.7 is derived from a murine tumor and 
is a frequently used model system for macrophages. Compared to mono-
cyte-derived dendritic cells, zymosan resulted in ~40% less ROS production 
in RAW264.7 cells, whereas zymosan hardly induced any ROS production in 
JAWS-II cells (Supplementary Figure 2).
Next, we investigated the duration of ROS production to obtain an estimate 
of the total amount of ROS produced by human monocyte-derived dendrit-
ic cells. The duration of ROS production cannot be determined with OCR 
measurements, because in a closed chamber the amount of oxygen is limit-
ed, resulting in complete depletion of oxygen, whereas in an open chamber 
the oxygen levels are also influenced by an ingress of oxygen diffusion from 
the atmosphere which is difficult to quantify. We therefore measured ROS 
production of the monocyte-derived dendritic cells with H2DCFDA137. Al-
though this probe does not allow quantitative measurements of ROS levels, 
it does allow qualitative monitoring of ROS production for extended periods 
of time after stimulation with zymosan. ROS production was still observed at 
least 10 hours post zymosan stimulation (Figure 2B). At later time points, the 
fluorescence increase of H2DCFDA in the zymosan exposed cells was similar 
to the non-stimulated control, indicating that zymosan-evoked ROS produc-
tion had stopped. Flow cytometry measurements using the fixable viability 
marker Zombie Violet showed that about ~10% of the dendritic cells died 
during the first 10 hours of zymosan incubation, whereas cell viability was 
not affected in absence of zymosan (Supplementary Figure 3).
Finally, to determine the OCRs during zymosan uptake, we measured 
real-time oxygen concentrations in the medium using a fiber optic sensor 
connected to a Fibox 3 LCD trace fiber-optic oxygen meter calibrated to 
37°C. These measurements were done in a closed 1 ml chamber contain-
ing 1∙106 monocyte-derived dendritic cells. After reaching a stable baseline 
OCR, we added zymosan at a ratio of 5 particles/cell, triggering phagocytic 
uptake and ROS production. This caused an average OCR increase from 28 
to 88 amol (1∙10-18)/cell/second (Figure 2C-D), although there was a large 
variation among donors. This large variation in ROS production within the 
human population, which is likely due to genetic and life style differenc-
es, has been reported before55 and is well known for other immunological 
readouts such as cytokine secretion. Compared to monocyte-derived den-
dritic cells, a more than tenfold higher rate of oxygen consumption was 
found in blood-isolated neutrophils following zymosan addition using the 
same methodology (Figure 2E; 1,059 amol/cell/second), which is in line with 
previous report37–39. To account for potential upregulation of cell metabolism 
following zymosan stimulation, we also treated monocyte-derived dendritic 
cells with the respiratory chain complex I inhibitor rotenone, which blocks 
oxidative phosphorylation138. We found that the increase in OCR following 
zymosan addition was comparable to cells not treated with rotenone (Figure 
2F; from 4 to 67 amol/cell/sec). Conversely, inhibition of the pentose phos-
phate pathway using 6-aminonicotinamide (6-AN), which blocks generation 
of the NOX2 substrate NAD(P)H, completely abrogated zymosan-induced 
oxygen consumption (Figure 2G). These findings confirm the well-known 
role of NOX2 in TLR-evoked ROS production in human monocyte-derived 
dendritic cells46,55,56,131.
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Figure 2. Determination of the oxygen consumption rate (OCR) of monocyte-derived 
dendritic cells following zymosan exposure.
A. ROS production by monocyte-derived dendritic cells exposed to a range of phagocytic 
cargoes and soluble TLR stimuli as determined by Amplex Red fluorescence. MFI: mean 
fluorescence intensity. Shown is the average of 3 donors ± SEM. The table shows results from 
linear regression analysis on the integrated curves (***: p < 0.001; ** p < 0.005; * p < 0.01). 
B. ROS production by zymosan-exposed monocyte-derived dendritic cells as determined 
by H2DCFDA fluorescence. MFI: mean fluorescence intensity. Shown is the average of 3 
donors ± SEM. p < 0.0001; linear regression analysis on the integrated curves. C. Temporal 
decline in oxygen levels in the culture medium before and after stimulation with zymosan 
in a closed container of a representative donor. D. Difference in oxygen consumption rate 
of monocyte-derived dendritic cells before and after stimulation with zymosan in a closed 
container. Each data point presents an individual donor (n = 9). p = 0.0005; paired Student’s 
t-test. E. Same as panel D, but with neutrophils (n = 3). p = 0.0143; paired Student’s t-test. 
F. Difference in oxygen consumption rate in monocyte-derived dendritic cells before and 
after stimulation with zymosan with simultaneous addition of the mitochondrial complex 
I inhibitor Rotenone (n = 3). p = 0.0256; paired Student’s t-test. (G) Difference in oxygen 
consumption rate before and after stimulation with zymosan in a closed container in cells 
pre-incubated for 1 hour with the glucose-6-phosphate dehydrogenase inhibitor 6-aminon-
icotinamide (6-AN) (n = 3). p = 0.9868; paired Student’s t-test. H. Frequency distribution 
of the number of zymosan particles taken up by monocyte-derived dendritic cells following 
30 minutes exposure to zymosan (99 cells pooled for 3 different donors; bin size: 1 particle). 
Insert: Representative epi-fluorescence microscopy image of a cell with phagocytosed Alexa 
Fluor 633-labelled zymosan (magenta). Scale bar: 10 µm. I. Frequency distribution of the 
volume of zymosan particles from microscopy (521 zymosan particles in total; bin size: 5 
µm3). J. Model figure of NOX2 activity during phagocytosis by monocyte-derived dendrit-
ic cells. NOX2 is already assembled and active before closure of the phagocytic cup and 
remains active on the phagosomal membrane for on average at least 10 hours. NOX2-medi-
ated conversion of oxygen (O2) to superoxide anion (O2•-) results in a production rate of ROS 
of approximately 0.5 mM/second.
These results indicate that on average 60 amol superoxide/cell/second was 
produced following zymosan addition. As quantitative microscopy showed 
that approximately 3 zymosan particles were ingested per cell (Figure 2H), 
this means that ~20 amol/second of superoxide anion is produced per 
phagosome. Because most zymosan particles are ~40 µm3 in size (or ~40 
fL) (Figure 2I), the average net superoxide anion production rate is ap-
proximately 0.50 mM/second within the phagosome. Combined with our 
estimation of the duration of ROS production by H2DCFDA measurements 
(Figure 2B), we estimate that the total amount of superoxide anion produced 
is approximately 720 fmol/phagosome, or about 4.2∙1011 molecules/phago-
some. Again, due to the large variation in phagocytic uptake among cells and 
oxygen consumption among donors55, this number is only a coarse estimate 
and is expected to vary widely among cells and donors.
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Discussion
In this study, we estimated the production of ROS by NOX2 in zymo-
san-containing phagosomes of human monocyte-derived dendritic cells. 
By subtracting baseline oxygen consumption from total cellular oxygen 
consumption following zymosan addition, we estimate a ROS production 
of approximately 0.50 mM/phagosome/second. This estimate is based on 
the assumption that the majority of ROS is produced within phagosomes as 
supported by our finding that assembled NOX2 is mostly located at phago-
somes. Moreover, we found that monocyte-derived dendritic cells assemble 
the NOX2 complex already at the nascent cup of phagosomes, allowing them 
to generate ROS within minutes upon encountering a pathogen, similar to 
neutrophils and macrophages38 (Figure 2J). The presence of NOX2 already 
at the phagocytic cup is in line with observations from our45,139 and other55 
laboratories that NOX2 is assembled during phagosome formation, remains 
present during the early phase of phagosomal maturation (early markers 
EEA1 and phosphatidylinositol 3-phosphate) and is removed from phago-
somes upon maturation to the late LAMP1 and V-ATPase positive stage. 
Unfortunately, direct quantitative measurements of ROS within the lumen of 
phagosomes are not technically feasible at present, but since our microscopy 
showed that assembled NOX2 was mainly present at phagosomal mem-
branes, we consider our assumption that the majority of ROS is produced 
within phagosomes justified. Our estimated ROS production of approxi-
mately 0.50 mM/phagosome/second should be regarded as a coarse estimate, 
since there is large variation in terms of phagocytic activity and oxygen 
consumption among individual cells as well as between different donors (see 
also Mantegazza et al., 200855). In addition, our ROS measurements show 
that these numbers differ depending on the TLRs that are stimulated (Figure 
2A). Nevertheless, despite being a coarse estimate, our results provide at least 
an order of magnitude of the ROS production in monocyte-derived dendrit-
ic cells.
Our data show that the ROS production in phagosomes of monocyte-de-
rived dendritic cells is about an order of magnitude lower than the 5 mM/
phagosome/seconds estimated for neutrophils37–39. However, we found that 
ROS production in dendritic cells is sustained for approximately 10 hours af-
ter uptake, which is at least an order of magnitude longer than in neutrophils 
and macrophages37–40. This means that although dendritic cells produce ROS 
at a lower rate, the cumulative ROS production over time in dendritic cells 
and neutrophils could be approximately similar. Viability of dendritic cells in 
this time frame is not much affected as ~90% of zymosan-pulsed cells sur-
vive. As noted in the introduction, both the lower, sustained ROS production 
and the maintained viability likely relate to the unique immune function of 
dendritic cells by promoting ROS-mediated MHC-I antigen cross-presenta-
tion to cytolytic T cells48,53,55,56,128–132 and modulating the epitope repertoire for 
MHC-II presentation to helper T cells54. The reduced activation of lysosomal 
proteases by ROS48,53,128,129,132 could also allow the antigen to be preserved for 
the time that the dendritic cell needs to travel from a site of infection to the 
nearest lymph node to present antigen to T cells99. The comparatively low but 
prolonged activity of NOX2 and their prolonged viability therefore directly 
contribute to the antigen presenting capacity of dendritic cells.
Given the role of phagosomal ROS in antigen presentation48,53–56,128–132, it 
would be interesting to measure ROS production by the three major types 
of dendritic cells found in human peripheral blood: plasmacytoid dendritic 
cells and CD1c and CD141 positive myeloid dendritic cells140. Plasmacytoid 
dendritic cells produce large amounts of type I interferons in response to 
microbial or viral infections and are key effectors of innate immunity and 
helper and cytolytic T cell priming141. Both CD1c and CD141 positive my-
eloid dendritic cells can produce large amount of interleukin-12 to promote 
Th1 responses and cytolytic T cell priming. Both these myeloid dendritic cell 
subsets can also cross-present exogenous antigens to prime naive cytolytic 
T cells142–147. It will also be interesting to measure ROS production by mono-
cyte-derived macrophages, which, although their ROS production is lower 
compared to dendritic cells55, are also capable of cross-presentation148.
Next to antigen presentation, a second effect of NOX2 activity is metabol-
ic reprogramming caused by the rapid consumption of both NADPH and 
oxygen112,149. An oxidative cellular redox state influences metabolism, and via 
this way promotes for example monocyte differentiation into pro-inflamma-
tory effector cells150. Moreover, ROS and its derivatives, particularly hydro-
gen peroxide and lipid aldehydes, are able to traverse membranes and signal 
inflammation in neighboring cells65,66. Thereby, ROS can amplify the inflam-
matory immune response, leading to production of more ROS. Thus, ROS 
have important functions in both innate and adaptive immune responses 
and having quantitative information on ROS generation is crucial for under-
standing dendritic cell function112.
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Methods
Cells
Dendritic cells were derived from human peripheral blood mononuclear 
cells (PBMCs) by IL-4 and GM-CSF as described previously99. Neutrophils 
were isolated from heparinized venous blood by Ficoll-Histopaque (Sigma 
Aldrich, St. Louis, USA) density gradient centrifugation followed by hy-
potonic erythrocyte lysis 151. Buffy coats and whole blood were obtained as 
anonymous coded specimens from the Dutch blood bank (Sanquin) and 
were handled according to known practice and legal guidelines. The re-
search with human blood samples at the Department of Tumor Immunol-
ogy complies with all institutional and national ethics regulations and has 
been approved by the ethics committee of Sanquin. All blood donors were 
informed of the research and have granted their consent. The age range of 
the donors was between 30 and 60 years. For OCR measurements, cells were 
cultured in phenol-red free RPMI-1640 (Thermo Fisher Scientific, Waltham, 
USA). JAWS-II (American Type Culture Collection (ATCC), CRl-11904) 
were cultured in MEM Alpha (Thermo Fisher Scientific) supplemented with 
20% FBS (Greiner Bio-one, Kremsmünster, Austria), 5 mM UltraGlutamine 
(Lonza, Basel, Switzerland), 1 mM sodium pyruvate (Thermo Fisher Sci-
entific), 0.05 mM 2-mercaptoethanol, 10 ng/ml recombinant mouse GM-
CSF and 1% antibiotic-antimycotic (Thermo Fisher Scientific). RAW264.7 
(ATCC, TIV-71) cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (Thermo Fisher) supplemented with 10% FBS (Greiner Bio-one), 2 
mM UltraGlutamine (Lonza) and 1% antibiotic-antimycotic (Thermo Fish-
er Scientific). Cells were stimulated with zymosan A (from Saccharomyces 
cerevisiae, Sigma-Aldrich, St. Louis, USA; 5 particles/cell), LPS (Lipopolysac-
charides from Escherichia coli O111:B4; Sigma Aldrich; final concentration 
of 1 µg/ml), PAM3CSK4 (InvivoGen, Toulouse, France) coated latex beads 
(5 beads/cell), depleted zymosan (InvivoGen; 5 particles/cell), naked latex 
beads (5 beads/cell), soluble ovalbumin (final concentration of 2.5 µg/ml; 
Endofit ovalbumin, InvivoGen) or Alexa Fluor 633-labelled zymosan A in 
serum-free RPMI-1640 (5 particles/cell). To inhibit NOX2 activity by block-
ing generation of NAD(P)H, cells were pre-incubated for 1 hour with 10 µM 
6-aminonicotinamide (Sigma Aldrich). To block mitochondrial respiration 
by inhibition of respiratory complex I, rotenone (Sigma Aldrich) was added 
together with the zymosan stimulus to a final concentration of 500 nM.
H2DCFDA measurements
Cells were loaded for 10 minutes with 10 µg/ml 2’,7’-dichlorodihydrofluores-
cein diacetate (H2DCFDA, Thermo Fisher Scientific) in DMSO, stimulated 
with 5 particles/cell of zymosan and fluorescence (ex: 485/20, em: 530/30) 
was measured using a CytoFluor II microplate reader (Thermo Fischer Sci-
entific). Background fluorescence was subtracted from all measurements.
Amplex Red measurements
50.000 monocyte-derived dendritic cells were stimulated with the stimuli 
specified above and plated in individual wells of a clear flat-bottom 96-wells 
plate. Cells were subsequently incubated for 1 hr at room temperature. After 
incubation, supernatant was removed and cells were washed once with phos-
phate-buffered saline. 50 µL Amplex Red (Thermo Fisher Scientific) mix (25 
µM Amplex Red and 0.1 U HRP in phosphate-buffered saline) was added to 
each well. Amplex Red fluorescence was measured every 10 minutes using a 
CytoFluor II microplate reader (excitation: 530/25, emission: 590/35)  (Ther-
mo Fisher Scientific).
Microscopy
Live cell imaging was performed on a Leica DMI-6000B inverted epi-fluo-
rescence microscope using a Leica HCX PL APO 40x/0.85 objective. NOX2 
assembly was imaged on a Leica SP8 confocal using a Leica HC PL APO 
CS2 63x/1.2 water immersion objective. For immunofluorescence, cells were 
fixed with 4% paraformaldehyde in PBS for 20 minutes, then permeabilized 
with 0.1% saponin in PBS. NOX2 subunits were stained using the following 
antibodies: mouse monoclonal IgG1 anti-CYBB (1:200; D162-3 MBL Inter-
national, Woburn, USA), rabbit polyclonal IgG anti-gp91 (1:100; ab180642 
Abcam, Cambridge, UK and rabbit polyclonal IgG anti-p67 (1:500; 07-002 
Millipore-Sigma, Burlington, MA, USA). EEA1 was stained with mouse 
monoclonal IgG1 anti-EEA1 (1:100; 610456 BD Biosciences, San Jose, CA, 
USA). Coverslips were mounted in mounting medium containing 0.01% 
Trolox (6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) and 68% 
glycerol in 200 mM sodium phosphate buffer at pH 7.5 with 0.1 µg/ml DAPI. 
Recruitment of NOX2 subunits gp91phox and p67phox was quantified by com-
paring fluorescent intensities in the cytosolic regions to phagosomal mem-
brane regions selected by thresholding for fluorescent zymosan particles 
partially or completely negative for FITC.
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NBT assay
Cells were incubated with 12 µg/ml NBT (Hoffmann-La Roche, Rish-Rot-
kreuz, Switzerland) in Live Cell Imaging Solution (Thermo Fisher Scientific) 
and stimulated with Alexa Fluor 633-labelled Zymosan A (5 particles/cell). 
Formazan crystal formation was quantified in regions of interest by thresh-
olding on the fluorescence of the zymosan particles using a custom imageJ 
script (Supplementary data 1) and measuring the intensities of these regions 
of interest in the bright-field channel. As NBT crystals are dark, pixel intensi-
ty decreases upon formation of NBT crystals and we normalized all values to 
those measured in the first frame.
OCR measurements
The OCR during zymosan uptake was measured on 1∙106 cells in a closed 1 
ml chamber, using a fiber optic trace oxygen meter (PreSens Precision Sens-
ing, Regensburg, Germany) with an Oxygen Sensor Spot (PreSens) placed 
inside. Measurement conditions were 37°C and 1 atm. Upon reaching a 
steady baseline OCR, 5 zymosan particles/cell were added by injection.
Viability assay
Cells were washed with PBS and incubated for 30 minutes with Zombie 
Violet fixable viability dye (1:2000 in PBS) (BioLegend, San Diego, CA, USA) 
in a V-bottom 96-well plate at 100.000 cells per well. Cells were then washed 
and fixed for 5 minutes in 4% paraformaldehyde in PBS and analyzed on a 
FACS Lyric flow cytometer (BD Biosciences).
Statistical analysis
Paired Student’s t-tests were applied to assess significance, unless indicated 
otherwise. For multiple comparisons, a repeated measures ANOVA with 
Bonferroni post-hoc testing was applied. For the H2DCFDA time course 
experiments and the comparison between various TLR stimuli, we integrat-
ed the curves and compared the slopes using linear regression analysis in 
Graphpad Prism 5.
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Supplementary Data
ImageJ script used for analysis of formazan crystal formation
windowname = getTitle();
roiManager(“Reset”);
//run(“Clear Results”); //Comment this command back in to 
clear the results window before each measurement.
/* Duplicates the channel containing zymosan 633 emission 
(channel 2).
 * Runs a user-defined threshold to generate ROIs for zymo-
san-633 positive particles.
 * Includes particles sized 12 square micrometer and up.
 */
run(“Channels Tool...”);
 Stack.setDisplayMode(“color”);
run(“Duplicate...”, “duplicate channels=2”); // Channel 2 
contains zymosan-633 signal.
 setAutoThreshold(“Default dark”);
run(“Threshold...”);
 waitForUser(“set appropriate threshold”); 
 setOption(“BlackBackground”, false);
run(“Convert to Mask”, “method=Default background=Dark calcu-
late”);
run(“Analyze Particles...”, “size=12-infinity include add 
stack”);
close();
/* Fits an ellipse around every ROI and enlarges it to in-
clude NBT signal in the entire phagosome.
 *  Then, measures MFI in transmission channel (channel 1) 
based on ROIs.
 */
run(“Set Measurements...”, “area mean standard display redi-
rect=None decimal=3”);
selectWindow(windowname);
Stack.setChannel(1); //Channel 1 contains bright field im-
age.
count = roiManager(“count”);
for (j=0; j<count; j++){
 roiManager(“select”, j);
 run(“Fit Ellipse”);
 run(“Enlarge...”, “enlarge=1”); //Enlarges ellipse 
by 1 micron.
 run(“Measure”);
 }
Supplementary Figure 1
gp91phox EEA1
merge
(zymosan + DAPI)
gp
91
ph
ox
ne
ga
tive gp
91
ph
ox
po
siti
ve
0
25
50
75
100 *
%
 o
f E
EA
1+
 p
ha
go
so
m
es
gp91phox is present on EEA1-positive phagosomes.
Representative confocal micrograph of monocyte-derived dendritic cell pulsed with Alexa 
fluor 633-labeled zymosan (magenta in merge) for 5 minutes and immunostained for 
gp91phox (cyan) and EEA1 (yellow). Arrowhead indicates a phagosome. The graph shows 
EEA1-positive phagosomes that were blindly assessed manually as positive or negative for 
gp91phox (n = 3, at least 40 phagosomes per donor). p = 0.0207; paired Student’s t-test.
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Supplementary Figure 2
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Abstract
Dendritic cells (DCs) constantly sample peripheral tissues for antigens, 
which are subsequently ingested to derive peptides for presentation to T-cells 
in lymph nodes. To do so, DCs have to traverse many different tissues with 
varying oxygen tensions. Additionally, DCs are often exposed to low oxy-
gen tensions in tumors, where vascularization is lacking, as well as in in-
flammatory foci, where oxygen is rapidly consumed by inflammatory cells 
during the respiratory burst. DCs respond to oxygen levels to tailor immune 
responses to such low-oxygen environments. In this study, we identified a 
mechanism of hypoxia-mediated potentiation of release of tumor necrosis 
factor alpha (TNF-α), a pro-inflammatory cytokine with important roles in 
both anti-cancer immunity and autoimmune disease. We show in human 
monocyte-derived DCs that this potentiation is controlled exclusively via 
the p38/MAPK pathway. We identified MAP3K8 as a target gene of Hypox-
ia Induced Factor (HIF), a transcription factor controlled by oxygen ten-
sion, upstream of the p38/MAPK pathway. Hypoxia increased expression 
of MAP3K8 concomitant with the potentiation of TNF-α secretion. This 
potentiation was no longer observed upon siRNA silencing of MAP3K8 or 
with a small molecule inhibitor of this kinase, and this also decreased p38/
MAPK phosphorylation. However, expression of DC maturation markers 
CD83, CD86 and HLA-DR were not changed by hypoxia. Since DCs play an 
important role in controlling T-cell activation and differentiation, our results 
provide novel insight in understanding T-cell responses in inflammation, 
cancer, autoimmune disease and other diseases where hypoxia is involved.
Introduction
Dendritic cells (DCs) are the gatekeepers of the adaptive immune system, 
residing throughout peripheral tissues where they constantly sample for 
antigens13,14. When a DC encounters a foreign antigen, it secretes many 
inflammatory cytokines, including tumor necrosis factor α (TNF-α), that 
activate or repress the functions of other immune cells and contribute to an 
inflammatory disease state. Extracellular antigens can be ingested by endocy-
tosis or phagocytosis, processed in the endolysosomal system and presented 
on major histocompatibility complex (MHC) class I and II on the surface 
of DCs. During this process, DCs traverse from the site of inflammation to 
the nearest draining lymph node, where they activate naive CD4+ and CD8+ 
T cells152. For the sampling of antigen and the traveling to the lymph node, 
a DC can pass many different tissues that display a wide range of oxygen 
levels, from almost atmospheric oxygen levels in the lung (20%) to hypoxic 
(<1%) oxygen tensions in the thymus and spleen153. On top of this, many 
disease states are characterized by low local oxygen levels. For example, the 
central region of solid tumors is very hypoxic due to a lack of vasculariza-
tion154,155. Moreover, sites of infection and inflammation are often hypoxic 
microenvironments, due to the combination of reduced perfusion following 
physical damage and the high metabolic load of the activated inflammatory 
cells caused by the respiratory burst156,157. Hypoxia has been linked to many 
auto-inflammatory diseases, including diabetes and atherosclerosis158–160. 
In cancer, hypoxia induces the neovascularization that can promote tumor 
growth and possibly cancer cell metastasis155. Hypoxia can also be a direct 
driver of metastasis by inducing single-cell dissemination161.
Oxygen levels are known to modulate many cellular processes, including 
metabolism, cell survival and various signaling pathways110,111. The most 
important class of oxygen-sensitive signaling proteins is hypoxia induced 
factor (HIF). HIFs are basic helix–loop–helix heterodimeric transcription 
factors involving three main subunits: HIF-1α, HIF-2α and HIF-1β110,111,114. 
All three subunits are constitutionally expressed, but under normoxic 
conditions proline residues on the α-subunits are modified by prolyl hydrox-
ylases (PHDs) in a process that consumes oxygen. After this hydroxylation, 
the Von Hippel-Lindau E3 ligase (VHL) can trigger ubiquitination of the 
α-subunit leading to subsequent proteasomal degradation110. Under hypox-
ic conditions, PHD does not efficiently hydroxylate the α-subunit due to 
lack of oxygen, allowing HIF-1α or HIF-2α to dimerize with HIF-1β. These 
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HIF complexes will then promote transcription of genes carrying hypoxic 
response elements (HREs) in their promoter regions115,116,162.
Oxygen levels regulate the mammalian immune response, as it was 
recently shown that mice negative for HIF-1α fail to clear invasive bacterial 
infections162. Oxygen levels also modulate DC differentiation and the acti-
vation triggered by maturation stimuli such as lipopolysaccharide (LPS), a 
bacterial ligand of Toll-like receptor 4 (TLR4)158,162,171–179,163–170. Specifically, 
hypoxic DCs were shown to have increased levels of HIF-1α, a metabolism 
shifted to glycolysis165,166,168, and altered expression of chemokines and 
chemokine receptors affecting DC migration163,165,167,169,179. The effect of 
hypoxia on the expression of DC-maturation markers (e.g., CD80, CD83, 
CD86, MHC-II) is controversial , with both reductions164,167,171,173,177–179, in-
creases165,166, and no effect163,170 being reported. Similarly, both increased166 
and reduced167,179 efficiencies of T cell activation by hypoxic DCs, and both 
stimulatory166,167,171 and inhibitory173,177,179 effects of hypoxia on TLR-induced 
cytokine release (e.g., interleukin (IL)-6, IL-10, IL-12, TNF-α) have been 
reported. 
The controversial findings of hypoxia on DC function likely arise from the 
fact that HIF not only modulates TLR signaling180, but TLR stimulation in 
turn also affects HIF signaling172,174,181. TLR stimulation can promote the sta-
bilization of HIF as well as upregulate its expression172,174. The group of target 
genes regulated by HIF differs between activation of HIF via TLR-stimula-
tion or hypoxia174 and this cross-talk between HIF and TLR signaling likely 
allows for fine-tuning of the cellular immune responses against different 
types of infections and disease states. However, the molecular mechanisms of 
the interplay between TLR and hypoxic signaling are still largely unknown. 
In this study, we describe a pathway by which hypoxia potentiates TNF-α 
secretion by human monocyte-derived dendritic cells (moDCs). MoDCs are 
differentiated from blood-isolated monocytes by culturing with interleukin-4 
(IL-4) and granulocyte-macrophage colony–stimulating factor (GM-CSF). 
Although their physiological role is unclear, moDCs are capable of migration 
to lymph nodes and of both MHC-I and II presentation163,165,178,179,167–171,175–177. 
We show an increase of LPS-induced secretion of TNF-α by moDCs upon 
hypoxia, in line with previous findings166,167. Our data show that this po-
tentiation is caused by hypoxia-promoted expression of mitogen-activated 
protein kinase kinase kinase 8 (MAP3K8; TPL-2; COT), which is a kinase 
involved in the MAP3K signaling pathway downstream of TLR4. Given the 
essential roles of DCs in T cell activation and differentiation, our results are 
important for understanding T cell responses in cancer, infection, autoim-
munity and other diseases and disorders associated with hypoxia.
Results
We started by studying the interplay of hypoxia and infection on the 
secretion of IL-6 and TNF-α. We used DCs differentiated from monocytes 
isolated from the blood of healthy volunteers by culturing in the pres-
ence of IL-4 and GM-CSF (moDCs). MoDCs are capable of endocyto-
sis, phagocytosis, antigen (cross-)presentation and activation of T cells 
and are a widely used model system for studying hypoxia on DC func-
tion163,165,178,179,167–171,175–177. Although moDCs are also found in vivo, they 
differ from conventional blood-circulating dendritic cell subsets and there 
has been an ongoing debate about their exact physiological role182–184. We 
characterized our moDC cultures by measuring expression of several DC, 
monocyte and macrophage surface markers. MoDCs were found to be a 
homogeneous population of CD11c+/CD11b+/CD16-/CD68- cells, of which 
~87% also expressed CD14+ (Supplementary Figure 1F-I). These results 
show that our cells are composed mainly of DC-like cells which express 
high levels of the DC marker CD11c. Monocytic lineage markers CD14 
and CD11b were also highly expressed, whereas only low expression of the 
monocyte/macrophage markers CD16 and CD68 was observed. The moDCs 
were cultured in a hypoxic environment of 1% oxygen, or in an atmospheric 
environment of 20% oxygen. Similar to previous reports163,166,170,171,177, flow 
cytometry experiments showed that culturing DCs overnight under hypoxic 
conditions did not significantly affect cell viability (Figure 1A-C). Culturing 
under hypoxic conditions trended towards decreased CD14 expression and 
a non-consistent increase of CD68 expression, however these differences are 
not significant. Expression of all other tested surface markers was unaltered 
(Supplementary Figure 1K-S).
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Figure 1. Hypoxia potentiates LPS-induced TNF-α secretion.
A-C. Cell viability of moDCs during atmospheric (20% O2) and hypoxic (1% O2) oxygen 
levels in presence or absence of LPS, determined by Zombie Violet as analyzed by flow cy-
tometry. Representative dot plot (A), histograms (B) and quantification for 3 donors (C; av-
erage ± SEM) are shown. D-I. LPS-induced maturation of moDCs cultured at atmospheric 
or hypoxic oxygen levels, determined by expression levels of maturation markers CD83 (D, 
G), CD86 (E, H) and HLA-DR (F, I). Representative histograms shown, as well as quantifi-
cation for 5 donors. J-K. Secretion by ELISA of the pro-inflammatory cytokines TNF-α (J) 
and IL-6 (K) from moDCs cultured at atmospheric or hypoxic oxygen levels. Quantification 
from 10 donors (average ± SEM) (*** p < 0.001; ** p < 0.005; * p < 0.05).
To stimulate an inflammatory response, we cultured the moDCs in the 
presence of LPS. Compared to LPS at atmospheric oxygen levels, LPS with 
hypoxia did not result in significant changes in surface expression of the 
maturation markers CD83 and CD86 (Figure 1D, E, G, H), as reported pre-
viously163,165,178, but contrasting with other studies166,167,171,173,177. Surface levels 
of MHC-II were also not changed by hypoxia (Figure 1F, I), which again 
corresponds with some studies163,165, while other studies report higher166 or 
lower164,167,173,177–179 MHC-II levels upon hypoxia. We observed the strongest 
potentiation for production of TNF-α, where hypoxia resulted in an about 
2-fold significant increase of LPS-triggered TNF-α secretion compared to 
atmospheric oxygen (Figure 1J). The increase in LPS-induced IL-6 secretion 
upon hypoxia was not significant compared to atmospheric oxygen levels 
(Figure 1K). A potentiation in TLR-stimulated TNF-α secretion by DCs 
upon hypoxia has been reported previously in some 166,167, but not all173,179, 
studies. Moreover, hypoxia-mediated potentiation of TNF-α secretion has 
been observed for macrophages116, osteoblasts185 and human hepatocellular 
carcinoma cells180. 
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Figure 2. Hypoxia-mediated potentiation of TNF-α secretion is controlled by p38/
MAPK.
A-F. Effects of inhibitors of p38/MAPK (1 µM SB203580; A-B, E-F) and/or IkB kinase (100 
nM IKK-16; C-F) on LPS-induced TNF-α secretion by moDCs cultured under atmospheric 
(20% O2; A, C, E) or hypoxic (1% O2; B, D, F) oxygen levels. Individual donors shown. G-H. 
Effects of SB203580 and/or IKK-16 on moDC viability, determined by flow cytometry with 
labeling with Zombie Violet as analyzed by flow cytometry. Representative histograms (G) 
and quantification for 4 donors (H; average ± SEM) (ns: not significant; *** p < 0.001; ** p < 
0.005; * p < 0.05).
TLR4 stimulation triggers TNF-α secretion via two distinct signaling 
pathways. In the first pathway, TNF-α expression is upregulated by activated 
nuclear factor kappa B (NF-κB) following IκB kinase (IKK) phosphorylation 
by TLR4. In the second pathway, TNF-α secretion is mediated via p38/
MAPK signaling, which is activated in tandem with NF-κB following TLR4 
stimulation186,187. We used specific inhibitors to elucidate the contribution 
of each pathway in the hypoxia-mediated potentiation of TNF-α secretion. 
Inhibition of p38/MAPK with SB203580, which inhibits the downstream 
catalytic activity of p38188,189, did not affect LPS-triggered TNF-α secretion 
under atmospheric oxygen levels (Figure 2A). In contrast, under hypoxic 
conditions, SB203580 resulted in a consistent and significant reduction 
of TNF-α secretion (Figure 2B). Blockage of IKK, which is responsible 
for activation of NF-κB190,191, by IKK-16 blocked TNF-α secretion almost 
completely (to ~20% of untreated) both under atmospheric and hypoxic 
conditions (Figure 2C-D). Simultaneous addition of both SB203580 
and IKK-16 had a comparable effect (Figure 2E-F). The residual TNF-α 
secretion might be due to incomplete inhibition of the NF-κB and/or p38/
MAPK pathways or due to the involvement of other signaling pathways. 
Under our conditions, SB203580 and IKK-16 did not affect the viability of 
the cells (Figure 2G-H). These findings suggest that the hypoxia-mediated 
potentiation of TNF-α release primarily occurs via increased activation 
of the p38/MAPK signaling pathway, while the IKK signaling pathway is 
activated by LPS irrespective of oxygen levels. In line with this, hypoxia was 
reported to promote TLR2 and TLR4-induced pro-inflammatory activation 
of macrophages via the p38/MAPK pathway, but not via IKK signaling192. 
In contrast to macrophages193, surface expression of TLR2 and TLR4 was 
unaffected by hypoxia (Supplementary Figure 2A-D), suggesting that the 
increased TNF-α secretion was not caused by increased expression of these 
pattern recognition receptors.
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Figure 3. LPS-induced phosphorylation of p38/MAPK is increased by hypoxia.
A. Representative Western blot of moDCs cultured at atmospheric (20% O2) or hypoxic (1% 
O2) oxygen levels and in presence or absence of LPS. The blot was stained with an antibody 
specific for phosphorylated p38/MAPK (top) and total p38/MAPK (bottom). B. Quantifi-
cation of panel A for 5 donors. p38/MAPK phosphorylation during hypoxic inflammation, 
normalized to unstimulated cells at atmospheric oxygen levels (LPS-, 20% O2) (* p < 0.05).
To directly investigate the activation of the p38/MAPK pathway by hypoxia 
and LPS, we determined activation of p38 by Western blot with phosphos-
pecific antibodies (Figure 3A). As described previously, LPS treatment of 
dendritic cells leads to activation of p38 by phosphorylation of the residues 
threonine 180 and tyrosine 182194. We observed a 3- to 4-fold increase of 
phosphorylated p38 upon LPS stimulation compared to unstimulated cells at 
atmospheric oxygen levels. Culturing the cells under hypoxic conditions in 
presence of LPS led to a further significant increase in p38 phosphorylation 
by about 50%, this increase was non-significant in absence of LPS (Figure 
3B). 
Hypoxia is well-known to increase expression of genes with an HRE in their 
promoter via the transcription factor HIF114,115. We therefore searched for 
genes coding for components in the p38/MAPK pathway carrying one or 
more HREs in their promoter. We identified MAP3K8 as a candidate gene 
downstream of HIF, since it is known to have a HIF-1β binding site and is 
upregulated under hypoxia116,119,195. Indeed, we identified 3 HREs and a HIF-
1 specific binding site upstream of the MAP3K8 gene on chromosome 10 
(GenBank accession AL161651.13) using PROMO (Figure 4A)196,197. Reverse 
transcriptase PCR showed that MAP3K8 is expressed in moDCs (Figure 4B). 
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Figure 4. Hypoxia increases expression of HIF-target gene MAP3K8.
A. Positions and sequences of hypoxic response elements (HRE) and HIF-binding site (HIF-
1) in the promoter region of human MAP3K8. B. MAP3K8 mRNA expression by moDCs 
as determined by PCR on cDNA obtained from unstimulated moDCs. Expected band size 
is 201 bp. C. mRNA expression levels of MAP3K8 in moDCs cultured at atmospheric or 
hypoxic conditions in absence or presence of LPS determined by RT-qPCR. Quantification 
from 6 donors (p < 0.001; ** p < 0.005; * p < 0.05).
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Since MAP3K8 is a key mediator of p38/MAPK signaling, we hypothesized 
that the hypoxia-induced TNF-α potentiation occurred via increased 
expression of MAP3K8. To address this hypothesis, we cultured moDCs 
under atmospheric or hypoxic conditions and with or without addition 
of LPS, followed by mRNA isolation to analyze expression of MAP3K8 by 
real-time quantitative PCR (RT-qPCR). Hypoxia led to a significant ~2-
fold increased expression of MAP3K8 in absence of LPS (Figure 4C). In the 
presence of LPS, this increase was even more pronounced and we observed 
an average ~14-fold increase in MAP3K8 expression. Overall, the expression 
of MAP3K8 mirrors the potentiation of TNF-α secretion by a combination 
of LPS and hypoxia (Figure 1J) and is in qualitative agreement with the 
increased phosphorylation of p38 (Figure 3B). These findings support our 
hypothesis that MAP3K8 potentiates LPS-induced TNF-α secretion under 
hypoxic conditions.
To obtain direct evidence that MAP3K8 is a key factor linking hypoxia to 
potentiation of LPS-stimulated TNF-α secretion, we performed knock-down 
experiments in moDCs where we targeted MAP3K8 with siRNA (MAP3K-
8siRNA). As a negative control, we transfected the moDCs with non-targeting 
siRNA. With this technique, we obtained an average reduction of about 40% 
of MAP3K8 at the protein level, as quantified by Western blot (Figure 5A-B). 
MAP3K8siRNA blocked the hypoxia-mediated potentiation of LPS-stimulated 
TNF-α secretion (Figure 5C). Phosphorylation of p38 was also reduced in 
MAP3K8siRNA moDCs following LPS stimulation at hypoxic, but not at atmo-
spheric oxygen levels (Figure 5D-E).
We further validated the role of MAP3K8 in potentiation of TNF-a secre-
tion with the small molecule inhibitor 4-[(3-chloro-4-fluorophenyl)ami-
no]-6-[(3-pyridinylmethyl)amino]-1,7-naphthyridine-3-carbonitrile (Tpl2 
Kinase Inhibitor). This molecule inhibits MAP3K8 by blocking binding of 
ATP to MAP3K8198 and did not affect cell viability (Figure 5G). In line with 
the results obtained with siRNA knock-down, we observed that overnight 
incubation with this inhibitor together with LPS stimulation decreased the 
hypoxia-mediated potentiation of TNF-α secretion (Figure 5F). We also 
investigated phosphorylation of p38/MAPK following incubation with this 
inhibitor (Supplementary Figure 3A-B), and while we observed a reduc-
tion of LPS-mediated p38/MAPK phosphorylation under hypoxic condi-
tions, this was not statistically significant. Together, these findings support 
that MAP3K8 promotes TLR-mediated TNF-α secretion under hypoxic 
conditions.
Another major downstream target of MAP3K8 is the MEK/Erk pathway, 
which is described in literature to promote neutrophil development and 
LPS-mediated TNF-α secretion199–201. Therefore, we also probed for Erk1/2 
phosphorylation in moDCs stimulated with LPS and cultured at hypoxic and 
atmospheric oxygen levels (Supplementary Figure 3C-D). We used inhibi-
tors for Erk1/2 (CAY10561)202 and MAP3K8 (Tpl2 Kinase Inhibitor) in this 
experiment and performed a TNF-α ELISA. MoDC viability was unaffected 
by these small molecule inhibitors (Supplementary Figure 3F, Figure 5G). 
However, we observed only low and inconsistent activation of Erk1/2 
following LPS and this was not altered by hypoxic culture. In contrast, a 
positive control of starved HeLa cells exposed to serum showed clear Erk1/2 
phosphorylation. Moreover, the increased TNF-α secretion under hypoxic 
conditions was not modified by inhibition of Erk1/2 (Supplementary Figure 
3E). Phosphorylation of p38/MAPK was also unaffected by this inhibitor 
(Supplementary Figure 3A-B). These results show that LPS-mediated activa-
tion of the p38 pathway is specifically potentiated via MAP3K8 under hy-
poxic conditions.
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Figure 5. MAP3K8 knockdown in moDCs blocks hypoxia-induced potentiation of LPS-
induced TNF-α secretion.
A. Representative Western blot of siRNA knockdown of MAP3K8 in moDCs (MAP3K8siRNA) 
stained with an antibody specific for MAP3K8 (top) and loading control (GAPDH; bottom). 
MoDCs were transfected with non-targeting siRNA as negative control. B. Quantification 
of panel A by band intensities normalized to GAPDH and shown relative to non-targeting 
control. Individual donors are shown. Compared using Wilcoxon matched-pairs signed 
rank test. C. TNF-α secretion by moDCs with or without MAP3K8siRNA and cultured at at-
mospheric (20% O2) or hypoxic (1% O2) oxygen levels. Quantification of 14 donors (average 
± SEM). D. Phosphorylation of p38/MAPK in moDCs with or without MAP3K8siRNA and 
cultured at atmospheric (20% O2) or hypoxic (1% O2) oxygen levels. Representative Western 
blot probed for phosphorylated and total p38/MAPK shown. E. Quantification of panel D 
for 6 donors. Shown are the ratios of p38/MAPK phosphorylation for MAP3K8siRNA moDCs 
compared to non-targeting siRNA controls. F. TNF-α secretion by moDCs following 
overnight incubation with LPS and Tpl2 Kinase Inhibitor (Tpl2 KI) normalized to atmo-
spheric oxygen condition (average ± SEM). G. Representative flow cytometry histogram 
showing Zombie Violet cell viability staining on moDCs incubated overnight with Tpl2 
Kinase Inhibitor (Tpl2 KI), DMSO negative control, or 2 minutes 70% ethanol (EtOH) as 
positive control (ns: not significant; *** p < 0.001; ** p < 0.005; * p < 0.05).
Discussion
Hypoxia is capable of both potentiating and suppressing the response of 
immune cells and other cells to TLR stimuli. In primary human macro-
phages, the TLR2 and 4 induced expression and secretion of various pro-in-
flammatory cytokines (among others IL-6, IL-8 and IL-1β) was shown to 
be increased by hypoxia. In osteoclasts, hypoxia induced TNF-α expression 
and this depended on HIF-1α expression185. However, the effects of hy-
poxia on human DC function are more controversial, and both the inhibi-
tion167,173,177,179 as well as stimulation166,167,171 of TLR-induced cytokine secre-
tion by hypoxia have been described (e.g., for IL-6, IL-10, IL-12, TNF-α). 
Antigen uptake by DCs was shown to be less efficient in hypoxic DCs165,179, 
although Bosseto et al. showed that uptake was not affected for Leishmania 
infections171. The effects of hypoxia on the subsequent activation of T cells 
by DCs are equally controversial, and Jantsch et al. described an increase in 
activation 166, while others reported a decrease167,179. The relatively modest 
effects observed in this study may explain the many contradictory reports on 
the effects of hypoxia on immune cells.
The divergent effects of hypoxia on immune cell regulation are probably 
caused by the complex interplay of hypoxia on intracellular signalling. In 
addition to the stabilization of HIF transcription factors, hypoxia causes 
a metabolic shift towards anaerobic glycolysis, as also shown for DCs203. 
This metabolic shift can further affect the secretion of cytokines, as shown 
for IL-1β secretion by macrophages204. Moreover, for immune phagocytes 
such as DCs, TLR signalling can cause local hypoxia due to the large oxy-
gen consumption by NAPDH oxidases that produce reactive oxygen spe-
cies (ROS) during the respiratory burst172,176. These ROS in turn can act 
as second messengers, further modulating the transcriptional profile of 
immune cells, and for instance the hypoxia-induced activation of NFκB is 
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redox sensitive205. TLR-signalling can also directly affect HIF-signalling via 
post-translational regulation and increased expression of HIF174,206–208. Ad-
ditionally, hypoxia was shown to upregulate both HIF and TLR4 expression 
in macrophages193 and synergistic induction of HIF-1α activity by hypoxia 
and TLR4 stimulation has been shown in macrophages209. Finally, TNF-α can 
already induce HIF-1α expression under atmospheric conditions210. All these 
interacting pathways make it difficult to discern cellular responses to hypoxia 
from those caused by TLR signalling.
Because of the multifactorial responses of cells to hypoxia, the molecular 
mechanisms of hypoxia-mediated regulation of immune cell differentiation 
are still largely unknown. In corneal epithelial cells, the hypoxia-mediated at-
tenuation of NF-kB and Erk1/2 activation and of IL-6 and IL-8 secretion are 
dependent on myeloid differentiation primary response gene 88 (MyD88) 
downstream of TLR4. In PC12 cells and primary human macrophages, 
the potentiation of inflammatory cytokine secretion (IL-1β, IL-6, IL-8) 
by hypoxia is controlled specifically via p38/MAPK and c-Jun N-terminal 
kinase (JNK) signaling, but not via IκBα192,211. In this study, we identified a 
new molecular link between hypoxia and TLR signaling in human moDCs 
(Figure 6). We found that MAP3K8 expression is directly regulated by hy-
poxia via several HREs, resulting in increased expression of MAP3K8116. As 
the MAP3K8 kinase is involved in activation of the p38/MAPK pathway212,213, 
its upregulation results in increased transcription of pro-inflammatory 
cytokines199. In this way, hypoxia induced MAP3K8 upregulation sensitizes 
the cells to TLR stimulation. Since studies with MAP3K8 knockout mice 
demonstrated that long term secretion of TNF-α, but not IL-6, is regulated 
by MAP3K8214, our findings explain why hypoxia leads to a potentiation of 
TLR-stimulated TNF-α secretion, but not or less of IL-6 secretion.
Cancer cells express p38/MAPK, and this pathway is activated by hypox-
ia215,216. MAPK signaling can induce angiogenesis and metastasis, as well 
as tolerance by polarization of macrophages to the tolerogenic M2 subtype 
and of T cells to Th17 cells161,217. In this way, MAP3K8 expression promotes 
tumor growth and progression as well as immune suppression218,219. On the 
other hand, MAPK signaling can also have tumor suppressing functions: its 
expression is associated with lung cancer patient survival via a p38 signaling 
pathway downstream of JNK220 and it suppresses colitis-associated tumori-
genesis 221. In line with this, MAP3K8-/- mice show more tumor initiation and 
faster progression of chemically induced skin cancer222. 
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Figure 6. Model of MAP3K8-mediated potentiation of TNF-α secretion in hypoxic 
inflammation.
(1) Hypoxia inhibits prolyl hydroxylase D (PHD) activity, leading to stabilization of HIF-1α. 
(2) HIF-1α dimerizes with HIF-1β and upregulates MAP3K8 expression, which potentiates 
the p38/MAPK signaling cascade. (3) LPS-induced dimerization of TLR4 activates the p38/
MAPK signaling cascade. (4) c-JUN is phosphorylated by phospho-p38α and upregulates 
TNF-α expression. (5) TNF-α is transported to the plasma membrane and released.
MAP3K8 is also involved in autoimmunity. For example, MAP3K8 links 
IL-17 receptor signaling to TAK1 activation, which leads to increased 
JNK, p38 and NFκB activity in Th17 cells, promoting autoimmune 
neuroinflammation223,224. Moreover, MAP3K8 activity in T cells limits reg-
ulatory T cell (Treg) function by inhibiting FoxP3 expression and lowering 
production of the immunosuppressive cytokines IL-10 and cytotoxic T lym-
phocyte-associated protein 4 (CTLA-4)225. In addition, TNF-α plays a pivotal 
role in a variety of autoimmune diseases, causing sustained inflammation 
and tissue damage226. In many autoimmune diseases, a negative feedback 
loop between tissue damage and inflammation exists, where MAP3K8 
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promotes myeloperoxidase activity, ROS production and recruitment of 
neutrophils and macrophages, causing tissue damage214. This tissue damage 
and ROS production might subsequently lead to local hypoxia which further 
upregulates MAP3K8 activity, contributing to the localized hypoxia observed 
in many autoimmune diseases. In line with this, patients suffering from sys-
temic sclerosis and cerebrovascular inflammation show clear signs of local-
ized hypoxia, and fibroblasts from these patients show marked increases in 
activation of p38227–229. In addition, MAP3K8-/- mice have reduced amounts 
of circulating neutrophils, which display impaired sensitivity to chemokines 
and lower TNF-α secretion199,200. Bone-marrow derived dendritic cells of 
MAP3K8-/- mice also show impaired TNF-α secretion230 and increased IL-
12231. It would be interesting to study DC function in these MAP3K8-/- mice 
under hypoxic conditions to confirm our in vitro findings.
In conclusion, we show that hypoxia potentiates LPS-stimulated TNF-α se-
cretion in human moDCs by upregulating expression of MAP3K8, a serine/
threonine kinase capable of activating the p38/MAPK signaling pathway. 
Since our data provides a mechanistic link between hypoxia and immune 
cell function, and since these are important factors in infection, cancer and 
autoimmune disease, MAP3K8 might be a promising therapeutic target for 
treatment of these diseases.
Methods
Cells and culture conditions
MoDCs were derived from peripheral blood mononuclear cells (PBMCs) 
obtained from buffy coats of healthy individuals as described previously99. 
Approval to conduct experiments with human blood samples was obtained 
from the blood bank and all experiments were conducted according to na-
tional and institutional guidelines. Informed consent was obtained from all 
blood donors by the Dutch blood bank. Samples were anonymized and none 
of the investigators could ascertain the identity of the blood donors. Brief-
ly, peripheral blood leukocytes (PBLs) were separated from monocytes by 
a 1 hour adhesion step at 5% CO2 and 37°C in RPMI-1640 (Thermo Fisher 
Scientific, Waltham, USA) with 2% human serum. Monocytes were differ-
entiated into DCs by culturing for 6 days at 5% CO2 and 37oC in RPMI-1640 
(Thermo Fisher Scientific) with 300 U/ml IL-4, 450 U/ml GM-CSF, 10% 
fetal bovine serum (FBS; Greiner Bio-one, Kremsmünster, Austria), 2 mM 
UltraGlutamine (Lonza, Basel, Switzerland) and 1% Antibiotic-Antimycotic 
(Gibco by Life Technologies, Kremsmünster, Austria). For hypoxic culture, 
moDCs were kept overnight at 1% O2, 5% CO2 and 94% N2, at 37°C (CB53 
incubator, Binder, Tuttlingen, Germany) in complete RPMI-1640 (Thermo 
Fisher Scientific) with 10% fetal bovine serum (FBS; Greiner Bio-one), 2 mM 
UltraGlutamine (Lonza, Basel, Switzerland) and 1% Antibiotic-Antimycotic 
(Gibco by Life Technologies). For normoxic culture, cells were kept at atmo-
spheric O2 (20%) with 5% CO2. To activate the DCs, 1 µg/ml of lipopolysac-
charide (LPS, Lipopolysaccharides from E. coli 0111:B4, Sigma-Aldrich, St. 
Louis, USA) was added to the medium. To quantify cytokine production, cell 
culture supernatants were collected and stored at -80°C until analysis with 
IL-6 and TNF-α specific ELISA (eBioscience, San Diego, USA).
Inhibitors and antibodies
To inhibit p38 signaling, we used 1 µM SB203580 (Cell Signaling 
Technology, Danvers, USA). To inhibit IκB kinase (IKK), we used 100 nM 
IKK-16 (R&D Systems, Minneapolis, USA), to inhibit MAP3K8 we used 
1 µM of Tpl2 Kinase Inhibitor (Cayman Chemical, Ann Arbor, USA), to 
inhibit Erk1/2 we used 250 nM of CAY10561 (Cayman Chemical). Primary 
antibodies used were: mouse-IgG1 anti-MAP3K8 (sc-373677, Santa Cruz 
Biotechnology, Dallas, USA), rabbit monoclonal IgG anti-p38/MAPK (8690, 
Cell Signaling Technology), rabbit monoclonal IgG anti-phospho-p38/
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MAPK (Thr180/Tyr182) (4511, Cell Signaling Technology), rabbit polyclon-
al anti-p44/p42 MAPK (Erk1/2) (Cell Signaling Technology), mouse-IgG1 
anti-phospho-p44/p42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling 
Technology), rabbit monoclonal IgG anti-GAPDH (2118, Cell Signaling 
Technology). The following secondary antibodies were used: goat anti-rabbit 
or anti-mouse IgG (H+L) IRDye 800 CW (926-32211, 926-32210, Li-Cor 
Biosciences, Lincoln, USA). Cell death was assessed with Zombie Violet 
fixable viability dye (BioLegend, San Diego, USA). The following direct-
ly labeled antibodies were used: CD11c-FITC (BD Biosciences, Franklin 
Lakes, USA), CD14-PE-Cy7 (Miltenyi Biotec, Bergisch Gladbach, Germa-
ny), CD16-APC (Miltenyi Biotec), CD11b-PE-Cy7 (Beckman Coulter, Brea, 
USA), CD68-APC (BioLegend), HLA-DR-PE (BD Biosciences), CD83-FITC 
(BD Biosciences), CD86-APC (BD Biosciences), TLR2-FITC (BioLegend), 
TLR4-APC (BioLegend).
Western blot
SDS-PAGE with Western blot was used to analyze MAP3K8 knock-down 
efficiency and phosphorylation of p38 and Erk1/2 using 10% acrylamide 
gels. Proteins were then transferred to PVDF membranes (Immobilon-FL 
0.45 µm, Merck, Burlington, USA), blocked for 1 hour with 5% BSA in Tris-
HCl-buffered saline and incubated overnight with primary antibodies (1:200 
– 1:500 dilution). These were labeled by incubating with IRDye800-conjugat-
ed secondary antibodies (1:5,000 dilution; Li-Cor Biosciences) and analyzed 
using the Odyssey CLx Infrared Imaging System and ImageStudio Lite 5.0 
analysis software (Li-Cor Biosciences).
Flow cytometry
For flow cytometry assays, moDCs were seeded at 100,000 cells per well 
in 100 µl complete RPMI in a V-bottom 96 well plate. After incubation at 
hypoxic or atmospheric oxygen levels and with or without inhibitors, as 
described above, cells were centrifuged at 1,500 rpm for 2 minutes at 4°C. 
Supernatant was discarded and cells were incubated for 30 minutes in the 
dark with PBS containing Zombie Violet fixable viability stain (BioLegend, 
1:2,000 dilution), then fixed with 4% PFA for 2 minutes and incubated for 
10 minutes in the dark on ice with 50 µl of phosphate-buffered azide (PBA; 
PBS containing 0.5% BSA and 0.01% NaN3) containing 1% human serum 
to block Fc receptors. Then, cells were incubated for 30 minutes in the dark 
on ice with 50 µl of PBA containing directly labeled antibodies. To perform 
compensation and set gates, AbC Total Antibody Compensation beads 
(Thermo Fischer Scientific) were stained in the same way as the cell samples. 
Cells were washed with 100 µl PBA, resuspended in 60 µl PBA and analyzed 
on a FACSCalibur or FACSVerse flowcytometer (BD Biosciences). 
Transfections
DCs were electroporated with siRNA against MAP3K8 (a 1:1:1 mix of GGC-
GUGUAAACUGAUCCCAGUAGAU, GGAAGGAGCUGGAACUUCCU-
GAGAA and UGGUUGUCAUCAGUCAGAUAUGGAA; Thermo Fischer 
Scientific) using a Neon electroporation system (Thermo Fischer Scientific). 
Briefly, DCs were thawed from liquid nitrogen storage, washed once with 
PBS and resuspended in R buffer (from the Neon kit) at 0.5-1.0 ∙ 106 cells in 
120 µl volume. 4 µg of plasmid DNA or 20 pmol siRNA mix was added and 
the cells were electroporated with 2 pulses of 1,000 V at 40 ms pulse width. 
Cells were then transferred to pre-warmed RPMI-1640 containing 2 mM 
UltraGlutamine. 4 hours post transfection, an equal amount of complete 
RPMI-1640 was added to the cells. Experiments were performed 24 hours 
post-transfection.
Primers and PCR reactions
MAP3K8 expression in untreated moDCs was checked with PCR on 
cDNA using primers for MAP3K8 (CTCCCCAAAATGGACGTTACC and 
GGATTTCCACATCAGATGGCTTA). Expression levels were quantified 
with RT-qPCR using validated primers for MAP3K8 (GAGCGTTCTA-
AGTCTCTGCTG and GCAAGCAAATCCTCCACAGTTC), TBP (GAG-
CCAAGAGTGAAGAACAGTC and GCTCCCCACCATATTCTGAATCT) 
and GUSB (GACACGCTAGAGCATGAGGG and GGGTGAGTGT-
GTTGTTGATGG). Briefly, messenger RNA was isolated from DCs using a 
Quick-RNA MiniPrep Plus kit (Zymo Research, Irvine, USA) and cDNA was 
generated in a standard reverse transcriptase reaction. qPCR reactions were 
done on a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, 
USA), using FastStart SYBR Green Master mix (Hoffmann-La Roche, Basel, 
Switzerland) and analyzed in CFX Manager software version 3.1 (Bio-Rad, 
Hercules, USA). Gene expression was first normalized (ΔΔCq) to house-
keeping genes (TBP and GUSB) validated with geNorm analysis, followed by 
normalization to untreated samples.
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Statistical analysis
For datasets with 2 paired conditions, paired 2-sided Student’s t-tests were 
applied to assess significance when data followed a normal distribution, 
otherwise Wilcoxon matched pairs signed-rank tests were used. One-way 
ANOVA with Bonferroni post-hoc tests were applied for multiple compari-
sons. Box plots indicate mean with whiskers indicating minimal and maxi-
mal values. A value of p < 0.05 was considered statistically significant (*** p 
< 0.001, ** p < 0.01, * p < 0.05).
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Characterization of moDCs before and after hypoxic culture.
A-E. Flow cytometry histograms of compensation beads to set gating thresholds (dotted 
lines) to identify labeled from unlabeled populations. F-I. Representative dot plots for 
expression of surface markers CD11c, CD14, CD16, CD11b and CD68 on unstimulated 
moDCs at atmospheric oxygen levels (20% O2). J-R. Representative flow cytometry his-
tograms of the expression levels of the surface markers CD11c, CD14, CD16, CD11b and 
CD68 following LPS stimulation and overnight culture at 20% or 1% O2. K-S. Quantification 
of panels J-R for 3 individual donors (average ± SEM) (ns: not significant).
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Surface expression of TLR2 and TLR4 on moDCs.
A-B. Representative flow cytometry histograms (A) and quantification (B; 3 individual do-
nors, average ± SEM) of surface expression of TLR2 on moDCs following stimulation with 
LPS and overnight culture at 1% or 20% O2. C-D. Same as panels A-B, but now for TLR4.
Phosphorylation of p38/MAPK and Erk1/2 at hypoxic culture. (next page)
A. Representative Western blot of moDCs cultured at 20% or 1% O2 in the presence of LPS, 
Erk1/2 inhibitor CAY10561 or Tpl2 Kinase Inhibitor. The blot was stained with an antibody 
specific for phosphorylated p38/MAPK (top) or total p38/MAPK (bottom). B. Quanti-
fication of panel A for 3 donors. p38/MAPK phosphorylation is normalized to unstimu-
lated cells at atmospheric oxygen levels (LPS-, 20% O2; average ± SEM). C. Representative 
Western blot of moDCs cultured at 20% or 1% O2 in the presence of LPS, Erk1/2 inhibitor 
CAY10561 or Tpl2 Kinase Inhibitor. The blot was stained with an antibody specific for 
phosphorylated Erk1/2 (top) or total Erk1/2 (bottom). As a positive control, HeLa cells were 
starved overnight in serum-free medium, then recovered in medium containing 10% FBS 
for 0 or 10 minutes before lysis. D. Quantification of panel C for 3 donors. Erk1/2 phos-
phorylation is normalized to unstimulated cells at atmospheric oxygen levels (LPS-, 20% O2; 
average ± SEM). E. TNF-α secretion by moDCs following overnight incubation with LPS 
and Erk1/2 inhibitor CAY10561 (average ± SEM). F Representative flow cytometry histo-
gram showing Zombie Violet cell viability staining on moDCs incubated overnight with 
CAY10561 (CAY), DMSO negative control, or 2 minutes 70% ethanol (EtOH) as a positive 
control.
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Ethylene, an early marker of systemic 
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L.M. Paardekooper, G. van den Bogaart, M. Kox, I. Dingjan,
A.H. Neerincx,  M.B. Bendix, M. ter Beest, F.J.M. Harren, T. Risby, 
P. Pickkers, N. Marczin, S.M. Cristescu
Scientific Reports 7, July 2017
70 | Chapter 4 Ethylene in breath as a marker for systemic inflammation | 71
4
Abstract
Ethylene is a major plant hormone mediating developmental processes and 
stress responses to stimuli such as infection. We show here that ethylene is 
also produced during systemic inflammation in humans and is released in 
exhaled breath. Traces of ethylene were detected by laser spectroscopy both 
in vitro in isolated blood leukocytes exposed to bacterial lipopolysaccharide 
(LPS) as well as in vivo following LPS administration in healthy volunteers. 
Exposure to LPS triggers formation of ethylene as a product of lipid perox-
idation induced by the respiratory burst. In humans, ethylene was detected 
prior to the increase of blood levels of inflammatory cytokines and stress-re-
lated hormones. Our results highlight that ethylene release is an early and 
integral component of in vivo lipid peroxidation with important clinical 
implications as a breath biomarker of bacterial infection.
Introduction
Ethylene (C2H4) is a major gaseous hormone in plants232,233, mediating 
growth and development, as well as stress responses234. Its production is 
upregulated in response to diverse biotic (e.g. pathogen attack) and physical 
stressors (e.g. wounding,  dehydration, chilling, ozone)235. Transcriptom-
ics revealed that ethylene synthesis and signaling have been conserved for 
at least 450 million years, predating even the colonization of land236. The 
molecular pathway of ethylene biosynthesis in higher plants is well-estab-
lished237; ethylene is enzymatically synthesized from methionine via the Yang 
cycle235,238,239.
No homologs of the plant ethylene biosynthetic enzymes are present in 
animals. However, there is evidence that mammals can form ethylene upon 
oxidative damage. In rat liver microsomes, copper treatment resulted in 
ethylene release240. This effect could be blocked by the lipophilic radical 
scavenger vitamin E, suggesting that ethylene is a product of lipid peroxi-
dation240. Indeed, the oxidation of unsaturated fatty acids in suspension can 
lead to acyl chain decomposition and formation of small alkenes including 
ethylene64,241. Exposing rats to nickel242 or mice to carbon tetrachloride or 
δ-aminolevulinic acid243 led to detectable ethylene levels in their breath. The 
human relevance of these model experiments is now emerging as well. We 
previously showed that humans can produce ethylene as a result of oxidative 
damage. After exposure to UV light, ethylene was found in exhaled breath 
and emanating from the skin of healthy volunteers244–246. In patients under-
going cardiac surgery, ethylene was released during specific moments of 
biological stress such as skin and tissue incision by diathermy or unprotected 
reperfusion of regional myocardial ischemic tissue247. Thus, ethylene can be 
formed in vivo as a product of oxidative damage.
Oxidative stress induced by reactive oxygen species (ROS) is a key compo-
nent of the mammalian innate immune system during infection and (sys-
temic) inflammation248,249. One of the most fundamental mechanisms in-
volving oxidative stress is the respiratory burst, occurring when neutrophils 
and monocytes encounter bacterial or fungal infections. During this burst, 
large amounts of ROS are rapidly produced by NADPH oxidases41,250. How-
ever, the effects of this response are indiscriminative, affecting both invading 
pathogens and host tissues. We hypothesized that ethylene is formed as part 
of endogenous lipid peroxidation caused by the respiratory burst and can be 
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detected as a gaseous signature of systemic inflammation in exhaled breath.
To test this hypothesis, we firstly utilized an isolated lipid model to consol-
idate basic chemical mechanisms of ethylene release by lipid peroxidation. 
We also investigated ethylene release and lipid peroxidation in isolated 
leukocytes activated by bacterial lipopolysaccharide (LPS) as a cellular model 
of infection. Finally, we evaluated ethylene release in vivo using the experi-
mental human endotoxemia (LPS administration in healthy volunteers), a 
well-characterized model of systemic inflammation. We compared exhaled 
ethylene with established biomarkers of endogenous lipid peroxidation and 
aimed to clarify the temporal and mechanistic relationship between ethylene 
release and other biomarkers of the inflammatory stress response. 
Results
Initially, we investigated whether the in vitro peroxidation of mamma-
lian lipids directly leads to formation of ethylene. We resuspended L-α-
phosphatidylethanolamine (PE) extracted from pig brain in water containing 
the surfactant Triton X-100 and treated this suspension with Fe(II)SO4, a 
catalyst of Fenton oxidation60. Brain PE consists of approximately 30% poly-
unsaturated and 25% monounsaturated fatty acids (Avanti polar lipids). An 
incubation of 30 minutes resulted in significant ethylene release (p = 0.02) 
(Figure 1A).
In order to explore which fatty acids caused the ethylene formation after de-
composition, we performed experiments with docosahexaenoic acid (DHA, 
22:6(n-3)), oleic acid (18:1(n-9)) and palmitic acid (16:0). Exposure of pure 
docosahexaenoic acid (DHA, 22:6(n-3)) and oleic acid (18:1(n-9)) to Fe2+ 
ions also generated significant amounts of ethylene (p < 0.01), while palmitic 
acid (16:0) showed no difference (p = 0.82) (Figure 1B). Since the fatty acids 
were completely peroxidized after 30 minutes, we calculated the ethylene 
released per fatty acid, which was approximately 2 × 10-5 mole ethylene per 
mole DHA and 0.5 × 10-5 mole ethylene per mole oleic acid, respectively 
(Figure 1C). In conclusion, peroxidation of unsaturated lipids leads to for-
mation of ethylene.
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Figure 1. Ethylene forms upon peroxidation of unsaturated lipids.
A. Ethylene released from pig brain L-α-phosphatidylethanolamine (PE) suspended in 
milliQ H2O with 0.1% Triton X-100 and in the presence or absence of 500 µM Fe(II)SO4 
after 30 minutes incubation (n=3). B. Ethylene released from cis-4,7,10,13,16,19-docosahex-
aeinoic acid (22:6 (n-3)), cis-9-Octadecenoic (18:1 (n-9)) or palmitic acid (16:0) fatty acids 
suspended in milliQ H2O with 0.1% Triton X-100 and 500 µM Fe(II)SO4 after 30 minutes 
incubation (n=3). Triton X-100: detergent control with 0.1% Triton X-100 (n=3). C. Ratio 
of ethylene released per molecule of fatty acid (FA) for cis-4,7,10,13,16,19-docosahexaeinoic 
acid (22:6 (n-3)) and cis-9-Octadecenoic acid (18:1 (n-9)). Bar graphs show mean with SEM 
(ns: not significant; *** p < 0.001; ** p < 0.005; * p < 0.05).
In order to expand to biological systems relevant to infection and inflamma-
tion, we investigated lipid peroxidation, ethylene release and inflammatory 
cytokine production in human cellular endotoxemia models. Monocyte-de-
rived dendritic cells (moDCs) acquired from healthy donor blood were 
utilized to study basic mechanisms of lipid peroxidation and cytokine release 
in response to either known inducers of lipid peroxidation or LPS. MoDCs 
contain the NADPH oxidase NOX2, which is activated via LPS, leading to a 
rapid and sustained production of ROS45,55,56. Two independent assays were 
used to monitor lipid peroxidation. First, we used Bodipy 581/591-C11, 
which is a fluorescent probe mimicking unsaturated fatty acids251. We also in-
vestigated formation of the highly specific lipid peroxidation product 8-iso-
prostane with an enzyme immunoassay (EIA)252. In addition, we measured 
secretion of IL-6, a prototype cytokine associated with cellular activation. As 
positive controls for lipid peroxidation, we treated moDCs with Fe(II)SO4. 
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Figure 2. LPS triggers lipid peroxidation and ethylene formation in leukocytes.
A. Lipid peroxidation in moDCs as measured by blue-shift of Bodipy581/591-C11 fluores-
cence. MoDCs were treated with 1 µg/ml LPS or 100 µM Fe(II)SO4 (n=4). B. Lipid peroxida-
tion in moDCs measured by EIA assay for 8-isoprostane. Cells were treated with either LPS 
or 100 µM Fe(II)SO4 in serum-free RPMI-1640 (n=3). C. Total ethylene released during 1 
hour stimulation of leukocytes with either 1 µg/ml LPS or 100 µM Fe(II)SO4, as detected by 
laser-based photoacoustic spectroscopy (n=11). Data points show mean with SEM (panels a 
and b) or geometric mean with 95% CI (panel c) (*** p < 0.001; ** p < 0.005; * p < 0.05).
Exposure of moDCs to Fe(II)SO4 led to a significant increase in Bodipy 
fluorescent intensity at 510 nm (p < 0.001) (Figure 2A). It also resulted in 
formation of 8-isoprostane (p < 0.001), confirming significant oxidative 
stress and lipid peroxidation in these cells (Figure 2b). Treating the moDCs 
for 1 hour with LPS also led to a blue-shift of the Bodipy 581/591-C11 probe 
(p = 0.004) (Figure 2A). This response was attenuated by the lipophilic 
antioxidant vitamin E (α-tocopherol) (p < 0.001, compared to LPS) and the 
iron chelator deferoxamine253 (DFO) (p = 0.005, compared to LPS), sug-
gesting that iron content plays a role in LPS-induced lipid peroxidation (see 
Supplementary Figure 1). LPS-activation of the moDCs also induced 8-iso-
prostane release (p = 0.004) (Figure 2B), further demonstrating the role of 
lipid peroxidation in the biological effect of LPS.
The LPS treatment of moDCs resulted in significant concentration-depen-
dent increases in IL-6 secretion with a maximum effect observed at 1 µg/ml 
LPS (p = 0.03) (see Supplementary Figure 2A), while exposure to iron did 
not induce IL-6 production (p = 0.55) (see Supplementary Figure 2B). Fur-
thermore, deferoxamine or α-tocopherol did not affect IL-6 secretion either 
(p = 0.31; p = 0.43, respectively). Cytotoxicity data from the MTT assay 
indicated that, although LPS induces lipid peroxidation, this does not affect 
cell viability (p = 0.57), whereas Fe(II)SO4 does (71% viability of control, p = 
0.024). Addition of α-tocopherol or deferoxamine did not affect viability (p = 
0.50; p = 0.75, respectively). These results suggest that lipid peroxidation is a 
physiological response to LPS exposure. Our observations confirm that LPS 
induces both lipid peroxidation and effective cellular signaling to activate 
cytokine release, however lipid peroxidation alone is insufficient to activate 
cytokine production.
To explore the direct link between LPS, lipid peroxidation and ethylene 
release in human leukocytes, we stimulated peripheral blood leukocytes 
(PBLs) with LPS or Fe(II)SO4 for 1 hour and measured ethylene release by 
laser-based photoacoustic spectroscopy254 (Figure 2C). Compared to untreat-
ed cells, both LPS and Fe(II)SO4 caused a significant increase in ethylene 
release (p = 0.04; p = 0.001, respectively). These data are supportive of the 
paradigm that human leukocytes produce ethylene upon LPS stimulation as 
a product of lipid peroxidation. 
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In order to determine whether systemic inflammation leads to lipid perox-
idation and ethylene release in vivo, we utilized the experimental human 
endotoxemia model. This is a well characterized, controlled and reproducible 
human model of systemic inflammation elicited by intravenous LPS admin-
istration255. In all 8 subjects that underwent endotoxemia, breath ethylene 
levels, detected by laser-based photoacoustic spectroscopy254 increased rap-
idly after LPS administration and reached maximum levels after 60 minutes  
(Figure 3A). In similar fashion, plasma levels of 8-isoprostane increased after 
LPS administration (Figure 3b). Peak levels of 8-isoprostane were detect-
ed about 30 minutes after peak ethylene levels in breath. There was also a 
correlation between peak plasma 8-isoprostane and ethylene levels (r = 0.76, 
p = 0.03). To investigate the placebo effect, 8-isoprostane in plasma samples 
from healthy volunteers injected with phosphate buffered saline (PBS) in a 
previous study with identical setting as reported here, was also measured. In 
contrast to LPS injection, saline treatment did not result in increase of 8-iso-
prostane (Figure 3B).
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Figure 3. Ethylene and 8-isoprostane release during human endotoxemia.
A. Time course of ethylene levels in breath of healthy volunteers after intravenous adminis-
tration of a single dose of LPS at t = 0. B. Time course of 8-isoprostane levels as determined 
by EIA in serum samples of healthy volunteers after intravenous administration of a single 
dose of LPS (present study, n = 8) or phosphate buffered saline (PBS) (previous study, n = 
6) at t = 0. Data points show median with interquartile range, asterisks indicate significance 
compared to baseline (t = -30 for ethylene, t = 0/-50 for 8-isoprostane PBS/LPS)  (*** p < 
0.001; ** p < 0.005; * p < 0.05).
Interestingly, breath ethylene showed a biphasic response with levels decreas-
ing below baseline 8 hours post-LPS, although this did not reach statistical 
significance. This might be caused by an increased antioxidant response, for 
example upregulation of glutathione levels or higher expression of ROS se-
questering proteins. Another potential explanation could be auto-oxidation 
of NOX2. As ROS are known to react with proteins, often inactivating them 
in the process45,256, this could self-limit the oxidative stress induced by LPS 
signaling.
Plasma levels of the pro-inflammatory cytokines/chemokines inter-
leukin (IL)-6, IL-8, tumor necrosis factor α (TNF-α), and monocyte 
chemoattractant protein 1 (MCP-1) as well as the anti-inflammatory cyto-
kines IL-10 and IL-1 receptor antagonist (IL-1RA) started to increase ap-
proximately 60 minutes after LPS administration and reached peak levels 
after 90–180 minutes (Figure 4A-C). All these cytokines are well known to 
increase upon infection257–260. However, the peak levels for the inflammato-
ry cytokines were detected at least 30 minutes later than the ethylene peak. 
Ethylene levels at various time-points (45 minutes, 90 minutes, and 120 min-
utes after LPS administration) correlated with peak levels of the archetypal 
anti-inflammatory cytokine IL-10 (r = 0.93, p = 0.002; r = 0.75, p = 0.03; r = 
0.77, p = 0.03). No correlations between ethylene and release of IL-6 or other 
cytokines were found.
In order to explore ethylene release in the context of broader stress respons-
es, we also determined plasma levels of the stress hormones epinephrine, 
norepinephrine and cortisol (Figure 4D). There were no changes in nor-
epinephrine levels over time, but epinephrine and cortisol levels increased 
significantly compared to their baseline, reaching peak levels at 90 and 180 
minutes after LPS administration, respectively. In addition, ethylene levels 
at various time-points (45, 90 and 120 minutes after LPS administration) 
correlated with peak levels of epinephrine (r = 0.89, p = 0.007; r = 0.85, p = 
0.007; r = 0.74, p = 0.04), but not with norepinephrine or cortisol. 
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Figure 4. Systemic inflammation and stress response during human endotoxemia.
Time course of cytokine levels as determined in plasma for (A) pro-inflammatory cytokines 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), (B) anti-inflammatory cytokines 
interleukin-1 receptor antagonist (IL-1RA) and interleukin-10 (IL-10) and (C) chemotactic 
cytokines monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) (n=8). D. 
Time dependent changes in plasma levels of epinephrine, norepinephrine and cortisol. Data 
points (n=8) show median with interquartile range, asterisks indicate significance compared 
to baseline (t = -50) (*** p < 0.001; ** p < 0.005; * p < 0.05).
Discussion
Building on the well-recognized role of ethylene as a stress hormone in 
plants232–235, and previous findings linking ethylene to mammalian oxidative 
stress240,242–246, we explored ethylene as a novel gaseous signature of the in-
flammatory response associated with bacterial infection. We have found that 
treating isolated leukocytes with LPS resulted in significant ethylene release 
caused by the respiratory burst. Furthermore, we show that humans produce 
ethylene as part of a systemic inflammatory response to bacterial endotoxin, 
and that this event precedes the classical inflammatory cytokine response. 
Collectively, these results signify ethylene as a novel biomarker for infection 
and oxidative stress with potentially important clinical implications. 
We have conducted experiments with isolated mammalian lipids to deci-
pher potential chemical mechanisms of ethylene formation during lipid 
peroxidation. Our data are relevant to both the general concept of oxida-
tive modification of lipid membranes and to the exact process of ethylene 
formation during lipid peroxidation. Firstly, lipids within biological mem-
branes  are relatively vulnerable to oxidative attack compared to other cel-
lular environments due to the high partition coefficient of oxygen in lipid 
membranes (≈5-fold compared to aqueous environment58) and due to the 
lack of lipophilic antioxidants (except for α/γ-tocopherol) protecting these 
compartments. Secondly, we propose that, during oxidative stress, ethylene 
production proceeds by decomposition of fatty acids by ROS. This occurs 
spontaneously and is not catalyzed by enzymes. In this point, this mecha-
nism would resemble the spontaneous isomerization of 7-dehydrocholesterol 
to previtamin D3 in the skin induced by UV-light261,262. In order to test this 
novel paradigm to infection, we used leukocyte activation by LPS as a mod-
el of the inflammatory and oxidative response to infection. Leukocytes are 
principle mediators of host defense during all phases of infection and basic 
mediators of the innate immune response. They mount a strong oxidative 
response against invading bacteria, which is crucial for their elimination, 
and also as a pathological mechanism of tissue injury during uncontrolled 
oxidative stress263.
The overall aim of these cellular model experiments was to show ethylene re-
lease in an in vitro inflammation model and to utilize this model to forecast 
in vivo human phenomena. We have done this by characterizing lipid per-
oxidation and inflammatory cytokine release. Our experiments confirmed 
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both intracellular lipid peroxidation to well-known stimuli and a clinically 
relevant oxidative stress biomarker response in the release of 8-isoprostane. 
Relevant to the inflammatory paradigm, activation of leukocytes by LPS also 
resulted in oxidative stress, 8-isoprostane release and ethylene production.  
The human relevance of these discoveries was tested in a well characterized, 
controlled and reproducible model of human systemic inflammation. Re-
markably, gaseous ethylene and 8-isoprostane in plasma were detected in 
such subjects for the first time and with important characteristics. Firstly, 
ethylene production started to increase rapidly following endotoxin admin-
istration to humans. It paralleled 8-isoprostane in plasma, thus providing 
an additional link between our in vitro and human data. Ethylene release 
appeared as part of the broader inflammatory and stress response, as we 
found it to correlate significantly with epinephrine and IL-10 release. The 
correlation with the archetypal anti-inflammatory cytokine IL-10 could in-
dicate a potential link between endogenous lipid peroxidation and a central 
host defense response in triggering anti-inflammatory mechanisms. Ethylene 
production occurred earlier than the pro- and anti-inflammatory cytokine 
responses. This suggests the potential for ethylene as an early biomarker of 
oxidative stress in infection.  For instance, the possibility of real-time breath 
analysis could be directly relevant to patients in intensive care units at risk of 
ventilator associated pneumonia264. 
Our observation that ethylene is released prior to inflammatory cytokines 
also raises the exciting possibility that lipid peroxidation or ethylene itself 
could be involved in mounting the cytokine response. Signaling by lipid 
peroxidation products has been investigated before265  and there are some 
indications that ethylene itself could have a signaling function. For in-
stance, several cell lines (of both mouse and human origin) responded with 
increased Ca2+ levels and altered gene expression after incubation with an 
ethylene-generating system266. In addition, ethylene has profound neurolog-
ical effects and was widely used as an anesthetic in the 1930s, although this 
required very high concentrations267.  Further studies are required to eluci-
date if ethylene is only a byproduct of lipid peroxidation or whether it has a 
signaling function.
In conclusion, we now show that humans release ethylene during system-
ic inflammation. The in vitro experiments suggested that blood leukocytes 
could be one of the cell types contributing to this. We could connect the 
chemical and biological factors causing the ethylene release in response to 
an inflammatory stimulus, showing that oxidation of unsaturated fatty acids 
plays a role in this reaction. Together, our results identify ethylene as a prom-
ising and novel biomarker for early onset of infection in the clinic.
Methods
Experiments with isolated lipid preparations
L-α-phosphatidylethanolamine from porcine brain (brain PE; 840022P, 
Avanti), cis-4,7,10,13,16,19-docosahexaeinoic acid (DHA; Sigma, St. Louis, 
USA), cis-9-Octadecenoic (oleic) acid (Sigma, St. Louis, USA) and palmitic 
acid (Sigma, St. Louis, USA) were suspended in milliQ H2O containing 0.1% 
Triton X-100, which was deoxygenated by bubbling N2 through it for 15 
minutes. Isolated lipid samples were placed into plastic closed-cap T25 flasks 
(3055, Corning, Corning, USA) that were previously equilibrated by expo-
sure to filtered air for >48 hours at 37°C.  Brain PE, oleic acid and palmitic 
acid were suspended at 1.4 g/l, while DHA was suspended at 0.7 g/l. To initi-
ate lipid peroxidation, Fe(II)SO4 (Sigma, St. Louis, USA) was added to a final 
concentration of 500 µM in 3 ml total volume. After Fe(II)SO4 addition, the 
flasks were closed to allow gas accumulation in the headspace of the samples 
for 30 minutes before connecting to the ethylene detector. 
In vitro experiments
Cells
Human peripheral blood leukocytes (PBLs) and monocyte derived dendritic 
cells (moDCs) were derived from peripheral blood mononuclear cells (PB-
MCs) obtained from buffycoats of healthy individuals as described previous-
ly99 and according to institutional guidelines. Briefly, PBLs were separated 
from monocytes by a 1 hour adhesion step at 5% CO2 and 37°C in RPMI-
1640 (Thermo Fisher Scientific, Waltham, USA) with 2% human serum. 
Monocytes were differentiated into moDCs by culturing for 6 days at 5% 
CO2 and 37oC in RPMI-1640 (Thermo Fisher Scientific, Waltham, USA) with 
300 U/ml IL-4, 450 U/ml GM-CSF, 10% fetal bovine serum (FBS; Greiner 
Bio-one, Kremsmünster, Austria), 2 mM UltraGlutamine (Lonza, Basel, 
Switzerland) and 1% Antibiotic-Antimycotic (Gibco by Life Technologies, 
Kremsmünster, Austria).
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Lipid peroxidation assays
For the Bodipy581/591-C11 assay, moDCs were activated with 2.2 
mM ovalbumin, 1 μg/ml LPS and cultured in the presence of 1 μM 
Bodipy581/591-C11 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bo-
ra-3a,4a-diaza-s-indacene-3-undecanoic acid; Thermo Fisher Scientific, 
Waltham, USA) in serum-free RPMI-1640 (Gibco by Life Technologies, 
Kremsmünster, Austria) for 60 minutes at room temperature. 25 µM 
deferoxamine (Sigma, St. Louis, USA), 100 μM α-tocopherol (Sigma, St. 
Louis, USA) or 100 μM freshly prepared Fe(II)SO4 (Sigma, St. Louis, USA) 
was added together with the Bodipy581/591-C11. After incubation, the 
Bodipy581/591-C11 fluorescence was measured by FACS (excitation: 488 
nm; emission: 530/30 nm; FACS Caliber, BD biosciences, Franklin Lakes, 
USA). The signal from unstained cells was subtracted for background cor-
rection. 
For ethylene measurements, PBLs in serum-free RPMI-1640 (Thermo Fisher 
Scientific, Waltham, USA) were placed into plastic closed-cap T25 flasks 
(3055, Corning, Corning, USA) that were previously equilibrated by expo-
sure to filtered air for >48 hours at 37°C. Fe(II)SO4 (Sigma, St. Louis, USA) 
was added to a final concentration of 500 µM in 4 ml total volume. LPS was 
added to a final concentration of 1 µg/ml in 4 ml total volume. After stimula-
tion, the flasks were closed to allow gas accumulation in the headspace of the 
samples for 60 minutes before connecting to the ethylene detector.
Cell viability assay
To assess peroxidation-induced cell death, moDCs were stimulated with 
1 µg/ml LPS. 25 µM deferoxamine (Sigma, St. Louis, USA), 100 μM 
α-tocopherol (Sigma, St. Louis, USA) or 100 μM freshly prepared Fe(II)SO4 
(Sigma, St. Louis, USA) was added and cells were subsequently cultured 
for 60 min at 37°C and 5% CO2 in serum-free RPMI-1640 (Gibco by Life 
Technologies, Kremsmünster, Austria). The medium was aspirated and cells 
were incubated for 1-4 hours with 0.5 mg/ml MTT (3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide). Finally, cells were lysed in 90% 
(v/v) iso-propanol, 40 mM HCl and 0.0125% (w/v) SDS. Absorbance at 595 
nm was read as a measure for cell viability.
IL-6 production assay
To assess IL-6 production, moDCs were stimulated with increasing concen-
trations of LPS ranging from 0.01 to 10000 ng/ml LPS, 25 µM deferoxamine 
(Sigma, St. Louis, USA), 100 μM α-tocopherol (Sigma, St. Louis, USA) or 
100 µM Fe(II)SO4 (Sigma, St. Louis, USA) in serum-free RPMI-1640 (Gibco 
by Life Technologies, Kremsmünster, Austria) for 60 minutes at 37°C after 
which supernatants were analyzed by ELISA (eBioscience, San Diego, USA) 
according to the manufacturer’s instructions.
In vivo experiments 
Subjects
Samples were collected from 8 healthy male volunteers (age range 19-27) 
participating in a randomized controlled human endotoxemia study268. This 
study was approved by the local ethics committee of the Radboud University 
Nijmegen Medical Centre (CMO-number 2012/455). All subjects provided 
written informed consent and experiments were in accordance with the Dec-
laration of Helsinki, including current revisions, and Good Clinical Practice 
guidelines. All subjects were allocated to the control group, as such, they 
received no intervention besides the administration of lipopolysaccharide 
(LPS). 
Experimental human endotoxemia
The study procedures are described in detail elsewhere268. Briefly, subjects 
were admitted to the research unit of the intensive care department where a 
cannula was placed in an antecubital vein to permit infusion of 0.9% NaCl 
solution; the subjects received 1.5 L 0.9% NaCl during one hour starting one 
hour before endotoxin infusion (pre-hydration) followed by 150 ml/h until 6 
hours after endotoxin infusion and 75 ml/h until the end of the experiment. 
The radial artery was cannulated using a 20-gauge arterial catheter (Angio-
cath, Becton Dickinson, Sandy, Utah) and connected to an arterial pressure 
monitoring set (Edwards Lifesciences LLC, Irvine, CA, USA) to allow the 
continuous monitoring of blood pressure and blood sampling. Heart rate 
was recorded using a 3-lead electrocardiogram. Purified LPS (US Standard 
Reference Endotoxin Escherichia Coli O:113) obtained from the Pharma-
ceutical Development Section of the National Institutes of Health (Bethesda, 
MD), supplied as a lyophilized powder, was reconstituted in 5 ml saline 0.9% 
for injection and vortex-mixed for at least 20 minutes after reconstitution. 
The LPS solution was administered as an intravenous bolus injection at a 
dose of 2 ng/kg body weight in one minute at t = 0 hours. Subjects were con-
tinuously monitored up till 8 hours after LPS administration. 
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Breath collection
Each subject provided two single mouth-exhaled breath samples collected 
separately in 1-liter Mylar bags (ABC ballonnen, Zeist, The Netherlands) 
with 40 seconds pause in between samples. Breath samples were collected 
using a hand held breath sampler that is custom-built according to the ATS 
Guidelines and validated previously269,270. The exhaled breath line consists of 
a bacterial filter (Air Safety Limited, Lancashire, UK), a discard bag (150 ml) 
for collection of the dead space, a pressure meter and ends with the sampling 
bag. The pressure meter provides a back pressure of 10 cm H2O that ensures 
soft palate closure and prevents nasal contamination and was calibrated for 
50 ml/s exhalation flow. After a few tests on the exhalation procedure, the 
subjects were asked to exhale while having visual feedback from 3 LEDs (two 
green and one red) indicating suitable pressure/exhalation flow rate for the 
sampling (when both green LEDs were on). Breath samples were collected 
before LPS administration (approximately 5 minutes), every 15 minutes 
from 0 to 2 hours after LPS administration, and every hour from 4-8 hours 
after LPS administration. In addition, ambient air samples were collected 
every hour.
8-isoprostane assay
8-isoprostane levels in supernatants from moDCs and in plasma samples 
from healthy volunteers undergoing experimental human endotoxemia were 
determined using an enzyme immune assay (EIA) according to the manufac-
turer’s instructions (Cayman Chemical, Ann Arbor, USA). 
Cytokine/chemokine/stress hormone assays
For the determination of circulating cytokine levels from healthy volunteers 
undergoing experimental human endotoxemia,  EDTA anticoagulated blood 
was centrifuged immediately after collection (2000g, 10 minutes, 4°C), after 
which plasma was stored at -80°C until analysis. Concentrations of TNF-α, 
IL-6, IL-8, MCP-1, IL-1RA, and IL-10 were measured using a simultaneous 
Luminex Assay according to the manufacturer’s instructions (Milliplex, 
Millipore, Billerica, MA, USA). Circulating levels of epinephrine, norepi-
nephrine, and cortisol were determined as described previously268.
Ethylene detection
Ethylene was detected by a CO2 laser-based photoacoustic detector (ETD-
300, Sensor Sense) as described previously254. Briefly, the ETD-300 uses a 
CO2 laser emitting light in the 10 μm region where ethylene presents the 
strongest absorption features. The energy from the laser light causes local 
heating of the gas sample and by switching the light on and off with a certain 
frequency, rapid heating/cooling occurs, resulting in a periodical pressure 
change (a sound wave). The amplitude of this sound wave is proportional 
to the absorbed energy, i.e., the concentration of the ethylene in the absorp-
tion cell, and this can be detected with high-sensitivity microphones. The 
ETD-300 is capable of measuring ethylene on-line in the 300 pptv (pptv = 
parts-per-trillion volume, 1:1012) range within a 5 seconds time scale. All gas 
samples were led through a KOH-CaCl2 scrubber before entering the detec-
tor to remove water and carbon dioxide. The ethylene released in the head-
space of the lipid samples during the 30 minute incubation was transported 
to the ethylene detector using clean air as carrier gas at a constant flow of 3 
L/hr. Each sample was measured for 10 minutes in stop and flow mode of the 
instrument271. The PBL samples were measured in the same way, but were 
incubated for 60 minutes. For ethylene detection in breath of healthy volun-
teers, the content of the sampling bags was introduced into the ethylene de-
tector with a small pump at a constant flow of 3 L/h. Each sample was mea-
sured for about 8 minutes (the steady state C2H4 concentration was reached 
within 2 min) and an averaged value of the last 2 minutes was determined. 
The ethylene concentration in exhaled breath was measured in duplicate for 
each subject and the average value used for analysis. All sampling bags were 
analyzed within 24 hours. The stability of exhaled ethylene in the Mylar bags 
was tested prior the endotoxemia experiment from 0 to 24 hours. 15 mL of 
ethylene from a certified calibrated mixture of 1 ppmv ethylene in air (Linde 
Gas Benelux, Netherlands) was injected into a Mylar bag filled with 1L ex-
haled breath. Each bag was analyzed directly after injection of ethylene, and 
randomly after 1, 2, 4, 8, 16 or 24 hours. The experiment was performed in 
triplicate and showed that ethylene concentration in the bags was preserved 
within a 2.6% error range.
Statistical analysis
In vitro results are presented as mean ± SEM or geometric mean with 95% 
CI of at least three different donors/independent experiments. Repeated 
measures one-way ANOVA with Bonferroni post-hoc tests, paired 2-sided 
Student’s t-tests or Wilcoxon matched-pairs signed rank tests were applied to 
assess significance. In vivo data are represented as median and interquartile 
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range. Friedman tests with Dunn’s post-hoc test were applied to assess signif-
icance for the in vivo data. Furthermore, Pearson correlation on log-trans-
formed data was used to investigate the relationship between parameters. A 
value of p < 0.05 was considered statistically significant (***p < 0.001, **p < 
0.005, *p < 0.05).
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Lipid peroxidation in moDCs as measured by blue-shift of Bodipy581/591-C11
fluorescence.
Except for the untreated sample, all cells were exposed to 1 µg/ml LPS (data point shown in 
Figure 2A). In addition, cells were treated with either 100 µM α-tocopherol or 25 µM defer-
oxamine. Both the lipophilic antioxidant α-tocopherol and the iron chelator deferoxamine 
were able to completely rescue LPS-induced lipid peroxidation (*** p < 0.001; * p < 0.05).
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Production of pro-inflammatory cytokine IL-6
A. Production of the pro-inflammatory cytokine interleukin-6 (IL-6) from moDCs exposed 
to different concentrations of LPS as measured by ELISA. Error bars indicate mean +/- SEM 
(n=3), asterisks indicate a significant difference compared to untreated cells. B. Production 
of IL-6 by moDCs after treatment with either 1 µg/ml LPS, 100 µM α-tocopherol, 25 µM 
deferoxamine or 100 µM Fe(II)SO4. Only LPS was able to induce an inflammatory response 
(p = 0.028), whereas addition of either antioxidants (α-tocopherol, deferoxamine) or a 
chemical inducer of lipid peroxidation (Fe(II)SO4) do not trigger cytokine secretion (*** p < 
0.001; ** p < 0.005; * p < 0.05).
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Abstract 
Solid tumors grow at a high speed leading to insufficient blood supply to 
tumor cells. This makes the tumor hypoxic, resulting in the Warburg effect 
and an increased generation of reactive oxygen species (ROS). Hypoxia and 
ROS affect immune cells in the tumor micro-environment, and thereby 
affect their immune function. Here, we review the known effects of hypoxia 
and ROS on the function and physiology of dendritic cells (DCs). DCs can 
(cross-)present tumor antigen to activate naive T cells, which play a pivotal 
role in anti-tumor immunity. ROS might enter DCs via aquaporins in the 
plasma membrane, diffusion across the plasma membrane or via extracellu-
lar vesicles (EVs) released by tumor cells. Hypoxia and ROS exert complex 
effects on DCs, and can both inhibit and activate maturation of immature 
DCs. Furthermore, ROS transferred by EVs and/or produced by the DC can 
both promote antigen (cross-)presentation through phagosomal alkaliniza-
tion, which preserves antigens by inhibiting proteases and by direct oxidative 
modification of proteases. Hypoxia leads to a more migratory and inflamma-
tory DC phenotype. Lastly, hypoxia alters DCs to shift the T- cell response 
towards a tumor suppressive Th17 phenotype. From numerous studies, the 
concept is emerging that hypoxia and ROS are mutually dependent effectors 
on DC function in the tumor micro-environment. Understanding their pre-
cise roles and interplay is important given that an adaptive immune response 
is required to clear tumor cells.
Introduction
When solid tumors grow, the oxygen demand increases rapidly while there is 
insufficient vascularization. This causes the tumor to become hypoxic at the 
tumor core and the edges of the invasive front272. Due to the lack of oxygen, 
ATP is mostly produced via a high rate of anaerobic glycolysis; this is called 
the Warburg effect. This effect leads to lactic acid fermentation in the cytosol 
and increased oxidative stress in the form of H2O2 and other radicals. H2O2 
activates the transcription factor Nrf2 which further upregulates glycoly-
sis-related genes and further contributes to the Warburg effect105,273. ROS is 
important for tumor growth via the kinase AMPK. AMPK can suppress cell 
proliferation via cell cycle arrest274 and its activation depends on reduction 
of cysteine residues by thioredoxin (Trx) at the catalytic subunit alpha275,276. 
However, these sites can be oxidized by ROS to inactivate AMPK, promoting 
tumor cell proliferation. The increase in oxidative stress also translates to the 
tumor microenvironment (TME). The TME comprises the tumor cells itself 
and the surrounding stromal cell compartment, containing blood vessels, 
cells from the immune system, fibroblasts and extracellular matrix154,277.
In cancer cells, there are multiple sources of ROS (Figure 1). Oncogenic mu-
tations (e.g., in Ras, Myc and p53) can cause mitochondrial dysfunction and 
increased leakage of ROS. This leakage occurs mostly at complex 1 or com-
plex 3 of the respiratory chain, where electrons from NAD(P)H or FADH2 
react with oxygen to form superoxide anion. Second, ROS is formed enzy-
matically by NAD(P)H oxidases (NOX), which can be activated by various 
growth factors, such as VEGF and angiopoietin which are often upregulated 
in cancer278,279. Third, exogenous radiation (e.g., UV light, radiotherapy) can 
cause the production of ROS280. Fourth, ROS are by-products of cellular 
metabolism such as from protein folding and beta-oxidation of fatty acids in 
the mitochondria and peroxisomes105,281. Last, intracellular enzymes, such as 
xanthine oxidase, cyclooxygenases, cytochrome p450 enzymes, lipoxygenas-
es and nitric oxide synthetase, generate ROS as a metabolic byproduct280,282. 
Tumor cells thus have to cope with comparatively high intracellular levels 
of ROS and they do this by upregulating antioxidative systems such as Trx, 
peroxiredoxin (Prx), catalase, superoxide dismutases (SOD) and generation 
of NAD(P)H282. Against superoxide anion specifically, dismutation to H2O2 is 
the primary protective mechanism and this can occur enzymatically by SOD 
or spontaneously in acidic environments. Subsequently, H2O2 can then be 
degraded into water and oxygen by catalase4.
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In addition to cancer cells, ROS-producing immune cells of myeloid origin 
are present in the TME121. These include DCs (see below), but are mainly 
macrophages that have differentiated from circulating monocytes283 and, 
depending on the stimulus, can develop towards more cytotoxic or im-
munosuppressive phenotypes284. However, tumor-associated macrophages 
in the TME are usually immunosuppressive, as they produce IL-10 and 
transforming growth factor β285 and recruit regulatory T cells via CCL22286. 
ROS produced by these cells was found to be detrimental for cancer pro-
gression, as increased H2O2 secretion by macrophages was shown to be a 
sufficient trigger for both tumor initiation and development of epithelial can-
cer287. This was further exacerbated by H2O2-mediated induction of TNF-α 
and TNF receptor 1 transcription, which lead to recruitment of more H2O2-
secreting macrophages. Additionally, ROS production by the monocyte 
precursors of these macrophages was shown to be a strong determinant for 
development towards an immunosuppressive phenotype288. 
Hypoxia and oxidative stress influence multiple functions of the cancer cells, 
such as angiogenesis, cell proliferation and apoptosis, and thereby can pro-
mote tumorigenesis. H2O2 promotes angiogenesis by activating the transcrip-
tion factors NF-κB and AP-1, leading to  activation of VEGF transcription 
factors NF-κB and AP1289, VEGF secretion290 as well as VEGF receptor 2 
transcription291. In addition, H2O2 can also activate VEGF receptor 2 in a 
ligand-independent manner via Src kinases292. VEGF activates NOX and 
thereby leads to the generation of more ROS, forming a positive feedback 
loop, and making NOX a potential therapeutic target for inhibition of angio-
genesis105,278. A major mechanism by which ROS affects physiological pro-
cesses is by the formation of disulfide bonds. For example, H2O2 modifies the 
thiolates of cysteine residues in redox sensitive proteins282 and particularly 
zinc-bound cysteines perform oxidative stress sensing293. Zinc-bound cyste-
ines are present in zinc finger transcription factors, for example the GATA 
family of transcription factors and Krüppel-like Factor 2, both of which are 
involved in ROS-mediated signaling pathways294–297. Lastly, ROS influence 
apoptosis induced by the dimerization of the kinase ASK1 with TRAF2, 
which causes apoptosis via activation of the kinases JNK and p38 MAPK. 
This dimerization is induced by H2O2, but blocked by thioredoxin (Trx)298,299. 
Trx is bound to ASK1 by a disulfide bond at the N-terminal domain of 
ASK1, leading to ubiquitination and proteosomal degradation of ASK1. High 
levels of H2O2 counteract the functioning of Trx and cause the release of Trx 
from ASK1, because of the formation of an intramolecular disulfide bond108.
It is not completely understood how hypoxia and ROS in the TME influence 
infiltrating immune cells, which is the focus of this review. Especially DCs 
play a major role in generating anti-tumor immunity, due to their ability to 
activate naive T cells. After encountering an antigen, DCs can maturate and 
migrate to the lymph nodes to present processed antigens to T cells. The abil-
ity of DCs to (cross-)present antigens and activate T cells is influenced by the 
inflammatory environments that the cells encounter15. Since DCs encoun-
ter a variety of environments that differ in oxygen tension and ROS levels 
during antigen uptake and migration to the lymph nodes, it is likely that 
these environments affect the final immune response. The aim of this review 
is to provide a comprehensive overview of the effects of TME-associated 
oxidative stress on DCs.
ROS entry in DCs
Solid tumors are frequently invaded by DCs and other immune cells, which 
hence are exposed to the hypoxia and radicals in the TME. ROS may affect 
the plasma membrane composition of invading immune cells through oxida-
tion of both the lipid bilayer and of membrane proteins300. However, to affect 
intracellular processes, ROS have to traverse the plasma membrane. Many 
species of ROS, such as superoxide anion, carry a free electron and cannot 
efficiently traverse the apolar lipid bilayers. However, either spontaneously 
or catalyzed by the abundant SODs, superoxide anion can dismutate to H2O2 
which is uncharged and does not carry a free electron. H2O2 has a lower 
reactivity compared to ROS species such as superoxide anion and hydroxyl 
radicals and this makes H2O2 relatively stable and also allows it to diffuse 
through membranes and to enter the nucleus to cause DNA damage280. Its 
relatively high stability even allows H2O2 to signal between different cells282. 
These properties allow H2O2 to increase the redox potential of the TME. 
H2O2 cannot only passively diffuse through lipid membranes, but also en-
ter cells through the aquaporin channel AQP8, as shown by heterologous 
expression in yeast301, and through AQP1, 3 and 8 in a human leukemia cell 
line302. Both immature and monocyte-derived dendritic cells express AQP3, 
7 and 9 and mature DCs express AQP7 and 9303,304, suggesting that H2O2 can 
enter DCs via these channels. Other aquaporins might be involved as well, as 
the homologs AQP7, AQP9, AQP10, AQP12A and AQP12B are all expressed 
by human immune cells305. Superoxide anion can enter endothelial cells by 
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diffusion through Cl- channel-3306 and might also enter immune cells via 
this channel, as it is expressed in human macrophages and peripheral blood 
mononuclear cells307,308. However, there is no experimental evidence yet that 
these channels mediate entry of H2O2 and superoxide anion in DCs.
ROS affect DC maturation
ROS are directly implicated in DC maturation by the activation of p38-
MAPK and ERK1/2. DCs treated with 1-fluoro-2,4-dinitrobenzene, a skin 
sensitizer which is perceived as a danger signal by DCs, showed increased 
ROS production and activation of p38-MAPK via an unknown mecha-
nism309. In line with ROS promoting DC activation, H2O2-treated human 
peripheral blood DCs were more efficient in promoting T cell proliferation 
and showed an upregulation of cell surface molecules MHC-II, CD40 and 
CD86, all important components of T cell activation310. The mechanism by 
which ROS promote DC maturation is not known.
ROS can also reduce DC maturation via ER stress. Danger signals such as 
1-fluoro-2,4-dinitrobenzene cause accumulation of misfolded proteins in 
the cell, leading to ER stress and an increase in mitochondrial ROS pro-
duction309. Oxidative stress can also affect ER function by disturbing Ca2+ 
homeostasis309. The accumulation of misfolded proteins activates the un-
folded protein response, aimed at restoring normal cell function by halting 
translation, degradation of misfolded proteins, and increasing expression 
of chaperone proteins. This study observed that ROS affected the PERK-
eIF2α-ATF4 axis of the unfolded protein response, which led to a short-term 
block of CD86, IL-1β and IL-12B expression in THP-1 monocytes. However, 
these genes were upregulated at later time points, indicating a pro-inflam-
matory response. ER stress is also caused by lipid peroxidation products 
that follow increased ROS production, such as 4-hydroxynonenal (4-HNE). 
This aldehyde readily forms protein adducts due to its reactivity with thiols 
and amine groups63, which can trigger the unfolded protein response. Ad-
ditionally, 4-HNE was shown to form adducts with ER-resident chaperone 
proteins311, leading to increased activation of ER stress transcription factor 
XBP1 in ovarian cancer-associated DCs84. This in turn inhibited anti-tumor 
immunity via accumulation of lipid bodies in the DC, which blocks translo-
cation of MHC-I to the cell surface83,84. As 4-HNE is relatively stable and able 
to diffuse through membranes, DCs may even internalize 4-HNE from the 
TME65,66. Likewise, malondialdehyde, another common lipid peroxidation 
product, also forms protein adducts which are shown to be strongly auto-im-
munogenic, which may hamper specific anti-tumor responses74–76. 
Effects of ROS on antigen presentation
ROS influence the ability of DCs to cross-present antigens to CD8+ cells48. 
Upon activation of Toll-like receptors (TLRs), NOX2 is activated in the DCs 
and produces large amounts of superoxide anion in endo/phagosomes56,129,312. 
This increases the endo/phagosomal pH through the consumption of pro-
tons by the dismutation of superoxide anion to H2O248,129. The increased 
pH impacts cross-presentation through antigen conservation, as lysosomal 
hydrolases with acidic pH optima are less activated48. In addition, ROS can 
affect the activity of the endosomal V-ATPase by formation of a disulphide 
bond between cysteine residues located within the nucleotide-binding 
subunits, leading to its inactivation and reduced acidification of the endo-
somal lumen52,129. Endo/phagosomal proteases like cathepsins are modified 
in a similar fashion, leading to altered epitopes for both MHC-I and MHC-
II49,53,54. ROS can also induce the release of antigen from phagosomes into 
the cytosol by causing leakage of antigens through lipid peroxidation of the 
endo/phagosomal membranes, and this can promote antigen cross-presenta-
tion56,131. 
However, the effect on antigen presentation depends on the cellular site of 
ROS production, as a study in aged mice suggested an inhibitory role for 
mitochondrial ROS in cross-presentation by bone marrow-derived DCs313. 
Aged DCs (16-20 months) show signs of mitochondrial dysfunction, leading 
to increased ROS production compared to young DCs (2-3 months). Scav-
enging ROS partially improved the cross-presentation efficiency of the aged 
DCs313. This finding indicates that, although DCs actively use endo/phagoso-
mal ROS to enable cross-presentation, a general increase in the environmen-
tal redox potential could also hamper cross-presentation.
Extracellular vesicle release by tumor cells
A recently identified source of ROS in the TME are EVs released by tumor 
cells. EVs  contain many different compounds, including ROS as shown 
by flow cytometry with a fluorescent ROS probe312. ROS was also found in 
EVs derived from hypoxic/reoxygenated human umbilical vein endothelial 
cells314. However, the source of EVs in the TME is still controversial, and 
it is debated whether cancer cells can dictate their content or they are only 
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membrane blebs or necrotic cell bodies315. There is some evidence for con-
trolled release of EVs in a process involving the endosomal sorting com-
plex316. This complex generates the intraluminal vesicles of multivesicular 
bodies by bulging the membrane inwards onto the lumen of late endosomes. 
When multivesicular bodies fuse with the plasma membrane, these intralu-
minal vesicles are released as EVs317,318. However, other mechanisms of EV 
formation have also been proposed, such as direct shedding from the plasma 
membrane319,320. EVs of intracellular origin are often called exosomes, while 
EVs shed from the plasma membrane are called microvesicles. However, this 
nomenclature and the methods to discriminate between various sources of 
EVs are not yet standardized, therefore we will use the general term EVs in 
this review315.
Several studies showed that hypoxia increases the release of EVs by different 
types of tumor cells, thereby suppressing the immune response321,322. In a 
study on breast cancer cells, it was found that the transcription factor HIF-
1α is responsible for this increase in EV production, since the release of EVs 
was blocked upon silencing of HIF-1α322. A second study on breast cancer 
cells came to a similar conclusion, and found that cells exposed to hypox-
ia overexpressed the small GTPase RAB22A in a HIF dependent manner, 
leading to increased formation of EVs in breast cancer323. The cargo of EVs is 
possibly influenced by hypoxia as well, as the level of the micro-RNA miR-
210 is elevated in EVs upon hypoxia322. Transcription of miR-210 is mediated 
by HIFs and it has target genes involved in cell survival, angiogenesis and 
metabolism324. 
Effects of extracellular vesicles on DCs
EVs influence immune cells and for instance may control macrophage differ-
entiation towards an immunosuppressive phenotype325, but also might exert 
effects on DC function. Multiple mechanisms are suggested for the uptake of 
EVs by recipient cells: fusion, receptor-ligand interactions and endocytosis. 
The uptake of EVs by DCs is mediated by several factors, including CD11a, 
intracellular adhesion molecule 1, phosphatidylserine and milk fat globule 
E8 on DCs, and tetraspanins CD9 and CD81 on EVs326. Glycosylation is also 
involved in targeting EVs, as uptake of EVs derived from Jurkat T cells by 
myeloid DCs was inhibited by blocking Siglec-1327. Siglec-1 preferentially 
binds to α2,3-linked sialic acids which decorate proteins on the surface of 
EVs. Furthermore, EV uptake by DCs involves interaction between LFA-1 
and C-type lectin receptors like DEC205 on DCs with CD54 or various gly-
coproteins on the EVs328. 
After uptake, the ROS present in EVs might affect DC function. EVs derived 
from ovarian cancer cells promote antigen cross-presentation in DCs via 
ROS-mediated phagosomal alkalization312, although in this study the effects 
of other EV components cannot be completely excluded. Moreover, it is 
unclear whether EV-derived ROS are directly responsible for ROS accumu-
lation inside the phagosomes, or whether this is the result of ROS produc-
ing enzymes carried by the EVs329 or other ROS-inducing components330. 
Besides changing the phagosomal pH, it is proposed that EVs induce anti-
gen-specific tolerance in DCs. Tumor EVs contain antigens and EVs taken 
up by immature DCs are shown to inhibit the maturation of DCs331. In this 
study, EVs were internalized by mouse CD11c+ cells, which subsequently 
downregulated expression of the maturation markers MHC-II and CD86, 
while levels of the anti-inflammatory cytokine transforming growth factor 
β1 were elevated in these DCs. This steered CD4+ T cells towards a regulato-
ry phenotype, capable of suppressing B cell responses. The uptake of EVs by 
DCs can however also promote CD8+ T cell responses, benefitting antitumor 
immunity, because mature DCs pulsed with EVs expressed MHC-I, MHC-II, 
CD40, CD54 and CD80 at higher levels than controls, while immature DCs 
pulsed with EVs did not respond328. In fact, mice bearing BL6-10OVA tumor 
cells were able to clear their tumors following adoptive transfer with mature 
DCs pulsed with OVA-containing EVs, while DCs pulsed with soluble OVA 
only reduced tumor growth temporarily328. These EVs might potentially 
contain ROS and tumor material which induces ROS and danger-associ-
ated molecular pathogen signaling via pattern recognition receptors. This 
would explain the more efficient cross-presentation of EV-derived antigens 
compared to soluble antigens312, as ROS are a major factor in upregulating 
cross-presentation48,53,54,56,132. However, the effects of EV-containing ROS 
on antigen presentation are difficult to discern from the effects of other EV 
components, such as micro-RNAs.
The molecular mechanisms how EVs affect DC maturation and the role of 
EV-encapsulated ROS in this process are still largely unknown. In murine 
CD11b+ myeloid DC precursors, tumor EVs inhibited the differentiation 
of DCs via enhanced expression of interleukin 6 (IL-6)332. After EV uptake, 
CD11c expression was significantly lowered and IL-6 expression was higher 
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than in the control cultures. Precursor DCs were able to differentiate in the 
CD11c+ phenotype, but these DCs were less able to mature as measured by 
analysis of the expression of the co-stimulatory molecules CD86 and CD80. 
The expression of CD86 and CD80 was significantly lower and correlated 
with the concentration of EVs added to the culture332. When DC precursors 
were isolated from IL-6 knockout mice, DC maturation was not inhibited, 
suggesting that the inhibition is mediated by IL-6. The authors observed sim-
ilar effects on differentiation of human CD14+ monocytes into monocyte-de-
rived DCs after stimulation with isolated EVs from the MDA-MB-231 breast 
cancer cell line. In conclusion, several immunologically relevant effects of 
EVs have been described, many of which are likely to depend at least partly 
on EVs containing ROS. However, the effects of other compounds present in 
EVs cannot be excluded and this requires further investigation.
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Figure 1. Targets and sources of ROS in DCs.
(Left) ROS can attack both mono- and poly-unsaturated lipids in membranes, causing endo-
somal leakage and loss of pH and electron gradients. Cysteine residues on proteins can oxi-
dize, resulting in the formation of disulfide bridges or a stepwise oxidation to sulfonic acid. 
This can activate redox-sensitive signaling factors, but also block enzymatic activity or cause 
protein misfolding. Finally, both free and DNA-helix incorporated guanine nucleotides can 
oxidize, leading to GC-TA or GC-CG transversion mutations. (Right) Sources of ROS for 
DCs in the TME: increased NOX (NAD(P)H oxidase) activity, ER stress due to the unfolded 
protein response, β-oxidation of fatty acids, abrogated electron transfer in mitochondria and 
uptake of ROS-containing tumor-derived EVs.
The TME is hypoxic
As mentioned above, a major cause for the generation of ROS in the TME is 
a disturbed metabolism of the cancer cells. Since ROS generation consumes 
molecular oxygen, this increases the hypoxic conditions caused by the poor 
vascularization frequently associated with tumors113. A major signaling 
component downstream of hypoxia is the HIF family of transcription factors, 
consisting of HIF-1α, HIF-2α and HIF-1β. At normoxic conditions, the alpha 
subunit is targeted for degradation via hydroxylation by prolyl hydroxylase 
domain enzymes and factor inhibiting HIF-1α. Upon hydroxylation, HIF-
1α and HIF-2α bind to the von Hippel–Lindau tumor-suppressor protein, 
allowing ubiquitination and ultimately proteasomal degradation110,111,114. 
The hydroxylation reaction requires oxygen and therefore cannot efficient-
ly occur under hypoxic conditions, resulting in the accumulation of the 
HIF-1α and/or HIF-2α subunits, allowing them to dimerize with HIF-1β 
and translocate to the nucleus. Here, the heterodimer binds to the hypoxic 
responsive element (HRE) in the promotor region of target genes115,116,162. 
Many of the HIF target genes are involved in angiogenesis and in erythropoi-
esis, and HIF also promotes glycolysis by upregulating expression of plasma 
membrane glucose transporters and inhibiting pyruvate dehydrogenase 
kinase, which blocks the translocation of pyruvate to the tricarboxylic acid 
cycle333,334. 
Hypoxia alters DC differentiation and maturation
The effects of hypoxia on the differentiation and maturation of DCs are quite 
well studied, although there is little consensus between studies. For example, 
expression of MHC-II is mostly reported to decrease in hypoxic environ-
ments164,167,173,177–179, but the opposite166 or no effect163,165 have been reported as 
well. The same holds for DC maturation markers like CD80, CD83 or CD86, 
where several studies found no effects163,165,178, but upregulation166 and down-
regulation167,171,173,177 were reported as well. Hypoxic alteration of MHC-I 
expression is less well studied, however HIF-1α activity is implied in upregu-
lating MHC-I expression335. These contradicting results likely arise from the 
complex interplay of ROS and hypoxia signaling with immune cell activation 
pathways. In particular, hypoxia is capable of altering TLR signaling180 and 
subsequently leads to altered cytokine secretion patterns166,167. Expression of 
TLR4193 and its downstream kinase MAP3K8 (also known as Cot or TPL-
2) are upregulated by hypoxia116,135. This leads to an hypoxic potentiation of 
TLR4-mediated secretion of TNF-α in human monocyte-derived DCs135. 
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In line with this, hypoxia has also been found to increase secretion of other 
pro-inflammatory cytokines such as IL-6, IL-8 and IL-1β in primary human 
macrophages and osteoclasts167,185,204,336. So, while hypoxia itself does not 
cause ROS formation, it can trigger inflammation which in turn promotes 
ROS formation. Since ROS formation consumes oxygen, it causes additional 
hypoxia, resulting in a feedback loop.
Hypoxia skews immature DCs towards a highly mobile phenotype by up-
regulating genes involved in cell motility169. The chemokine receptors CCR2, 
CCR3, CCR5, CX3CR1, C5R1 and FPR3 are upregulated upon hypoxia, 
while expression of chemokines CCL26, CCL24 and CCL14 are inhibited by 
hypoxia179,337. This suggests that immature DCs differentiated in a hypoxic 
TME migrate away towards normoxic tissues, potentially suppressing an-
ti-tumor immunity. Moreover, a variety of tumors secrete elevated levels of 
prostaglandin E2, which is a strong migratory stimulus for immature DCs337. 
Prostaglanding E2 is generated by cyclooxygenases, many of which are HIF 
target genes116,185. In contrast, mature DCs downregulate expression of CCR7 
in hypoxic conditions. CCR7 is the chemokine receptor which signals DCs 
to migrate to draining lymph nodes in response to lymph node derived 
chemokines179. This observation is in line with the poor chemotactic ability 
of hypoxic mature DCs in response to the lymph node chemokine MIP-3β. 
Thus, evidence suggests that the hypoxic TME promotes the expulsion of 
immature DCs from the tumor, whereas the migration of mature DCs to the 
lymph nodes is reduced. 
The effects of hypoxia on DC maturation might well be transient. Murine 
DCs cultured under low oxygen tensions expressed lower levels of MHC-II, 
CD80 and CD86 compared to DCs under normoxic conditions173. However, 
reoxygenation of hypoxia-differentiated DCs restored the levels of these mat-
uration markers, suggesting that once these DCs migrate towards the lymph 
nodes they can regain full functionality173. Finally, hypoxia affects antigen 
uptake as it decreased the phagocytic capacity of immature DC compared 
to DCs cultured under normoxic conditions179. In conclusion, hypoxia can 
both increase and decrease DC maturation, likely depending on the presence 
of ROS and other inflammatory stimuli in the TME. Moreover, hypoxia can 
promote tumor progression, as it stimulates migration of immature DCs 
out of the TME while restricting migration of mature DCs to prevent T cell 
activation in draining lymph nodes.
Hypoxia skews T helper cell differentiation by DCs
T cell priming is an essential function of DCs and this process is affected by 
the TME as well. Immature blood monocyte-derived DCs cultured at hy-
poxic conditions were found to be biased towards a Th2-stimulatory phe-
notype by switching to secretion of IL-4 instead of IFN-γ179. These T cells 
mostly stimulate a humoral immune response and suppress DC activation 
via IL-10 secretion. In addition, DCs cultured under hypoxia secreted in-
creased amounts of osteopontin, which strongly promotes tumor cell mi-
gration179. However, osteopontin might also promote an immune response, 
as it promotes IFN-α production via TLR9 signaling in plasmacytoid DCs, 
which upregulates the expression of MHC-I338. The TME also affects T cell 
recruitment to the tumor, as long-term hypoxia for multiple days was shown 
to increase the expression cytokines CCL3, CCL5 and CCL20 in mature 
DCs339. These cytokines are chemotactic for both activated and memory T 
cells, monocytes and immature DCs. Finally HIF-1α activates transcription 
of retinoic acid receptor-related orphan nuclear receptor gamma (RORγt) 
and together these two factors regulate the transcription of IL-17340. There-
fore, hypoxia increases the differentiation towards regulatory T helper 17 
(Th17) cells via IL-6 in a uniquely TGF-β independent fashion341.  Regulatory 
Th17 cells are associated with host defense and autoimmune inflammatory 
responses224,342 and promote tumor growth 340.
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Figure 2. Combined effects of ROS and hypoxia in the TME.
ROS promote DC maturation, antigen cross-presentation, DC migration and CD8+ T cell 
responses needed for anti-tumor immunity. In contrast, hypoxia can both lower or increase 
DC maturation and skews T cell responses towards a tolerogenic Th17 response. Moreover, 
hypoxia can inhibit ingress of immature DCs into the tumor whilst blocking migration of 
mature DCs from the tumor to draining lymph nodes. Hypoxia does however promote 
secretion of various inflammatory cytokines such as TNF-α.
Discussion
In this review, we discussed how the hypoxic, oxidative environment of 
the TME influences invading immune cells. Figure 2 shows an overview of 
the major effects that have been found so far. The effects of the cytokines 
and chemokines found in the TME have been quite extensively studied. In 
contrast, comparatively little is known about the effects of localized ROS 
and hypoxia that frequently hallmark the TME on tumor-invading immune 
cells. Both the tumor cells and the immune cells produce various forms of 
ROS, that directly affect the cell physiology but can also target neighboring 
cells, either by diffusion of ROS or by ROS encapsulated in EVs (Figure 1). 
ROS generation consumes oxygen and is therefore often paired with local 
hypoxia, whereas hypoxia can promote formation of ROS, making it difficult 
to differentiate the effects of ROS and hypoxia from each other. As described 
in this review, the effects of hypoxia on DC phenotype and maturation are 
under debate. It is becoming increasingly clear that hypoxia stimulates mi-
gration of immature DCs but prevents migration of mature DCs. This might 
result in the TME becoming an immunosuppressive “DC trap”, with limited 
influx and maturation of immature DCs while the egress of activated DCs is 
prevented. However, in contrast to this, hypoxia seems to upregulate secre-
tion of various pro-inflammatory anti-tumorigenic cytokines. Maybe these 
contradicting effects are the result of ROS signaling. 
A major question is whether tumor cells use EV release as a protective mech-
anism from oxidative damage as a result of their high anaerobic metabolic 
activity, or as an active defense mechanism to prevent immune responses. 
However, due to the small size and heterogeneity of EVs, it is difficult to 
study their content. In vitro approaches using artificial membranes carrying 
ROS might help to overcome this problem. Another problem is that resolv-
ing the physiological effects of specific sources and types of ROS remains 
challenging, due to their highly transient nature and the lack of specific 
probes that offer adequate spatiotemporal resolution. Controlling specific 
redox signaling and antioxidant pathways would be a valid approach to this 
problem, since these parameters can be modified with genetic techniques. In 
addition, ROS can be induced with organellar precision using fusion con-
structs of proteins with known cellular location with photosensitizer proteins 
like SuperNova343. Likewise, culture media can be supplemented with a wide 
range of antioxidants or radical-generating systems. 
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Another key question is whether ROS can be used to treat cancer. A possible 
avenue would be local administration of pro-oxidants in the TME. Tumor 
cells often display a defective Nrf2 pathway, rendering them more suscepti-
ble to oxidative stress344, while DCs maturation can be enhanced by ROS as 
described above. In a xenograft mouse model of chronic lymphocyte leuke-
mia, pro-oxidative treatment strongly reduced tumor burden344. However, 
since ROS also has pro-tumorigenic effects, the opposite approach of admin-
istrating anti-oxidants is also possible. There have been several randomized 
controlled trials in which prophylactic effects of such antioxidant supple-
mentation was investigated. However, for incidence of prostate and total 
cancer in men, supplemental vitamin E had no effects345–347 and in one study 
even significantly increased prostate cancer incidence348.
Since the effects of ROS on cancer and immune cells are complex and de-
pendent on the site of ROS generation and the interplay with hypoxia and 
immune signaling, targeting ROS by simply administering pro- or antiox-
idants on might not be sufficient. Targeting ROS or antioxidants to a spe-
cific cell type may provide a more successful strategy to combat cancer. For 
instance, promoting ROS formation in the lumen of endo/phagosomes of 
DCs could be a strategy to promote antigen cross-presentation48,53–56,129,131, 
whereas blockage of mitochondrial ROS formation might increase T cell 
activation in the lymph nodes313. In the paper by Dingjan et al., the photo-
sensitizer protein KillerRed349 was employed to increase endosomal ROS in 
DCs by transfecting a plasmid encoding a KillerRed fusion protein targeted 
to phagosomes. However, transfection of tumor-associated DCs in vivo is 
still very challenging. An alternative approach would be to target DCs with 
nanoparticles carrying a ROS-inducer350–352, for example an iron core that 
promotes generation of highly reactive hydroxyl radicals through Fenton 
chemistry353,354. 
In a similar fashion, cancer cells might be specifically targeted with anti-
oxidants to block the pro-tumorigenic effects of ROS. While, as described 
above, systemic antioxidant therapy proved unsuccessful in cancer, localized 
interventions are still worth considering. Endosomal NOX2 activity was 
recently shown to play an important role in progression of prostate cancer355, 
which could be targeted (for instance with antibodies) with antioxidant-car-
rying small particles for exclusive uptake via endocytosis by tumor cells356. 
Another interesting targeting approach is ROS-responsive nanoparticles 
for targeted delivery of hydrophilic and cationic drugs in ROS-producing 
cells357. In this study, Meng et al. show that MnO2-based nanoparticles selec-
tively release the HIF-1 inhibitor acriflavine in tumor cells after oxidation by 
H2O2 in vitro and in mouse model of colon cancer. Although the authors did 
not investigate uptake by phagocytic cells, it is likely that this method is also 
capable of releasing compounds in phagosomes. Finally, it might be highly 
beneficial to sequester lipid peroxidation products such as MDA and 4-HNE 
due to their negative impact on DC function, as described above. Doing so 
would protect DCs against these effects without interfering with ROS-in-
duced cross-presentation and DC maturation. Several potential compounds 
have been identified recently that warrant further investigation, of which 
histidine-containing dipeptides are currently the most promising358–360.
Given that cancer cells use hypoxia and ROS to reprogram immune and 
stromal cells in the TME to prevent an immune response and augment tumor 
progression, while at the same time the immune system uses ROS to signal 
inflammation and combat infection, ROS have huge therapeutic potential for 
combating cancer. Given this duality, the timing and localization of pro- or 
antioxidant interventions is likely highly critical. Understanding the intricate 
pathways of the production, signalling and effector responses of hypoxia and 
ROS is essential for designing such therapies.
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Abstract
Cells are exposed to radical stress, as reactive oxygen species (ROS) are a 
common byproduct of metabolism in mitochondria, especially upon hy-
poxia. ROS are also enzymatically generated in the inflammatory response 
at the cell membrane and in endosomal compartments. Lastly, ROS arise 
from external sources such as irradiation. Radicals can cause cellular damage 
leading to cell death, as they react indiscriminately with surrounding cellu-
lar components like lipids, proteins and nucleotides, and cells evolved ROS 
neutralizing mechanisms to cope with radical stress. However, cells should 
not neutralize all ROS, as they are important for many physiological process-
es within the cell, including signaling, pathogen killing and chemotaxis. The 
sensitivity of cells to ROS therefore likely depends on the subcellular location 
of ROS production, but how this affects cell viability is poorly understood. In 
this study, we developed an optogenetic toolbox for organelle-specific gen-
eration of ROS using the photosensitizer protein SuperNova that produces 
superoxide anion upon excitation with 590 nm light. We fused SuperNova to 
organelle specific localization signals to induce ROS with organellar preci-
sion. Selective ROS production did not affect cell viability in most organelles 
except for the nucleus. We conclude that cells are more sensitive to ROS 
production in the nucleus compared to other organelles, likely because of 
DNA damage. SuperNova is a promising tool to induce locally targeted ROS 
production opening up new possibilities to investigate processes and orga-
nelles that are affected by localized ROS production.
Introduction
Reactive oxygen species (ROS) are a common byproduct of aerobic respira-
tion and lipid metabolism5,361. Moreover, ROS can be present at high levels 
in disease environments due to enzymatic production by NADPH oxidation 
complexes (NOX)41 and as a consequence of hypoxia105,273. Cells are also 
exposed to ROS from the outside environment, e.g. from UV light, radioac-
tive radiation and ozone. ROS and other radicals are generally short-lived 
species as they rapidly and indiscriminately react with lipids, proteins and 
nucleic acids4,59,280. Too high ROS levels are well known to trigger cell death 
via caspase-mediated apoptosis or necrosis362. Prolonged elevated ROS levels 
have widespread effects on general health and, for example, correlate with 
onset of frailty363. Cells evolved molecular mechanisms in order to cope 
with ROS, including ROS-scavenging antioxidants and ROS neutralizing 
enzymes4. However, ROS are also needed for many physiological processes. 
In fact, many cellular processes and signaling pathways strongly depend on 
ROS, like growth factor signaling289, Src kinase activation106, chemotaxis364,365, 
metabolic feedback regulation366, induction of autophagy96, inflammasome 
formation367 and tumor necrosis factor (TNF)-α induced apoptosis108. Under 
inflammatory conditions, ROS synergize with hypoxia to stabilize HIF-1α368 
and upregulate its transcriptional activity135,209. In the immune system, ROS 
have many important functions, including killing of pathogens, antigen 
degradation and inflammatory signaling to other cells of the immune sys-
tem46,98,129,282,369. ROS are also a key regulator of antigen (cross-)presenta-
tion55,56,370. In order to allow these physiological functions, cells should not 
completely degrade and/or sequester ROS and have to cope with a certain 
level of radical stress.
Both the generation and functioning of ROS occur at distinct subcellular 
sites. Due to their roles in aerobic respiration and lipid oxidation, mitochon-
dria are exposed to relatively high levels of ROS371,372. In immune cells and 
endothelial cells, NOX complexes can generate large amounts of ROS at the 
plasma membrane and in the lumen of endosomes and phagosomes41. Com-
paratively little is known about ROS in the endoplasmic reticulum (ER) or 
Golgi compartments, but it is suggested that NOX activity and the concom-
itant change in pH play a role in disulfide bond formation during protein 
folding in the ER, as well as glycan alterations and Ca2+ homeostasis in the 
Golgi373,374. The nucleus can be expected to be exposed to comparatively low 
amounts of ROS, as external ROS has to diffuse first through the cytoplasm 
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where it can react or scavenged by antioxidant mechanisms. Additionally, the 
nucleus is protected by superoxide dismutase 14. Thus, different organelles 
are exposed to different levels of ROS and the sensitivity of cells to ROS-in-
duced cell death likely depends on the organelle. However, in most experi-
ments addressing ROS, ROS are induced systemically (i.e. through the entire 
cell) by addition of compounds such as tert-butyl hydroperoxide (TBHP), ar-
senic or iron to the culture medium. However, since the effects of ROS likely 
depend on the subcellular location of ROS generation, a method that allows 
for targeted production of ROS would be a valuable addition to the field.
In this study, we developed an optogenetic toolkit to induce ROS with or-
ganellar precision. We used SuperNova, a monomeric genetically-encoded 
photosensitizing fluorescent protein derived from KillerRed, which shows 
improved localization and does not perturb mitotic cell division343,349,375. The 
open structure of the β-barrel of SuperNova creates a water channel which 
connects to the chromophore375. ROS (singlet oxygen and superoxide anion) 
are generated upon excitation of this chromophore and can subsequently exit 
through the water channel. We generated constructs coding for SuperNova 
fusion proteins targeted to mitochondria, endosomes, trans-Golgi, nucleus 
and ER. We verified the localization of these SuperNova fusion proteins to 
their target organelles by microscopy. The effects of localized ROS produc-
tion on cell viability were assessed to compare the effects or radical stress in 
specific organelles. We found that cell viability was only affected upon ROS 
induction in the nucleus, but not in other organelles, indicating that cells 
are particularly sensitive to ROS in the nucleus. Our results show that our 
SuperNova fusion protein toolbox is a viable method of inducing ROS with 
organellar precision.
Results
In order to enable the induction of radical stress at specific organelles, we 
targeted SuperNova to  designated subcellular sites by fusing it to proteins 
and targeting sequences that locate to specific organelles (Figure 1). We 
fused SuperNova to the mitochondrial protein cytochrome c oxidase subunit 
8A (COX8), the luminal site of the endosomal vesicle associated membrane 
protein 8 (VAMP8), the trans-Golgi network integral membrane protein 2 
(TGON2), the ER protein calreticulin and to a nuclear localization signal 
(NLS) of human c-myc (PAAKRVKLD)376.
SuperNova Myc 27.7 kDaN C
SuperNova MycCOX8N C 32.9 kDa
SuperNova MycVAMP8N C 39.8 kDa
SuperNova TGON2N C 66.0 kDa
SuperNovaCalreticulin KDELN C 29.4 kDa
SuperNova MycNLSN C 29.0 kDa
Figure 1. Schematic overview of SuperNova fusion proteins. Myc: myc-tag; COX8: mito-
chondrial protein cytochrome c oxidase subunit 8A; VAMP8: endosomal vesicle associated 
membrane protein 8; TGON2: trans-Golgi network integral membrane protein 2; calretic-
ulin: ER protein; KDEL: ER-retention signal; NLS: nuclear localization signal. Molecular 
weights of the fusion constructs are indicated.
To validate the correct localization of these SuperNova fusion proteins to the 
targeted organelles, we performed confocal microscopy experiments in HeLa 
cells. In addition to the plasmids coding for the SuperNova fusion proteins, 
mCherry-N1 and SuperNova-N1 empty vector plasmids were used as con-
trols, which locate uniformly in the nucleus and cytoplasm. The excitation 
and emission spectra of mCherry overlap with SuperNova, but it does less 
efficiently induce ROS production upon excitation343. Counterstains with 
organelle-specific antibodies were applied to confirm the localization of the 
SuperNova fusion proteins. For all SuperNova constructs, they correctly 
localized to the target organelles (Figure 2A), which was quantified by deter-
mination of the Pearson’s colocalization coefficient between the SuperNova 
fluorescence and the antibody staining (Figure 2B). For VAMP8-SuperNova, 
the colocalization with early endosomal marker EEA1 was relatively low, be-
cause VAMP8 is also present on late endosomes377. Likewise, the colocaliza-
tion of TGON2 with giantin was relatively low due to giantin being a marker 
of cis- and medial-Golgi378,379, whereas TGON2 localizes from medial- to 
trans-Golgi380. KDEL-tagged constructs are retrieved from cis-Golgi to the 
ER and therefore not only localize to the ER but also partially to the Golgi381, 
which can explain the comparatively lower R value of ER-SuperNova.
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Figure 2. Localization of SuperNova fusion constructs.
A. Representative confocal images of HeLa cells transfected with constructs encoding for 
SuperNova fusion proteins with appropriate counter stain for the target organelle. DAPI is 
in blue. Cytosolic: SuperNova-N1. Scale bar; 15 µm. B. Pearson’s colocalization coefficients 
of the SuperNova fusion proteins with the organellar markers from panel A. Three technical 
repeats, each dot represents a microscopy image.
SuperNova, and its precursor KillerRed, are known to be able to induce 
cell death in a variety of mammalian cell lines and Caenorhabditis ele-
gans349,382,383. However, in these studies, they used untagged probes that 
uniformly distributed through the cell or targeting to mitochondria. In this 
study, we compared the effects on cell viability upon radical stress induced 
by SuperNova targeted to other organelles. First, we determined the trans-
fection efficiencies for all constructs using flow cytometry. A gate for viable 
COS-7 cells was set with an untransfected control COS-7 sample (Figure 
3A), after which the percentage SuperNova positive cells within this gate 
was determined for each sample (Figure 3B). Depending on the experiment 
and the construct, we achieved a transfection efficiency of 55-80% in COS-7 
cells (Figure 3C). We then evaluated the effects of targeted ROS production 
on cell viability by flow cytometry using Zombie Violet, a fixable live-dead 
staining. Zombie Violet is an amine-reactive fluorescent dye that is only per-
meable to cells with compromised membranes (Figure 3D). The transfected 
COS-7 cells were exposed to 590 nm light for 1 hour to activate SuperNova. 
The cells were stained directly after light exposure. mCherry-N1 was used 
to evaluate the effect of ROS production by conventional fluorescent pro-
teins. Although exposure to 590 nm light was able to induce cell death for all 
constructs compared to dark controls, SuperNova-induced ROS production 
caused the largest increase in cell death when it was targeted to the nucleus 
(Figure 3E).
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Figure 3. SuperNova fusion construct expression levels and viability upon light expo-
sure.
A. Representative scatter plot of COS-7 cells. B. Fluorescent intensity histograms of Super-
Nova in COS-7 cells expression SuperNova fusion proteins after gating as shown in A. At 
least 20,000 cells were included in each measurement. (C) Percentage of COS-7 cells positive 
for SuperNova as shown in B, each dot represents a technical repeat. (D) Representative 
fluorescent intensity histograms of COS-7 cells expressing SuperNova fusion protein (cyto-
solic) after stimulation with 590 nm excitation light for 1, 4 or 24 hours and stained with the 
Zombie Violet cell viability dye. (E) Percentage of cell death in COS-7 after stimulation with 
590 nm excitation light for 24 hours, each dot represents a technical repeat. Control cells 
were kept in the dark for 24 hours. At least 20,000 cells were included in each measurement.
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Discussion
In this study, we compared the effects on cell viability of radical stress at dif-
ferent organelles. We developed an optogenetic toolkit to induce ROS with 
organellar precision based on the superoxide-producing photosensitizer pro-
tein SuperNova fused to various organellar localization motifs343. We found 
that excitation of SuperNova caused significant cell death in cells when it 
was targeted to the nucleus, whereas targeting SuperNova to other organelles 
did not strongly affect cell viability. This study contrasts other studies where 
activation of mitochondrial and untargeted SuperNova and KillerRed were 
found to induce cell death343,349,382 which may be caused by a difference in 
excitation light intensity and/or cell type. The nucleus might be more sensi-
tive to radical stress, as it can cause DNA damage, whereas many antioxidant 
mechanisms are preferentially located in the cytosol and mitochondria 4. 
Additionally, nuclear ROS may directly induce Bax-mediated apoptosis via 
activation of nucleophosmin384,385.
An advantage of SuperNova is that it yields great temporal control of ROS 
production at specific organelles382,383,386. To date, the roles of ROS in endo-
somes15,129 and mitochondria129,282,387 are quite well studied, but knowledge of 
their impact on other organelles is still limited. In addition, radical-inducing 
proteins such as SuperNova provide new possibilities for the development 
of animal models for studying ROS in diseases. Because SuperNova allows 
to kill specific cell types (using specific promotors), induce radical stress at 
specific locations (using localized excitation light) and trigger sterile inflam-
mation, it offers new opportunities to study disease mechanisms, for example 
anti-cancer immunity and early onset mechanisms in autoimmune diseases. 
Shirmanova et al. used KillerRed fused to the nuclear protein histone 2B as 
well as to a mitochondrial targeting motif to study the effects of localized 
ROS production in cancer radiation therapy in a mouse xenograft tumor 
model388. Teh et al. developed zebrafish models expressing membrane-tagged 
KillerRed in the hindbrain and in the heart389. Shibuya et al. demonstrated 
slower development of C. elegans larvae expressing mitochondria-targeted 
KillerRed in muscle tissue382. Williams et al. also developed a C. elegans mod-
el, expressing KillerRed specifically in neurons383. In this study, activation 
of untargeted KillerRed resulted in neuronal degeneration and cell death, 
whereas ROS production in mitochondria only caused organelle fragmen-
tation but did not affect viability383. Our data now indicate that the targeting 
of optogenetic sensitizers to the nucleus might be the most effective for light 
induction of cell death compared to other organelles.
Materials and methods
Cloning
The SuperNova plasmid was a gift from Takeharu Nagai (Addgene plasmid 
#53234). The construct for cytosolic expression of SuperNova was construct-
ed by replacing EGFP in pEGFP-N1 with SuperNova using restriction sites 
BamHI and NotI. Mitochondrial targeting was achieved by inserting COX8A 
into the cytosolic SuperNova vector using restriction sites XhoI and HindIII, 
tagging the C-terminus of COX8A with SuperNova. Endosomal targeting 
was achieved by inserting VAMP8 into the cytosolic SuperNova vector using 
restriction sites HindIII and BamHI, tagging the C-terminus of VAMP8 with 
SuperNova which results in luminal localization of SuperNova. Trans-Golgi 
targeting was achieved by inserting synthetic DNA coding for TGON2 with 
N-terminal SuperNova into pcDNA3.1(+) using restriction sites NheI and 
XbaI. Targeting of the ER was achieved by inserting synthetic DNA coding 
for calreticulin with C-terminal SuperNova into pcDNA3.1(+) using restric-
tion sites HindIII and XbaI. Additionally, an ER retention signal (KDEL) 
was added to the C-terminus of SuperNova. Nuclear targeting was achieved 
by replacing EGFP in pEGFP-C1 with synthetic DNA coding for SuperNova 
with an N-terminal c-myc nuclear localization signal (NLS) using restric-
tion sites NheI and HindIII. Additionally, the vectors encoding COX8A-, 
VAMP8-, NLS- and empty vector SuperNova feature a myc-tag at the Su-
perNova C-terminus. All sequences and plasmid maps are shown in Supple-
mental Figure 1. Plasmids have been deposited to Addgene.
Cells, transfection and ROS induction
All experiments were performed in COS-7 cells (ATCC® CRL-1651), except 
for the localization experiments which were performed in HeLa (ATCC® 
CCL-2). Both cell lines were obtained from ATCC. COS-7 cells were cul-
tured in complete DMEM containing glutamine, 10% fetal bovine serum and 
1% Antibiotic-Antimycotic. HeLa cells were cultured in complete RPMI con-
taining 10% fetal bovine serum and 1% Antibiotic-Antimycotic. Constructs 
mCherry-N1, SuperNova-N1, COX8-SuperNova, VAMP8-SuperNova, Su-
perNova-TGON2, NLS-SuperNova and calreticulin-SuperNova-KDEL were 
transfected of HeLa or COS-7 cells using Lipofectamine 3000 (Invitrogen; 
ref# 3000-015) in Opti-MEM Reduced Serum Medium (Life technologies; 
ref# 11058-021). To activate SuperNova, we cultured cells in phenol-red free 
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culture media and placed them under a 1.4 mW/cm2 590 nm LED array (LI-
U590A, Thor Labs) with diffuser (DG20-600, Thor Labs) at 37°C, 5% CO2. 
Microscopy
Localization experiments were performed in HeLa cells (5·104 cells/glass) 
24 hours post-transfection seeded on ethanol-sterilized 12 mm microscopy 
glasses. 500 nM MitoTracker Deep Red FM (Thermo Fisher; cat# M22426) 
was added to COX8-SuperNova transfected cells prior to fixation. Samples 
were stained as described previously13 with mouse monoclonal anti-Myc 
(sc-40; Santa Cruz), rabbit polyclonal anti-EEA1 (610456, BD Biosciences), 
mouse monoclonal anti-Giantin (ALX-804-600, Enzo), mouse monoclo-
nal anti-PDI (NB300-517; Novus Bio) (all at 1:100 dilution v/v, except for 
anti-Giantin 1:500 v/v) in combination with donkey anti-mouse Alexa488 
(A21202; Thermo Fisher), donkey anti-rabbit Alexa647 (A31573; Thermo 
Fisher), donkey anti-mouse Alexa647 (A31571; Thermo Fisher) or donkey 
anti-rabbit Alexa647 (A21447; Thermo Fisher) (all at 1:400 dilution v/v). The 
cells were fixed with mounting medium containing DAPI (0.1 μg/ml), 0.01% 
Trolox (6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) and 68% 
glycerol in 200 mM sodium phosphate buffer at pH 7.5 and imaged on a 
Leica SP8 confocal microscope using a Leica HC PL APO CS2 63x/1.2 water 
immersion objective.
Flow cytometry
Transfection efficiency and cell viability were determined in COS-7 cells. 
Cells were transfected with mCherry and SuperNova constructs in a 6-well 
plate (2.5·105 cells/well), trypsinized 24 hours post-transfection, washed 
and resuspended in 100 µL PBS for flow cytometry analysis with a BD 
FACSVerse flow cytometer (BD Biosciences). Untransfected cells were used 
to apply gating and to discriminate between SuperNova-positive and neg-
ative cells. For cell viability evaluation, the culture medium of the cells was 
changed to phenol-red free prior to illumination of the SuperNova. Super-
Nova was activated with 590 nm light for 0, 1, 4 or 24 hours. Cells were 
collected in 96-wells v-bottom plates by trypsinization after treatment and 
stained with Zombie Violet fixable viability dye (BioLegend; cat# 423113; 
1:2000 dilution v/v). Cells were fixed in 4% PFA for 5 minutes, washed with 
PBS containing 1% BSA and 0.05% sodium azide (PBA) and resuspended in 
100 µL PBA for flow cytometry analysis with a BD FACSVerse flow cytome-
ter (BD Biosciences). Flow cytometry data was analyzed using Flowjo X.
Statistical analysis
The data of the viability assay was analyzed using a one-way ANOVA with 
a post-hoc Dunnett’s multiple comparisons test. Two-sided P values < 0.05 
were considered to be statistically significant (*** p < 0.001, ** p < 0.01, * p < 
0.05).
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Supplementary data
Sequences
SuperNova-myc-N1
ATGGGCAGCGAGGTGGGCCCCGCCCTGTTCCAGAGCGACATGACCTTCAAGATCTTCATCGAC-
GGCGAGGTGAACGGCCAGAAGTTCACCATCGTGGCCGACGGCAGCAGCAAGTTCCCCCACGGC-
GACTTCAACGTGCACGCCGTGTGCGAGACCGGCAAGCTGCCCATGAGCTGGAAGCCCATCTGC-
CACCTGATCCAGTACGGCGAGCCCTTCTTCGCCCGCTACCCCGACGGCATCAGCCACTTCGCCCAG-
GAGTGCTTCCCCGAGGGCCTGAGCATCGACCGCACCGTGCGCTTCGAGAACGACGGCACCATGAC-
CAGCCACCACACCTACGAGCTGGACGACACCTGCGTGGTGAGCCGCATCACCGTGAACTGCGACG-
GCTTCCAGCCCGACGGCCCCATCATGCGCGACCAGCTGGTGGACATCCTGCCCAGCGAGACCCACAT-
GTTCCCCCACGGCCCCAACGCCGTGCGCCAGACCGCCACCATCGGCTTCACCACCGCCGACGGCGG-
CAAGATGATGGGCCACTTCGACAGCAAGATGACCTTCAACGGCAGCCGCGCCATCGAGATCCCCGGC-
CCCCACTTCGTGACCATCATCACCAAGCAGACCCGCGACACCAGCGACAAGCGCGACCACGTGTGC-
CAGCGCGAGGTGGCCTACGCCCACAGCGTGCCCCGCATCACCAGCGCCATCGGCAGCGACGAGGAC-
GAGCAGAAGCTGATCAGCGAGGAGGACCTGTAA
COX8-SuperNova
ATGAGCGTGCTGACCCCCCTGCTGCTGCGCGGCCTGACCGGCAGCGCCCGCCGCCTGCCCGTG-
CCCCGCGCCAAGATCCACAGCCTGAAGCTTCGAATTCTGCAGTCGACGGTACCGCGGGCCCG-
GGATCCACCCGTGGCCACCATGGGCAGCGAGGTGGGCCCCGCCCTGTTCCAGAGCGACAT-
GACCTTCAAGATCTTCATCGACGGCGAGGTGAACGGCCAGAAGTTCACCATCGTGGCCGACGGCAG-
CAGCAAGTTCCCCCACGGCGACTTCAACGTGCACGCCGTGTGCGAGACCGGCAAGCTGCCCAT-
GAGCTGGAAGCCCATCTGCCACCTGATCCAGTACGGCGAGCCCTTCTTCGCCCGCTACCCCGACG-
GCATCAGCCACTTCGCCCAGGAGTGCTTCCCCGAGGGCCTGAGCATCGACCGCACCGTGCGCTTC-
GAGAACGACGGCACCATGACCAGCCACCACACCTACGAGCTGGACGACACCTGCGTGGTGAGCCG-
CATCACCGTGAACTGCGACGGCTTCCAGCCCGACGGCCCCATCATGCGCGACCAGCTGGTGGA-
CATCCTGCCCAGCGAGACCCACATGTTCCCCCACGGCCCCAACGCCGTGCGCCAGACCGCCACCATC-
GGCTTCACCACCGCCGACGGCGGCAAGATGATGGGCCACTTCGACAGCAAGATGACCTTCAACGG-
CAGCCGCGCCATCGAGATCCCCGGCCCCCACTTCGTGACCATCATCACCAAGCAGACCCGCGACAC-
CAGCGACAAGCGCGACCACGTGTGCCAGCGCGAGGTGGCCTACGCCCACAGCGTGCCCCGCATCAC-
CAGCGCCATCGGCAGCGACGAGGACGAGCAGAAGCTGATCAGCGAGGAGGACCTGTAA
VAMP8-SuperNova
ATGGAGGAGGCCAGTGGGAGTGCCGGAAATGACCGAGTTAGGAACCTGCAGAGTGAGGTGGAG-
GGAGTCAAGAATATTATGACCCAGAATGTGGAGCGGATCTTGTCCAGAGGGGAGAACCTGGAC-
CACCTCCGAAACAAGACAGAGGACTTGGAAGCCACGTCTGAACACTTCAAGACAACGTCCCAGAAG-
GTGGCCCGGAAGTTCTGGTGGAAGAATGTGAAGATGATTGTCATCATCTGTGTGATTGTCCTTAT-
CATCGTCATCCTCATTATACTTTTTGCCACTGGTACCATCCCCACTAAGGATCCACCCGTGGC-
CACCATGGGCAGCGAGGTGGGCCCCGCCCTGTTCCAGAGCGACATGACCTTCAAGATCTTCATC-
GACGGCGAGGTGAACGGCCAGAAGTTCACCATCGTGGCCGACGGCAGCAGCAAGTTCCCCCACG-
GCGACTTCAACGTGCACGCCGTGTGCGAGACCGGCAAGCTGCCCATGAGCTGGAAGCCCATCTGC-
CACCTGATCCAGTACGGCGAGCCCTTCTTCGCCCGCTACCCCGACGGCATCAGCCACTTCGCCCAG-
GAGTGCTTCCCCGAGGGCCTGAGCATCGACCGCACCGTGCGCTTCGAGAACGACGGCACCATGAC-
CAGCCACCACACCTACGAGCTGGACGACACCTGCGTGGTGAGCCGCATCACCGTGAACTGCGACG-
GCTTCCAGCCCGACGGCCCCATCATGCGCGACCAGCTGGTGGACATCCTGCCCAGCGAGACCCACAT-
GTTCCCCCACGGCCCCAACGCCGTGCGCCAGACCGCCACCATCGGCTTCACCACCGCCGACGGCGG-
CAAGATGATGGGCCACTTCGACAGCAAGATGACCTTCAACGGCAGCCGCGCCATCGAGATCCCCGGC-
CCCCACTTCGTGACCATCATCACCAAGCAGACCCGCGACACCAGCGACAAGCGCGACCACGTGTGC-
CAGCGCGAGGTGGCCTACGCCCACAGCGTGCCCCGCATCACCAGCGCCATCGGCAGCGACGAGGAC-
GAGCAGAAGCTGATCAGCGAGGAGGACCTGTAA
SuperNova-TGON2
A T G G T A A A G C T T G G T T C A G A G G T G G G C C C C G C C C T G T T C C A G A G C G A C A T -
GACCTTCAAAATCTTCATCGACGGCGAGGTGAACGGCCAGAAGTTCACCATCGTGGCCGACGGCAG-
CAGCAAGTTCCCCCACGGCGACTTCAACGTGCACGCCGTGTGCGAGACCGGCAAGCTGCCCAT-
GAGCTGGAAGCCCATCTGCCACCTGATCCAGTACGGCGAGCCCTTCTTCGCCCGCTACCCCGACG-
GCATCAGCCATTTCGCCCAGGAGTGCTTCCCCGAGGGCCTGAGCATCGACCGCACCGTGCGCTTC-
GAGAACGACGGCACCATGACCAGCCACCACACCTACGAGCTGGACGACACCTGCGTGGTGAGCCG-
CATCACCGTGAACTGCGACGGCTTCCAGCCCGACGGCCCCATCATGCGCGACCAGCTGGTGGA-
CATCCTGCCCAGCGAGACCCACATGTTCCCCCACGGCCCCAACGCCGTGCGCCAGACCGCCACCATC-
GGCTTCACCACCGCCGACGGCGGCAAGATGATGGGCCACTTCGACAGCAAGATGACCTTCAACGG-
CAGCCGCGCCATCGAGATCCCCGGCCCACACTTCGTGACCATCATCACCAAGCAGACCAGGGACAC-
CAGCGACAAGCGCGACCACGTGTGCCAGCGCGAGGTGGCCTACGCCCACAGCGTGCCCCGCATCAC-
CAGCGCCATCGGTAGCGACGAGGATTCGAATTCTATGCAGTTCCTGGTGGCCCTGCTGCTGCTGAG-
CGTGGCCGTGGCCCGCGCCCTGCCCAGCGCCAGCAAGCCCAACAACACCAGCAGCGAGAACAAC-
CCCCCCATCCAGCCCAGCACCCCCCTGCCCCCCGGCGTGGACATCAGCCAGCAGGTGAAGACCAAC-
CGCCCCACCGACCAGCGCCTGGAGAGCGACAAGGAGGGCCAGGACAAGACCGTGGCCCGCACCAG-
CGCCAGCGTGAGCAGCGGCGTGGAGAGCGCCACCAACCTGAACCTGGACGACAGCAAGAAGCAC-
CCCGAGACCGCCGACGCCAAGCTGAAGGAGACCCTGCAGCAGCTGCTGCCCGTGGACCCCAAGCAG-
GAGAAGAGCGGCCAGAAGTTCACCAAGGACAGCGGCAGCCCCACCGGCGGCGACAGCGACAACAC-
CACCGGCGGCGACAGCAACAAGACCACCGGCGTGGACAGCGACAAGACCAGCGGCGGCGACAGCAA-
CAAGCCCACCGGCAGCGACAACGACAAGCCCACCGGCGGCGACAGCAACAAGCCCACCAGCAAGGT-
GCCCAGCAACACCGAGACCCCCAAGATCGACAAGGTGCAGCTGACCGAGAAGGGCCAGAAGCCCAC-
CCTGATCAGCAAGACCGAGAGCGGCGAGAAGCTGGCCGGCGACAGCGACTTCAGCCTGAAGC-
CCGAGAAGGGCGACAAGAGCAGCGAGCCCACCGAGGACGTGGAGACCAAGGAGATCGAGGAGGGCGA-
CACCGAGCCCGAGGAGGGCAGCCCCCTGGAGGAGGAGAACGAGAAGGTGCTGGGCCCCAGCAGCAG-
CGAGAACCAGGAGGGCACCCTGACCGACAGCATGAAGGACGAGAAGGACGACCACTACAAGGACAA-
CAGCGGCAACACCAGCGCCGAGAGCAGCCACTTCTTCGCCTACCTGGTGACCGCCGCCGTGCTGGT-
GGCCGTGCTGTACATCGCCTACCACAACAAGCGCAAGATCATCGCCTTCGCCCTGGAGGGCAAGCG-
CAGCAAGGTGACCCGCCGCCCCAAGGCCAGCGACTACCAGCGCCTGAACCTGAAGCTGCGGGATC-
CACCCGGGATCTAG
ER-SuperNova
ATGGATCTGCTGAGCGTGCCCCTGCTGCTGGGCCTGCTGGGCCTGGCCGTGGCCCGGGATCCAG-
GTTCAGAGGTGGGCCCCGCCCTGTTCCAGAGCGACATGACCTTCAAAATCTTCATCGACGGCGAGGT-
GAACGGCCAGAAGTTCACCATCGTGGCCGACGGCAGCAGCAAGTTCCCCCACGGCGACTTCAACGTG-
CACGCCGTGTGCGAGACCGGCAAGCTGCCCATGAGCTGGAAGCCCATCTGCCACCTGATCCAGTAC-
GGCGAGCCCTTCTTCGCCCGCTACCCCGACGGCATCAGCCATTTCGCCCAGGAGTGCTTCCCCGAG-
GGCCTGAGCATCGACCGCACCGTGCGCTTCGAGAACGACGGCACCATGACCAGCCACCACACCTAC-
GAGCTGGACGACACCTGCGTGGTGAGCCGCATCACCGTGAACTGCGACGGCTTCCAGCCCGACGG-
CCCCATCATGCGCGACCAGCTGGTGGACATCCTGCCCAGCGAGACCCACATGTTCCCCCACGGC-
CCCAACGCCGTGCGCCAGACCGCCACCATCGGCTTCACCACCGCCGACGGCGGCAAGATGATGGGC-
CACTTCGACAGCAAGATGACCTTCAACGGCAGCCGCGCCATCGAGATCCCCGGCCCACACTTCGT-
GACCATCATCACCAAGCAGACCAGGGACACCAGCGACAAGCGCGACCACGTGTGCCAGCGCGAGGTG-
GCCTACGCCCACAGCGTGCCCCGCATCACCAGCGCCATCGGTAGCGACGAGGATCTCGAGACCGGTA-
AGGACGAGCTGTAA
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Plasmid maps
HSV TK poly(A) signal
CMV promoter
NheI  (591)
BmtI  (595)
AfeI  (596)
PaeR7I - TliI - XhoI  (613)
Eco53kI  (618)
SacI  (620)
HindIII  (622)
EcoRI  (629)
MCS
PstI  (638)
SalI  (639)
AccI  (640)
Acc65I  (645)
KpnI  (649)
SacII  (652)
TspMI - XmaI  (656)
SmaI  (658)
BamHI  (660)
BclI*  (1406)
Myc
PpuMI  (1419)
NotI  (1430)
XbaI*  (1440)
SV40 poly(A) signal
AmpR promoter
SuperNova-myc-N1
4762 bp
HSV TK poly(A) signal
CMV promoter
NheI  (591)
BmtI  (595)
AfeI  (596)
PaeR7I - TliI - XhoI  (613)
COX8
HindIII  (706)
EcoRI  (713)
PstI  (722)
SalI  (723)
AccI  (724)
Acc65I  (729)
KpnI  (733)
SacII  (736)
TspMI - XmaI  (740)
SmaI  (742)
BamHI  (744)
BclI*  (1490)
Myc
PpuMI  (1503)
NotI  (1514)
XbaI*  (1524)
SV40 poly(A) signal
AmpR promoter
COX8-SuperNova-myc
4846 bp
NLS-SuperNova
ATGCCCGCCGCCAAGCGCGTGAAGCTGGACGTGGATCCAGGCAGCGAGGTGGGCCCCGCCCTGTTC-
CAGAGCGACATGACCTTCAAGATCTTCATCGACGGCGAGGTGAACGGCCAGAAGTTCACCATCGTGG-
CCGACGGCAGCAGCAAGTTCCCCCACGGCGACTTCAACGTGCACGCCGTGTGCGAGACCGGCAAGCT-
GCCCATGAGCTGGAAGCCCATCTGCCACCTGATCCAGTACGGCGAGCCCTTCTTCGCCCGCTAC-
CCCGACGGCATCAGCCACTTCGCCCAGGAGTGCTTCCCCGAGGGCCTGAGCATCGACCGCACCGTGC-
GCTTCGAGAACGACGGCACCATGACCAGCCACCACACCTACGAGCTGGACGACACCTGCGTGGTGAG-
CCGCATCACCGTGAACTGCGACGGCTTCCAGCCCGACGGCCCCATCATGCGCGACCAGCTGGTGGA-
CATCCTGCCCAGCGAGACCCACATGTTCCCCCACGGCCCCAACGCCGTGCGCCAGACCGCCACCATC-
GGCTTCACCACCGCCGACGGCGGCAAGATGATGGGCCACTTCGACAGCAAGATGACCTTCAACGG-
CAGCCGCGCCATCGAGATCCCCGGCCCCCACTTCGTGACCATCATCACCAAGCAGACCCGCGACAC-
CAGCGACAAGCGCGACCACGTGTGCCAGCGCGAGGTGGCCTACGCCCACAGCGTGCCCCGCATCAC-
CAGCGCCATCGGCAGCGACGAGGACGAGCAGAAGCTGATCAGCGAGGAGGACCTGTAA
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HSV TK poly(A) signal
CMV promoter
NheI  (591)
BmtI  (595)
AfeI  (596)
PaeR7I - TliI - XhoI  (613)
Eco53kI  (618)
SacI  (620)
HindIII  (622)
EcoRI  (629)
KpnI  (930)
BamHI  (943)
PspOMI  (976)
ApaI  (980)
BclI*  (1689)
Myc
PpuMI  (1702)
NotI  (1713)
XbaI*  (1723)
SV40 poly(A) signal
AmpR promoter
VAMP8-SuperNova-myc
5045 bp
AmpR promoter
AmpR
CAP binding site
lac promoter
lac operator
M13 rev
SV40 poly(A) signal
CMV promoter
T7 promoter
NheI  (895)
BmtI  (899)
AfeI  (900)
HindIII  (910)
EcoRI  (1632)
BamHI  (2712)
XbaI*  (2726)
PmeI  (2741)
bGH poly(A) signal
SuperNova-TGON2
7163 bp
AmpR promoter
AmpR
CAP binding site
lac promoter
lac operator
M13 rev
SV40 poly(A) signal
CMV promoter
T7 promoter
NheI  (895)
BmtI  (899)
AflII  (908)
HindIII  (911)
BlpI  (929)
Calreticulin
SfiI  (957)
BamHI  (976)
PaeR7I - TliI - XhoI  (1697)
AgeI  (1703)
ER retention signal (KDEL)
XbaI  (1724)
bGH poly(A) signal
ER-SuperNova
6161 bp
HSV TK poly(A) signal
CMV promoter
NheI  (591)
BmtI  (595)
AfeI  (596)
MCS
PaeR7I - TliI - XhoI  (613)
c-myc NLS
BmgBI  (648)
MCS
Myc
PpuMI  (1395)
NotI  (1406)
HindIII  (1414)
EcoRI  (1421)
PstI  (1430)
SalI  (1431)
AccI  (1432)
MCS
Acc65I  (1437)
KpnI  (1441)
SacII  (1444)
TspMI - XmaI  (1448)
SmaI  (1450)
XbaI*  (1464)
SV40 poly(A) signal
AmpR promoter
NLS-SuperNova-myc
4793 bp
Chapter 7
Discussion and future perspectives
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It is well established that the oxidative burst is a key element of both the 
innate and adaptive immune response used for pathogen killing and subse-
quent processing of antigens. Many of the secondary effects of the oxidative 
burst response, as well as its dynamics in cells other than neutrophils, are not 
well understood. In this thesis, I described the dynamics of NOX2-mediated 
ROS production during phagocytosis in monocyte-derived dendritic cells. 
NOX2 produces more ROS in dendritic cells compared to macrophages40,55 
and ROS production is maintained for hours after antigen uptake48, in 
contrast to the short respiratory burst in neutrophils37–39. Since ROS react 
indiscriminately, NOX2 activation has many secondary and off-target effects. 
Especially unsaturated lipids are a major target of ROS, since they are abun-
dant and relatively vulnerable due to a lack of lipophilic antioxidants. In this 
thesis, I describe how ethylene is formed during lipid peroxidation and how 
it might be used in clinical settings as a real-time biomarker for early onset 
systemic inflammation. The high reactivity and lack of molecular specificity 
make ROS difficult to study and modulate in a subcellular context. There-
fore, I developed an optogenetic toolkit to target specific organelles with a 
light-sensitive ROS producing protein, which allows for greater spatiotem-
poral control of ROS production. An additional off-target effect of NOX2 
activation is the rapid consumption of all locally available oxygen, leading to 
hypoxia. I describe how this affects secretion of the important pro-inflam-
matory cytokine TNF-α in dendritic cells via potentiation of MAP kinase 
signaling. The results described in this thesis contribute to a better under-
standing of the secondary effects of NOX2-mediated ROS production, their 
dynamics and subsequent signaling events in monocyte-derived dendritic 
cells, as well as their significance in the context of anti-tumor immunity.
Dynamics of NOX2 recruitment and activation
NOX2 is a transmembrane protein complex consisting of the mem-
brane-bound subunits gp91phox and p22phox, the cytosolic subunits p40phox, 
p47phox, p67phox and a small GTPase (either Rac1 or Rac2). Once the cytoso-
lic subunits are recruited to the membrane-bound subunits, the complex is 
active and generates superoxide anion by transferring electrons from NA-
DPH to luminal molecular oxygen via two haem groups that are anchored 
in gp91phox 41–43. The interaction between subunits gp91phox, p67phox and Rac 
facilitates electron transfer390,391, while p47phox stabilizes the protein complex 
by bridging p22phox to p67phox 392. Interestingly, Rac1 is responsible for NOX2 
activation in neutrophils393,394, while macrophages rely more on Rac2395. In 
dendritic cells, this difference is less pronounced, as mouse CD8+ dendritic 
cells use Rac2 for assembly of phagosomal NOX2, whereas Rac1 controls 
assembly of NOX2 at the plasma membrane in CD8- dendritic cells396. This 
could be a means to control the different superoxide production rates be-
tween neutrophils and other phagocytes.
NOX2 recruitment and its subsequent activation is an extremely rapid 
process. As described in chapter 2 of this thesis, NOX2 is recruited to the 
phagocytic cup well before phagosome formation is completed. However, the 
details of this process remain unknown and this warrants further research. 
Since the NOX2 complex contains both cytosolic and membrane-bound sub-
units, there are several distinct trafficking processes involved in NOX2 com-
plex formation. Both p40phox and p47phox contain PX domains and their trans-
location to the membrane is mediated by phosphoinositides (PIs), which 
was shown to be specifically dependent on PI3-kinase activity397. It is unclear 
how p67phox is recruited to the NOX2 complex, but it could be co-transported 
with p40phox by forming a heterodimer via their PB1 domains398,399. However,  
both p47phox and p67phox were present on phagosomes in NOX2-expressing 
COS7 cells lacking p40phox or in PLB-985 cells (a human neutrophil cell line) 
in which p40phox expression was silenced by shRNA400,401. In mouse neutro-
phils, p67phox was shown to be dependent on Rac, as either deletion of Rac1 
in a Rac2-/- mouse or a H69E mutation of p67phox (which no longer binds 
Rac) prevented p67phox translocation and subsequent ROS production402.
NOX2 itself is sensitive to oxidation, so to maintain intraphagosomal ROS 
production, oxidized NOX2 needs to be replenished on phagosomes during 
maturation. Recycling endosomes positive for the SNARE (soluble N-eth-
ylmaleimide-sensitive factor accessory protein (SNAP) receptor) protein 
VAMP8 shuttle gp91phox from lysosomes to the phagosome, where they 
complex with phagosomal SNAREs Stx7 and SNAP23 to perform membrane 
fusion45. In similar fashion, gp91phox is also trafficked to endosomes to pro-
mote cross-presentation130,131. Other proteins involved in recruiting gp91phox 
to phagosomal membranes are the small GTPase Rab27a128 and synapto-
tagmin-11, a Ca2+ sensor403. Although these studies describe recruitment of 
gp91phox to endo-/phagosomes, these proteins are likely to be involved in its 
recruitment to the phagocytic cup as well. SNAP23 has long been known to 
localize to the plasma membrane404 and its expression is upregulated follow-
ing LPS stimulation405, making it a possible candidate for the trafficking of 
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gp91phox to the phagocytic cup.
It is also possible that there is a mechanosensing component to the recruit-
ment of at least some NOX2 subunits, as diaphragm explants of mice show 
immediate ROS production when stretched, which is absent in p47phox-/- 
mice406. In addition to this, the PX domain of p47phox can interact with 
moesin, an actin-binding protein which may transduce a mechanical sig-
nal407,408. Such a mechanosensitive component might explain why stimulation 
with large (≈6 µm diameter) and relatively rigid zymosan particles induces 
more ROS than soluble LPS in neutrophils409. Another process involved in 
NOX2 regulation might be ion channel-mediated signaling. Ca2+ signaling is 
required for phagocytosis and activation of NOX2410,411, as deletion of even 
a single Ca2+ channel (TRPV4) abolishes ROS production in neutrophils412. 
However, the timing of for example TRPV2 recruitment does not match the 
speed of NOX2 recruitment, as TRPV2 only shows increased plasma mem-
brane localization in macrophages after 30 minutes413. In contrast, NOX2 
assembly in DCs or neutrophils occurs within 5 minutes after tethering of a 
pathogen to the membrane, as described in chapter 2 of this thesis.
NOX2 deficiency
Mutations in the genes coding for NOX2 subunits are the cause of chronic 
granulomatous disease (CGD), a disease with a very high morbidity414. CGD 
patients suffer from recurring (opportunistic) bacterial and fungal infections 
and increased levels of pro-inflammatory cytokines415. Interestingly, the 
severity of these symptoms depends on which NOX2 subunit is affected; mu-
tations in gp91phox completely abolish ROS production, whereas patients with 
defects in p47phox are able to produce some ROS, likely due to partial com-
pensation by p67phox 416. The increased pro-inflammatory cytokine produc-
tion observed in CGD patients415 is interesting, as it provides hints to new 
ROS-regulated signaling pathways in immune cells. CGD neutrophils have 
increased expression of IL-8, a strong chemotactic factor as well as an induc-
er of phagocytosis. Scavenging ROS in healthy neutrophils replicated this 
phenotype, indicating that IL-8 expression is directly mediated by ROS417. 
CGD neutrophils also showed upregulation of many cell surface markers 
such as CD14, CD11c, IL-4 receptor and intercellular adhesion molecule-1 
(ICAM-1)418. Many of these markers are important for dendritic cell func-
tion, as they regulate cell migration and activation, thus it would be relevant 
to investigate whether ROS can directly influence their expression. In addi-
tion to IL-8, CGD lymphocytes, monocytes and macrophages (PBMCs) also 
showed heightened IL-6 and TNF-α secretion compared to healthy control 
and in response to LPS stimulation419. There could be a link between this 
observation and the effects of hypoxia described in chapter 3, as lowering 
oxygen availability likely inhibits NOX2 activity as well.
NOX2 in viral infections
In antiviral responses, the role of NOX2 and other members of the NOX 
family is less clear than for microbial infections, as both beneficial and detri-
mental effects have been reported. NOX2 activity plays a role in the signaling 
pathways following viral recognition by receptors such as TLR3 or retinoic 
acid-inducible gene I (RIG-I). In A549 cells, a cell line of human lung epi-
thelium, superoxide scavenging greatly reduced expression of the antiviral 
genes IFNB and IFIT1 following Sendai virus infection420. Expression of 
Mitochondrial Antiviral Signaling Protein (MAVS), an important compo-
nent of β interferon signaling following RIG-I activation, was also strongly 
reduced. Likewise, NFκB421 and the MAP kinase pathways ERK and JNK422 
were also shown to be under control of NOX2 activity following viral infec-
tions. In contrast, however, CD33+ myeloid-derived suppressor cells induced 
by hepatitis C virus were shown to strongly upregulate p47phox expression. 
These cells strongly suppress effector T cell responses, but this effect could be 
reversed by addition of catalase to scavenge H2O2423. Influenza A infections 
also induce NOX2 activity424 and NOX2 activity is a major determinant for 
disease burden. gp91phox knockdown or addition of catalase increased the ex-
pression of several pro-inflammatory cytokines (H3N2 and H1N1 strains)425 
and reduced viral entry and bronchial tissue damage in mice (H3N2 and 
H1N1 strains)424. Remarkably, NOX1 activity seems to play an opposing role, 
as it suppresses airway inflammation and upregulates interferon-γ and IL-10 
expression (H3N2 strain)426. This also points to the importance of the loca-
tion of ROS production, as NOX2 is the canonical phagocyte oxidase, while 
NOX1 is mainly expressed by endothelial and epithelial cells41.
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Improving ROS probes
Sensitive and specific detection of radical species is inherently difficult so 
far due to their transient nature and the generation of many nonspecific side 
products in oxidation reactions. In addition, most fluorescent probes cur-
rently available are sensitive to more than one radical species133,427. Therefore, 
either measurement of changes in oxygen consumption or the products of 
oxidation reactions are often applied instead as measures of ROS produc-
tion. Some advances have been made over the past few years and especially 
intracellular H2O2 is now detectable with fairly high precision using boro-
nate-based fluorescent probes428 or hydrocyanines429. Likewise, HOCl  can 
now be detected with high precision by a BODIPY-derivative, although its 
hydrophobicity may limit intracellular use430. However, a superoxide an-
ion-specific intracellular probe is still sorely lacking. Hydropropidine is 
the only available probe so far that is specific for superoxide anion, but this 
compound is cell-impermeable and requires mass-spectrometry to be quan-
tified431. However, the development of DNA nanostructures may solve these 
problems in the near future, as this allows the combination of small-mole-
cule probes with the stable and precise localization of a biological macro-
molecule432. Functional moieties such as a fluorescent probe, click handle or 
intracellular targeting signal are coupled to complementary DNA strands 
which are then conjugated, allowing for highly customizable, biocompatible 
molecules433. This method was already applied to create a phagosome-target-
ed probe that simultaneously indicates HOCl and pH434.
Alternatively, the use of genetically encoded fluorescent probes such as the 
H2O2-specific HyPer can be a viable method for measuring ROS, since it 
allows to sense ROS production at specific cellular regions. The HyPer probe 
is constructed by insertion of a circularly permutated yellow fluorescent pro-
tein (cp-YFP) into the regulatory domain of the H2O2 sensitive Escherichia 
coli protein OxyR435,436. This regulatory domain contains two cysteine resi-
dues that are sensitive to oxidation, leading to conformational change of the 
cp-YFP which results in a ratiometric shift in fluorescent intensity. One of 
the cysteine residues is in a hydrophobic pocket inaccessible to charged ROS 
species like superoxide anion, making HyPer specific only for H2O2. A major 
advantage of genetically encoded probes is that they permit live-cell exper-
iments with subcellular precision by creating fusion proteins. In addition, 
the oxidation of HyPer is reversible, allowing it to reflect the current redox 
status, whereas most chemical probes undergo an irreversible oxidation and 
therefore indicate an accumulation of all previous redox states.
Signaling by ROS and oxidation products
Both ROS and various oxidation products have important cellular sig-
naling functions. A variety of ROS-dependent signaling pathways have 
already been discovered, which are described in the introduction section 
and in chapter 5 of this thesis. The most important ROS species involved in 
this signaling is H2O2, as it is comparatively stable, membrane permeable 
and capable of oxidizing cysteine residues in ROS-sensitive proteins such 
as thioredoxin112,282,293. In contrast, less is known about the effects of lipid 
peroxidation-derived compounds such as malondialdehyde (MDA) and 
4-hydroxynonenal (4-HNE) in immune cells. Lipid peroxidation in den-
dritic cells is strongly increased following NOX2 activation56,134. Due to their 
stability, both MDA and 4-HNE can diffuse across membranes to attack not 
only endocytic cargo, but targets throughout the entire cell65,66. The effects of 
MDA on cell function are poorly described, but 4-HNE has several effects 
highly relevant to dendritic cell function, including activation of PTEN86 and 
PI3K85 which mediate phagocytosis402,437,438 and autophagy439. Both 4-HNE 
and MDA can also form adducts with proteins or DNA59,67,77, which can 
inactivate genes in dendritic cells or modify the endosomal cargo which may 
enhance or inhibit antigen processing and presentation440,441. Macrophage 
receptor with collagenous structure (MARCO), part of the class A scavenger 
receptor family, is an important receptor for these protein adducts. Activa-
tion of MARCO was shown to upregulate many genes such as CD40, IL12B 
and PSME2 via increased TLR signaling442 and to inhibit homing of DCs 
from the tumor to draining lymph nodes443, leading to tolerance. In chapter 
4, we describe the formation of ethylene, a small alkene, by lipid peroxi-
dation. Although the ethylene receptor is exclusive to plants232, it was once 
used as an anesthetic444. In addition, several cell lines responded to ethylene 
perfusion with increased Ca2+ levels and altered gene expression patterns266. 
Therefore, an increase in ethylene or other small alkenes upon lipid peroxi-
dation might have local physiological effects. 
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MAP3K8
In chapter 3 we describe a new mechanism of how hypoxia primes a MAP 
kinase signaling pathway downstream of TLR4 activation. We found a main 
target for HIF signaling in this pathway to be MAP3K8, otherwise known 
as Cot or Tpl-2. MAP3K8 is mostly known as an oncogene and often upreg-
ulates p38-MAPK signaling in cancer cells under hypoxic conditions215,216, 
which in turn induces angiogenesis, metastasis and tolerance by shifting 
macrophages to an M2 phenotype and T cells to a Th17 phenotype161,217,222. 
However, macrophages and bone marrow-derived DCs from MAP3K8-/- 
mice showed increased production of IL-12231, which can greatly enhance 
anti-tumor responses by inducing Th1 T cell responses and activating nat-
ural killer cells and CD8+ T cells445, as well as inhibiting tumor angiogenesis 
via interferon-γ446. Despite these pro-inflammatory effects in immune cells, 
it may be better overall to inhibit MAP3K8 in cancer because it plays such 
an important role in tumor progression and induction of tolerance. By now, 
there are several small-molecule inhibitors targeting MAP3K8 and it would 
be interesting to test whether they can reduce tumor growth in mouse mod-
els198,447–450.
A major downstream signaling target of MAP3K8 is Erk1/2, which itself has 
many downstream effects on regulation of cell proliferation and differen-
tiation451. In immune cells specifically, Erk1/2 is an important mediator of 
TNF-α secretion and neutrophil development199–201. However, as described 
in chapter 3, we could not find any effects of hypoxia on Erk1/2 activity in 
DCs. This leads us to conclude that other pathways must be involved in the 
phenotype we observed. There are many candidates for this role; based on 
several transcriptional analyses115,116,195,452,453, hypoxia induces expression of 
many immunologically relevant genes aside from MAP3K8. Various cyto-
kines, chemokines and their receptors are upregulated, such as IL-6, IL-23A, 
TNF-α and IL-12B. In terms of immune cell signaling, some of the relevant 
genes are NFKB2, TNF receptor-associated factor 1 (TRIF1), MAP3K13, 
signal transducer and activator of transcription (STAT) 4, STAT6 and IL-1 
receptor-associated kinase (IRAK) 3, all of which are highly important in 
regulation of immune responses.
Studying anti-tumor responses in conditions that mimic the tumor mi-
croenvironment
As described in chapter 5, the tumor microenvironment is often hypoxic and 
contains high levels of ROS, both of which can extensively modify immune 
cell phenotypes and activation. To better understand anti-cancer immunity, 
as well as to aid in the development or improvement of immune therapies 
like DC vaccination, NK cell therapy and checkpoint inhibition, the influ-
ence of the TME on the effector cells of these therapies needs to be studied. 
Our findings that ROS production increases antigen cross-presentation56 and 
that hypoxia potentiates TNF-α secretion135 suggest that dendritic cell im-
munotherapy may be improved by stimulating ROS production in dendritic 
cells. However, dendritic cell-produced ROS were also shown to increase the 
inflammatory potential of CD4+ T cells by oxidizing thiol groups on the cell 
surface, skewing them towards a Th2 type, which is not beneficial for anti-tu-
mor immunity454–456. In line with this, H2O2 was found to inhibit CD8+ T cells 
in hepatitis C virus infections423, as discussed above. However, this could be 
an indirect effect since this inhibition is mediated by myeloid-derived sup-
pressor cells with upregulated p47phox expression following stimulation with 
hepatitis C virus core.
There are clear parallels between the TME and various autoimmune diseas-
es. In rheumatoid arthritis, for example, the synovium is transformed into 
a tumor-like structure with abnormal proliferation, neovascularization and 
infiltration of inflammatory cells457. A hypoxic microenvironment is formed 
here as well and this furthers disease progression160. Therefore, an under-
standing of the interplay of hypoxia and ROS on immune cell function might 
also be important for our understanding of autoimmune disease.
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Figure 1. Proposed mechanism for alkene formation via lipid peroxidation.
(A) Possible pathway of ethene formation by oxidation of an omega-3 polyunsaturated fatty 
acid (for example DHA), initiated by a hydroxyl radical (1). The protonation of the lipid 
peroxyl radical (4) can self-propagate the oxidation reaction by deprotonation of another 
unsaturated fatty acid (8). The formation of ethene can occur via Fe2+-mediated β-scission of 
the lipid hydroperoxide (5, 6) and subsequent Fe3+-mediated deprotonation of the reaction 
intermediate (7). (B) The position of the final carbon-carbon double bond in a fatty acid 
likely correlates with the alkene formed via the reaction described in (A).
Breath analysis as a diagnostic tool in the clinic
In chapter 4 we describe the possibility of ethene (ethylene) for use as a 
clinical biomarker for systemic inflammation. For patients at risk, for exam-
ple those on mechanical ventilation in intensive care units, this technique 
could be implemented with relative ease as their breath is already contin-
uously monitored for CO2, volume and flow458. We showed that ethylene 
formation is a byproduct of lipid peroxidation and expect that other gaseous 
hydrocarbons are formed as well. While the advantages of ethylene are its 
complete lack of enzymatic formation in mammals and the high specificity 
by which it can be detected, monitoring for a mix of gases opens up more 
possibilities. Other small hydrocarbons, such as ethane and/or butane, may 
be formed in far greater quantities than ethene, which could increase the 
sensitivity of detection. Chromatographic analysis of the lipid fragments 
following peroxidation may reveal mechanistic details of the reactions taking 
place during lipid peroxidation. Additionally, we expect alkene formation 
during lipid peroxidation mainly occurs through transition metal-mediated 
β-scission (Figure 1A)459,460. This would mean that omega-3 fatty acids form 
ethene upon oxidation, whereas omega-6 fatty acids form more 1-pentene 
and omega-9 fatty acids form predominantly 1-heptene (Figure 1B). The 
pentene:ethylene ratio might (coarsely) indicate the inflammation site since 
lipid composition differs between tissues461–463. Perhaps this could be used to 
quickly identify bacterial meningitis, as brain tissue is strongly enriched in 
polyunsaturated fatty acids461. We studied ethene production only in a model 
of systemic inflammation, which primarily involves endothelial cells and 
all blood cells, but other studies already showed ethene release during more 
localized events, for example cardiac surgery247 and UV-induced skin dam-
age246. It is likely that there are many more factors causing lipid peroxidation, 
as oxidative stress is a common feature of many diseases and injuries. This 
indicates the broad applicability for alkene detection as a diagnostic tool.
138 | Chapter 7 Discussion and future perspectives | 139
7
Conclusion and future perspectives
Oxygen is a double-edged sword in immunology: ROS are critical for a 
strong response to both pathogens and cancer37,40,55,56, but they also damage 
important cellular components4,59. In addition, their generation consumes 
valuable oxygen that would otherwise be used for respiration. In this thesis, 
I described downstream effects of both the indiscriminate reactions of ROS 
with dendritic cells and how hypoxia alters cytokine secretion following 
bacterial infection.
In a human model of systemic inflammation caused by infection with 
Gram-negative bacteria, I showed how the rapid generation of ROS leads to 
lipid peroxidation that can be detected in breath in real-time. This method 
is both faster and less invasive than diagnostics based on blood cytokine 
levels and therefore has potential for clinical use. Unlike neutrophils, the 
viability of dendritic cells is unaffected following ROS production, making 
them an interesting subject to study ROS-mediated signaling. This discrep-
ancy between neutrophils and DCs may be explained by their differences in 
NOX2 activity during phagocytosis. Chapter 2 describes how DCs produce 
ROS at a roughly ten times lower rate than neutrophils. However, in con-
trast to the short respiratory burst in neutrophils37,39,122, ROS production is 
sustained for many hours in dendritic cells. For these experiments we used 
real-time measurement of oxygen consumption as a proxy for NOX2 activity 
to allow quantification of the ROS production rate. These experiments also 
show that oxygen levels are likely the rate-limiting factor in NOX2-medi-
ated ROS generation, meaning that DCs rapidly become hypoxic following 
activation. Chapter 3 describes how hypoxia upregulates expression of the 
kinase MAP3K8 to potentiate the p38-mediated secretion of TNF-α by DCs. 
There is however a much larger variety of HIF-controlled genes  relevant to 
DCs and other immune cells115–117 and studying their effects may provide 
useful insights and therapeutic targets for cancer immunotherapy, autoim-
mune disease and inflammation. For example, autophagic flux is controlled 
by HIF-1α in macrophages464, which could in turn control LC3-associated 
phagocytosis97,98 and subsequent antigen processing. In B-cells, HIF-1α activ-
ity contributes to IL-10 secretion465, a potent anti-inflammatory cytokine that 
downregulates MHC-II antigen presentation466, cytokine production467 and T 
cell activation468.
Studying oxygen radicals is challenging due to their high reactivity and in-
terconversion into different ROS species. To overcome this problem, I devel-
oped a toolkit for controlled generation of ROS within live cells with organ-
ellar precision using a light-sensitive protein. Previous methods are mostly 
based on introducing radical-generating systems into the culture media, 
which lacks the spatial resolution to study effects on specific organelles. Im-
munologically relevant effects of endo-/phagosomal ROS56 as well as effects 
of ROS in the endoplasmic reticulum309, mitochondria313 and nucleus469 have 
already been described. However, these effects could  differ greatly between 
immune cell types or radical species due to differences in cell morphology 
and function. Our optogenetic toolkit allows to address these questions. 
Moreover, for many other organelles, such as the Golgi apparatus, the immu-
nologically relevant effects of ROS have not yet been studied. Especially in 
the Golgi, oxidative modification of cargo proteins, loss of the pH gradient 
due to membrane leakage470 as well as generalized trafficking defects can be 
expected. These would directly affect cytokine secretion, translocation of 
surface receptors, replenishing of gp91phox at endo/phagosomes, and other 
immunological processes.
A key challenge for the future would be to use oxygen either directly or in 
the form of radicals to steer immune responses towards either a pro- or an-
ti-inflammatory phenotype, especially if these levels were to be controlled lo-
cally, for example in the tumor or lymph nodes. This poses a large challenge 
but may be achieved injecting (nano)particles loaded with NOX2 activators, 
hydrogen peroxide or even transition metals and target them to dendritic 
cell-specific surface markers such as DC-SIGN. In the case of anti-tumor 
immunity, a local increase in oxygen levels could counteract the DC trapping 
effect of the tumor microenvironment described in chapter 5, while simulta-
neously allowing DCs to generate more ROS to aid in cross-presentation of 
tumor antigens to cytotoxic T cells53–56. Controlling oxygen and ROS levels is 
probably easiest realized in dendritic cell immunotherapy, where oxygen lev-
els can be controlled during the ex vivo steps of tumor antigen loading and 
culture media can be supplemented with ROS-generating compounds such 
as tert-butyl hydroperoxide, hydrogen peroxide or low levels of a transition 
metal to promote cross-presentation. In conclusion, the work in this thesis 
demonstrates that both oxygen and oxygen-derived radicals play important 
but underappreciated roles in dendritic cell function. Their effects should be 
taken into account when studying the immune system or designing immu-
nological therapies.
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Nederlandse samenvatting
Zuurstofradicalen
Een van de belangrijkste stappen in de evolutie van de aarde was een snelle 
omschakeling van de zuurstofarme (≈0.002% O2) atmosfeer naar het huidige 
niveau van 21% O2 ongeveer 2.4 miljard jaar geleden1. De effecten hiervan 
waren tweeledig: enerzijds is de synthese van ATP uit glucose met behulp 
van zuurstof ongeveer 16 maal efficiënter dan zonder, wat het ontstaan van 
eukaryote, multicellulaire levensvormen mogelijk maakte3. Anderzijds is 
zuurstof zeer reactief: via het stapsgewijs opnemen van vier elektronen oxi-
deert zuurstof naar water. De tussenstappen van deze reactie vormen echter 
zeer reactieve zuurstofradicalen (Figuur 1A-B)4. Daarbovenop kunnen tran-
sitiemetalen de vorming van hydroxylradicalen katalyseren, welke bijzonder 
schadelijk zijn voor cellulaire componenten (Figuur 1C). Om dit te overle-
ven moesten organismen ofwel beschermingsmechanismen ontwikkelen, of 
terugtrekken naar een zuurstofarme niche5. Tegenwoordig vormen zuurstof-
radicalen niet alleen maar een bedreiging, maar worden ze ook ingezet voor 
onder andere cellulaire communicatie en de verdediging van ons lichaam 
tegen ongewenste indringers, zoals bacteriën en virussen (pathogenen).
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Figure 1. Reactive oxygen species.
A. The meest gangbare zuurfstofradicalen in de biologie. B. Zuurstof neemt stapsgewijs 4 
elektronen op en vormt daarbij verscheidene reactieve radicalen. C. Transitiemetalen kataly-
seren de vorming van hydroxylradicalen, welke zeer schadelijk zijn voor de cel.
Het immuunsysteem
Ons immuunsysteem is een zeer divers orgaan, dat zich door het gehele 
lichaam bevindt om het te beschermen tegen pathogenen. De eerste barriè-
res die ons lichaam opwerpt tegen pathogenen zijn de huid, slijmvliezen en 
de aspecifieke immuuncellen. Deze cellen zijn gespecialiseerd in het tijdig 
en juist herkennen om welk pathogeen het gaat (bijvoorbeeld een virus, 
parasiet of bacterie). Veel bacteriën hebben karakteristieke lichaamsvreemde 
moleculen aan hun oppervlak, zoals bepaalde eiwitten of suikers, en virus-
sen bestaan vaak uit lichaamsvreemde DNA- of RNA-sequenties6. Al deze 
specifieke patronen kunnen door immuunreceptoren op de immuuncellen 
herkend worden, wat tot activatie van ons immuunsysteem leidt. Dit heeft 
de uitscheiding van specifieke signaalstoffen (cytokines) tot gevolg, welke 
immuuncellen rekruteren die het beste aangepast zijn om het pathogeen te 
bestrijden22. Dit zijn de cellen van het adaptieve immuunsysteem.
Hoewel de activatie van het adaptieve immuunsysteem enige tijd vergt, kent 
het een zeer groot voordeel: de opbouw van immuungeheugen. Dit stelt ons 
lichaam in staat om doelgericht en efficiënt te reageren op herhaalde bloot-
stellingen aan eenzelfde pathogeen, wat aan de basis staat van bijvoorbeeld 
vaccinaties8. De effectorcellen van het immuunsysteem (B-cellen en T-cel-
len) worden aangestuurd door antigen-presenterende cellen (monocyten en 
dendritische cellen). Deze cellen speuren het hele lichaam af naar pathoge-
nen om ze te internaliseren (fagocyteren) in afgesloten blaasjes (fagosomen), 
te fragmenteren en herkenbare onderdelen (antigenen) te presenteren aan 
de effectorcellen. Deze zorgen vervolgens voor het doden van het herkende 
pathogeen en voor de generatie van immuungeheugen.
Radicalen tijdens fagocytose
Bij het proces van fagocytose zijn zuurstofradicalen betrokken die worden 
gebruikt om het geïnternaliseerde pathogeen te doden. In hoofdstuk 2 be-
schrijf ik de kinetiek van de generatie van die radicalen tijdens de beginstap-
pen van fagocytose met een kwantitatieve methode. In de biologie worden 
veel processen met fluorescente moleculen gemeten, aangezien deze vaak 
zeer gevoelig en specifiek zijn. Echter, bij moleculen zo reactief en verganke-
lijk als zuurstofradicalen is dit problematisch133,427. Er zijn diverse moleculen 
ontwikkeld die van fluorescentie veranderen na oxidatie door radicalen, 
maar deze zijn niet specifiek. Echter, het omzetten van zuurstof naar ra-
dicalen consumeert zuurstof en zuurstofconcentratie is wel zeer specifiek 
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te meten. Deze metingen, gecombineerd met microscopie en fluorescente 
indicatoren, lieten toe de zuurstofconsumptie per fagosoom te schatten, 
welke in dendritische cellen op 0.5 mM/fagosoom/seconde komt. In de be-
langrijkste effectorcel van het aspecifieke immuunsysteem, de neutrofiel, ligt 
deze waarde ongeveer een tienvoud hoger37–39 . De neutrofiel sterft tijdens dit 
proces samen met het aangevallen pathogeen. Dendritische cellen overleven 
dit proces wel, zodat deze antigenen kunnen presenteren. Ook hebben we 
aangetoond dat ze naar schatting tien keer langer doorgaan met radicalen 
produceren dan neutrofielen, waardoor de netto activiteit ongeveer gelijk 
blijft.
Hypoxie
Zoals hierboven beschreven consumeert het genereren van radicalen zuur-
stof. Dit heeft tot gevolgd dat de lokale zuurstofconcentratie sterk kan dalen 
en uit literatuur is bekend dat dit grote effecten kan hebben op onder andere 
het cellulair metabolisme, de secretie van cytokines of de differentiatie van 
immuuncellen110,111,162,165,177,206. Deze veranderingen worden veelal geregu-
leerd door een aantal eiwitten die onder de noemer Hypoxia Induced Factors 
(HIFs) vallen. Deze eiwitten worden bij voldoende zuurstof constant afge-
broken, waardoor ze hun effect niet uit kunnen oefenen. Op het moment dat 
er zuurstoftekort optreedt, kunnen twee HIFs aan elkaar binden, waarna ze 
een grote verscheidenheid aan genen activeren115,116. In hoofdstuk 3 beschrijf 
ik hoe een van die genen door HIF geactiveerd wordt en vervolgens specifiek 
de secretie van een pro-inflammatoire cytokine (TNF-α) in dendritische cel-
len verhoogt. Deze cytokine is onder andere betrokken bij diverse auto-im-
muunziekten, zoals reuma en scleroderma. Aangezien ontsteking bijdraagt 
aan verhoogde zuurstofconsumptie, ontstaat hierdoor een vicieuze cirkel en 
wordt de ontstekingsreactie niet langer afgerond. Deze aanhoudende ontste-
kingen staan aan de basis van vele auto-immuunziekten.
Ook in kanker staan dendritische cellen vaak bloot aan lokaal verlaagde 
zuurstofconcentraties. Tumoren zijn veelal slecht doorbloed, maar vertonen 
tegelijkertijd wel een sterk verhoogde stofwisseling. Dit leidt ertoe dat de 
directe omgeving van een tumor vaak zuurstofarm is en veel zuurstofradica-
len bevat. Veel immuuncellen zijn hier gevoelig voor, wat kan leiden tot een 
inadequate reactie op de tumor, waardoor deze door kan blijven groeien. In 
hoofdstuk 4 staat een uiteenzetting van de mogelijke effecten van de tumo-
romgeving op immuuncellen gebaseerd op een literatuurstudie. Ik conclu-
deer dat de zuurstofarme omgeving van de tumor een immunosuppressieve 
val voor dendritische cellen vormt: inactieve dendritische cellen worden 
afgestoten, terwijl geactiveerde juist in de tumor vastgehouden worden. Hoe-
wel dendritische cellen radicalen ook inzetten voor een adequate antitumor-
respons, is hun functie sterk geremd door deze zuurstofarme en radicaalrijke 
tumoromgeving. Met name geoxideerde vetten lijken aan deze remming bij 
te dragen.
Zoals hierboven beschreven genereren fagocyten grote hoeveelheden radi-
calen wanneer zij bacteriën herkennen. Deze radicalen reageren willekeu-
rig met een verscheidenheid aan cellulaire bouwstenen in hun omgeving, 
bijvoorbeeld met eiwitten, maar ook met de vetten waaruit het celmembraan 
bestaat. De oxidatie van vetten is zeer schadelijk voor cellen en weefsels om-
dat deze reactie zichzelf in stand houdt59. Hierbij komen allerhande reactie-
producten vrij, waaronder ook het gas ethyleen. In hoofdstuk 5 beschrijf ik 
hoe ethyleen gemeten kan worden in uitgeademde lucht, wat kan dienen als 
snelle detectiemethode voor levensbedreigende infecties, zoals bloedvergifti-
ging.
De effecten van radicalen op cellen worden al geruime tijd uitvoerig bestu-
deerd. Dit gaat echter veelal middels de toediening van oxiderende chemi-
caliën aan de celkweek. Een groot nadeel hiervan is dat hiermee niet gericht 
bepaalde onderdelen van een cel bestudeerd kunnen worden. In hoofdstuk 
6 beschrijf ik een methode om gericht radicalen te induceren middels een 
lichtgevoelig eiwit dat met hoge precisie in cellen geïntroduceerd kan wor-
den. Hiermee heb ik aangetoond dat de effecten van radicalen inderdaad 
afhangen van hun precieze locatie in de cel.
Samenvattend beschrijft dit proefschrift hoe zowel zuurstof als zuurstofradi-
calen bijdragen aan het functioneren van dendritische cellen, alsmede enkele 
mogelijkheden om hun effecten toe te passen voor nieuwe diagnostische en 
therapeutische doeleinden.
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Dankwoord
Na ruim 4 jaar aan de inhoud van dit boekje gewerkt te hebben, is het mo-
ment dan toch echt daar, het boekje is af! Als er één ding is wat ik zeker ge-
leerd heb in deze tijd, dan is het wel dat wetenschap bij uitstek een teamsport 
is. Zonder de hulp, goede raad, steun en ook afleiding van veel mensen was 
ik bij het maken van dit proefschrift dan ook niet veel verder gekomen dan 
de voorkant.
Geert, jouw tomeloze enthousiasme, gedrevenheid en optimisme waren 
zonder twijfel de grootste drijvende kracht achter mijn labwerk. Ook dat je 
altijd bij ons op het lab bent blijven zitten waardeer ik enorm en dit heeft 
zeker bijgedragen aan het snel opstarten van mijn projecten. Je gezonde 
afkeer van conventies en je feilloze talent voor het herkennen van een goed 
idee hebben ertoe geleid dat we samen een aantal heel creatieve publicaties 
hebben uitgebracht, waar ik erg trots op ben. Ook je geweldige gevoel voor 
humor, muziekcollectie en verzamelwoede zijn erg inspirerend gebleken, of 
het nou oude objectieven of singletjes van Mental Theo betreft. Daarnaast 
hebben we ook altijd veel gelachen tijdens de nieuwjaarsborrels, science days 
en andere uitjes. Je hebt hiermee een hechte groep gecreëerd waarin ik mij 
altijd thuis heb gevoeld. Ik twijfel er dan ook niet aan dat je deze trend in 
Groningen doorzet en ik wens je heel veel succes daar!
Carl, ik heb diepe bewondering voor de manier waarop je een lab leidt dat 
zo divers is als TIL. Dit blijkt wel uit het feit dat, hoewel we elkaar niet weke-
lijks spraken, je tóch altijd goed op de hoogte was van de voortgang van mijn 
projecten en altijd scherpe vragen en opmerkingen (of gewoon een leuke 
anekdote) paraat had.
Timothy, we spraken elkaar misschien niet heel geregeld, maar juist daarom 
ben ik je dankbaar voor je vertrouwen en de vrijheid die je me gegund hebt. 
Met je kennis van de immunologie in de patiënt heb je mijn fundamentele 
kant van de sclerodermapuzzel van de broodnodige achtergrond en moti-
vatie voorzien. Wiola, Andrea, I am grateful for our collaboration. While 
our busy schedules sometimes got in the way of planning meetings, we still 
managed to share two beautiful manuscripts. I admire your dedication and 
deep immunological knowledge and wish you all the best in your future 
endeavours!
Wilco, Simona and Matthijs, you have shown me the strength that lies in 
collaboration. Without your insight, dedication and efforts, this thesis would 
have been a lot thinner. I am grateful for the trust you put in me and very 
proud of what we have achieved together.
Martin, zonder jouw enorme kennis, kunde en kritische blik was
waarschijnlijk geen enkel proefschrift uit onze groep tot stand gekomen, 
maar zeker deze niet! Je befaamde ‘Martin blots’ hebben heel wat proeven 
weer op de rails gekregen. Daarnaast had ik in jou iemand om een scherp 
gevoel voor humor mee te delen, misschien soms tot groot (on)genoegen van 
de rest van de groep, maar dat deert ons gelukkig weinig.
Peter, dankjewel dat je mijn paranimf wil zijn! Naast je Python skills en 
kritische data analyses, waren je suggesties voor de vrijdagse 80s playlist en 
kennis van synths en toetsenborden ook erg welkom! Ook vond ik in jou al 
snel iemand om samen de studenten mee in de maling te nemen, uiteraard 
een essentiële taak van elke promovendus. Tot slot bewonder ik je weten-
schappelijke visie en gedrevenheid en daardoor ben ik nu al erg benieuwd 
naar jouw boekje.
Elke, dankjewel dat ook jij mijn paranimf wilde zijn! We waren er al snel 
achter dat een kopje koffie een grote verbindende factor is, maar je humor, 
gezelligheid en je beroemde WOO-factor zorgen ervoor dat ik altijd bij je 
terecht kan voor wat afleiding tijdens een drukke dag (als je überhaupt weer 
eens in Nederland bent tenminste…). Je talent voor netwerken en samenw-
erkingen opzetten gaan je nog heel ver brengen.
Ilse, ik was nog student toen jij bij Geert begon en we samen de lab-intro-
ductie door moesten. Daar hadden we gelijk een klik en dat heeft ons nog 
veel opgeleverd: naast een aantal gedeelde publicaties ook veel gezelligheid! 
Ook heb ik altijd veel bewondering gehad voor je winnaarsmentaliteit. Je 
bent altijd welkom om in Nijmegen te overnachten als je, terecht, de trein 
een keer wilt mijden. Daniëlle, door jouw zangtalent was het nooit stil in de 
kweek, iets dat ik in mijn laatste jaar zeker heb gemist. Ik ben blij dat ik altijd 
gebruik heb mogen maken van je scherpe oog voor posterontwerp, anders 
had ik nooit een hot pink poster gemaakt. Ook kon ik gelukkig altijd bij je 
terecht voor een stevige discussie over ons onderzoek of gewoon even een 
kop koffie. Ook ben ik blij dat je de 80s playlist wel kon waarderen ;-).
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Maxim, het was een voorrecht om het Utje altijd met jou te mogen delen. Je 
doorzettingsvermogen kent geen gelijke en ik heb erg genoten van je humor, 
je interesse en onze vele discussies. Ook wil ik jou en Joshua bedanken voor 
alle gezelligheid buiten het lab. Natalia, I admire your drive to do everything 
exactly right. Combined with your creativity and warm personality I am sure 
you will always be very successful. It was an honor to be at your wedding and 
I wish you all the best together with Cristian and Oliver.
Frans, toen je bij de groep kwam, nam je gelijk een hoop gezelligheid mee. 
Pubquizzen, een dagje kanoën of een etentje… jij regelde het wel even en ik 
heb altijd met veel plezier mee gedaan.  Ik heb veel bewondering voor hoe 
snel je je eerste beurs hebt binnen gehaald en wens je veel geluk samen met 
Marijke en Eva. Femmy, Sjors, Pieter and Harry, you form a great team as 
Geert’s new Groningen crew! I admire your cool-headedness in the chaos of 
reorganizing the lab and greatly enjoyed the time we spent together on the 
Science Days and your Vierdaagse visit.
Tijdens de afgelopen jaren heb ik het voorrecht gehad een aantal zeer getal-
enteerde studenten te mogen begeleiden. Maura, Lieke, Ellen, Isabelle en 
Willemijn, ik heb altijd met veel plezier jullie vragen beantwoord en resul-
taten bediscussieerd, maar gelukkig hebben we samen ook veel gelachen en 
over de meest uiteenlopende dingen gepraat. Ik heb veel van jullie geleerd 
(jullie hopelijk ook wat van mij) en ben trots op de publicaties die we samen 
hebben behaald! Ik ben benieuwd naar waar jullie terecht gaan komen.
The TIL lab has felt like home ever since I first set foot in it six years ago as a 
master student. I was ecstatic when I heard I could come back to do my PhD 
and it has been one hell of a ride! It were not just the big events that made a 
lasting impression; the many conversations during lunch and at the coffee 
machine, Friday afternoons at the Aesculaaf or the willingness to help each 
other out are something truly unique. Nevertheless, it is impossible not to 
mention the legendary Christmas parties (which I also had great fun orga-
nizing!), nor the yearly TIL Day Out. The creative themes, abundant deco-
rations, amazing costumes and delicious food are proof of the immense fire 
that drives TILers to always go the extra mile. I am truly proud to have been 
a part of them!
Speaking of the Christmas parties, no acknowledgements section is complete 
without mentioning the legendary TIL band! Whenever I hear a Bon Jovi 
song, I’m reminded life is hard when you live in a monolayer. I can never 
unhear those brilliant lyrics! Christian, Jonas, Ben, Svenja, Martijn, Koen, 
Loek, Paul, Yusuf, Daniëlle, Glenn and Iris, it was amazing to conquer the 
hearts of so many fans with you.
Although I am afraid I have to break rule #1 (don’t talk about Whisky Club), 
I have to thank its members for their hospitality during the many enjoy-
able tasting nights and the great conversations we had. Een van de jaarlijkse 
hoogtepunten in Nijmegen is natuurlijk de Vierdaagse. Eric, door jouw 
organisatietalent is de Roze Woensdag iets waar ik elk jaar weer naar uitkijk. 
Ook de weekendjes weg naar Berlijn en Kopenhagen waren geweldig! En 
natuurlijk de spelletjesavonden (met dank aan Sjoerd), die waren aan mij 
wel besteed. Inge, Xander, Koen, toch wel apart dat wetenschappers zo gek 
zijn dat ze zelfs tijdens hun lunchpauze nog over wetenschap praten. Toch 
heb ik hier altijd van genoten en vooral ook veel gelachen! Bas, Felix, Rens, 
echt heel gezellig om met jullie op maandagavond nog even een bordspel uit 
de kast te trekken. Ik hoop dat we dat ritueel nog lang vol kunnenhouden. 
Ilja en Jeanette, hoe jullie dagelijks met de gekte van zo’n grote groep TILers 
omgaan is bewonderenswaardig! Dank voor alle hulp, het beantwoorden van 
al mijn vragen, maar ook de interesse en gezelligheid aan de koffietafel.
De afgelopen jaren was ik niet alleen lid van TIL, maar ook van de ICI 
groep. Hier heb ik zo veel geweldige mensen ontmoet en, ondanks dat we 
elkaar maar een paar keer per jaar zagen, hebben we een bijzondere band 
met elkaar opgebouwd. Anna, Berend, Brett, Dennis, Dion, Elko, Eveline, 
Jolien, Jorieke, Joost, Lina, Loek, Martje, Sabina, Sebastiaan, Sophie, Tim 
en alle anderen: ik ben jullie dankbaar voor jullie openheid en de diepgaande 
gesprekken, maar ook voor de vele gezellige etentjes die erop volgden. Ik had 
het voor geen goud willen missen!
Maarten, Esther, Rob, Annemarie, Roos, Abel, Joost en Linsey, het is 
geweldig dat ik altijd bij jullie aan kan kloppen voor een avondje (of een heel 
weekend!) bordspellen. Of we nou hemels bier brouwen, strijden op een veel 
te kleine kaart, steden van energie voorzien of elkaar in het geheim trachten 
te verraden, gezellig is het altijd!
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Jules, Olaf en de overige roegers, jullie hebben altijd voorzien in de nodige 
dosis (gist)cultuur. Maar ook de vele luidruchtige concerten,
bedevaarten naar Berlijn of Antwerpen en bizarre feestjes waren altijd weer 
een hoogtepunt. Flof! Sjeng, Giel, Guido, Thijs en Loes, we kennen elkaar 
al zo lang en ik twijfel er niet aan dat we verbonden zullen blijven. Samen 
muziek maken was altijd de perfecte afleiding van het drukke laboratorium-
leven. Koen, ook jou ken ik al zo lang en ik heb je enthousiasme en passie 
altijd heel aanstekelijk gevonden. Ik ben benieuwd waar je in de toekomst 
terecht komt.
Conny, Maarten, Diederick, Amber, Bep, Maarten, Henk, Annie, Anneke 
en Johan, dankjewel dat jullie mij met open armen in jullie familie hebben 
ontvangen. Ik voel me altijd welkom bij jullie en ben dankbaar voor jullie 
steun en de interesse die jullie altijd in mijn bezigheden hebben getoond.
Lieve pap, lieve mam, ik ben dankbaar dat jullie mij altijd onvoorwaardelijk 
hebben gesteund, gemotiveerd en aangemoedigd mijn hart te volgen. Zonder 
jullie had ik nooit het beste uit mezelf kunnen halen. Ik hoop dat ik jullie 
toewijding eer aan kan doen en ik ben blij dat ik altijd bij jullie terecht kan. 
Lieve Martine, mijn super getalenteerde zusje. Ik ben zo trots op wat je alle-
maal al bereikt hebt en hoe waanzinnig goed jij kookt, tekent en piano speelt! 
Ik zal er altijd voor je zijn.
Lieve Rosalie, jij bent me het dierbaarst van alles. Je bent de slimste,liefste, 
grappigste, mooiste persoon in mijn leven. Onze fantastische vakanties,
lekker eten, fijne muziek, een spelletje, onze lieve poes Molly… dat ik alles 
met jou mag delen maakt me gelukkig. Met jou aan mijn zijde durf ik alle 
avonturen aan. Waar we ook terechtkomen, zolang ik bij jou ben, ben ik 
thuis.
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Curriculum Vitae
Laurent Paardekooper was born on October 21st 1990 in Venlo, the Netherlands. 
After completing his secondary education in 2009, he started his BSc degree in 
Biomedical Sciences at the Radboud University in Nijmegen, the Netherlands. For 
his bachelor internship, he joined the group of dr. Fang Yang at the Department 
of Biomaterials of the Radboud University Medical Center. Under the supervision 
of Na Yu, MSc, he investigated the use of biodegradable nanowire substrates for 
periodontal tissue regeneration. In 2012, Laurent obtained his BSc degree majoring 
in Human Pathobiology. As follow up, he chose to pursue a MSc degree in Bio-
medical Sciences at the Radboud University with a major in Human Pathobiology 
and the elective track Infectious Diseases. In his first internship, Laurent had his 
first foray into cell biology, as he investigated the interplay between membrane 
curvature-sensing proteins and the actin cytoskeleton in the context of podosome 
structure and dynamics in dendritic cells, under the supervision of dr. Alessandra 
Cambi at the Tumor Immunology Laboratory of the Radboud Institute for Molec-
ular Life Sciences. For this internship, he also closely collaborated with dr. Johan 
Slotman and prof. Adriaan Houtsmuller of the Department of Pathology at the 
Erasmus Medical Center in Rotterdam, the Netherlands to perform super-resolu-
tion microscopy on the podosome structure. For his second internship, he charac-
terized bacterial pantothenate kinases as targets for a novel antibiotic strategy based 
on vitamin B5  derivates under the supervision of dr. Patrick Jansen and prof. Joost 
Schalkwijk at the department of Dermatology of the Radboudumc. In 2014, Laurent 
obtained his MSc bene meritum.
With a background in both cell biology and biochemistry, Laurent started his PhD 
degree in the Membrane Trafficking group of the Tumor Immunology Laboratory 
at the Radboud Institute for Molecular Life Sciences in Nijmegen, the Netherlands, 
under the supervision of dr. Geert van den Bogaart and prof. Carl Figdor. As a 
member of the Institute for Chemical Immunology, he collaborated with dr. Wioleta 
Marut, Andrea Ottria, MSc and prof. Timothy Radstake of the Laboratory of Trans-
lation Immunology of the University Medical Center in Utrecht, the Netherlands to 
unravel the effects of both hypoxia and oxygen radicals on dendritic cells. Laurent 
has presented his work at various international conferences and has also published 
several papers in peer-reviewed international scientific journals, which make up the 
content of this thesis.
Curriculum Vitae
Laurent Paardekooper is geboren op 21 oktober 1990 te Venlo. Na het voltooien van 
de middelbare school in 2009, is hij gestart met de bachelor opleiding Biomedische 
Wetenschappen aan de Radboud Universiteit te Nijmegen. In zijn bachelorstage 
heeft hij in de groep van dr. Fang Yang gewerkt aan de afdeling Biomaterialen 
van het Radboudumc. Onder begeleiding van Na Yu, MSc, heeft hij biologisch 
afbreekbare nanosubstraten ontwikkeld met als toepassing het regenereren van 
periodontaal bindweefsel. In 2012 heeft Laurent zijn bachelordiploma Biomedische 
Wetenschappen behaald, met als hoofdvak Humane Pathobiologie. Hierna heeft hij 
zijn opleiding vervolgd met de master Biomedical Sciences aan de Radboud Uni-
versiteit, wederom met als hoofdvak Human Pathobiology en een extra keuzetraject 
Infectious Diseases. Tijdens zijn eerste masterstage kwam Laurent voor het eerst in 
aanraking met de celbiologie. Onder leiding van dr. Alessandra Cambi heeft hij de 
interactie tussen membraancurvatuur-gevoelige eiwitten en het actine cytoskelet 
onderzocht in dendritische cellen. Dit deed hij in het Tumor Immunology Labo-
ratory van het Radboud Institute for Molecular Life Sciences. Tijdens deze stage 
heeft Laurent ook nauw samengewerkt met dr. Johan Slotman en prof. Adriaan 
Houtsmuller van de afdeling Pathologie aan het Erasmus MC te Rotterdam, waar 
hij superresolutie microscopie op de structuur van podosomen van dendritische 
cellen heeft verricht. Zijn tweede masterstage vond plaats onder leiding van dr. 
Patrick Jansen en prof. Joost Schalkwijk van de afdeling dermatologie van het 
Radboudumc. Hier heeft hij bacteriële pantothenaat-kinase enzymen gekarakteri-
seerd als doelwit voor een nieuwe antibioticumstrategie gebaseerd op vitamine B5 
derivaten. In 2014 studeerde Laurent bene meritum af voor zijn master.
Met een achtergrond in zowel celbiologie als biochemie, startte Laurent zijn pro-
motieonderzoek in de Membrane Trafficking Group van het Tumor Immunology 
Laboratory aan het Radboud Institute for Molecular Life Sciences, onder super-
visie van dr. Geert van den Bogaart en prof. Carl Figdor. Als lid van het Institute 
for Chemical Immunology heeft hij samengewerkt met dr. Wioleta Marut, Andrea 
Ottria, MSc en prof. Timoty Radstake van het Laboratorium voor Translationele 
Immunology aan het UMC Utrecht om de effecten van zowel hypoxie als zuurstof-
radicalen op dendritische cellen te ontrafelen. Laurent heeft zijn werk op diverse in-
ternationale congressen gepresenteerd en verscheidene manuscripten gepubliceerd 
in internationale, peer-reviewed wetenschappelijke bladen. Deze publicaties vormen 
tevens de inhoud van dit proefschrift.
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N. Vazirpanah, S. Silva-Cardoso, A.J. Affandi, E. Chouri, M van der Kroef, 
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S. Garcia Perez, A. Pandit, F. Bonte-Mineur, K.A. Reedquist,
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HIF-2α stabilization by hypoxia and TLR9 activation drives CXCL4
production in plasmacytoid dendritic cells
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Radical stress is more detrimental in the nucleus than in other organelles
International Journal of Molecular Sciences 20 p. 4147, 2019
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Human monocyte-derived dendritic cells produce millimolar
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antigen release
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